{"0c9ccfea04db7ea79ad167239b4fe68a13ab0295": [["They worked in hospitals including temporary infectious disease hospitals and in medical isolation units.", [["infectious disease", "DISEASE", 45, 63]]], ["Due to factors such as the lockdown of Wuhan, prolonged isolation, family infections, lack of medical resources, and witnessing death, these physicians generally experienced stress symptoms or bereavement-related depression.", [["infections", "DISEASE", 74, 84], ["death", "DISEASE", 128, 133], ["bereavement", "DISEASE", 193, 204], ["depression", "DISEASE", 213, 223], ["prolonged isolation", "TREATMENT", 46, 65], ["stress symptoms", "PROBLEM", 174, 189], ["depression", "PROBLEM", 213, 223]]], ["1 Faced with patient's infectiousness and psychological needs, as well as locked wards, separation from home, and continuous work, medical staff experienced emotional pain, insomnia, stress reactions and exhaustion.", [["emotional pain", "DISEASE", 157, 171], ["insomnia", "DISEASE", 173, 181], ["stress reactions", "DISEASE", 183, 199], ["patient", "ORGANISM", 13, 20], ["patient", "SPECIES", 13, 20], ["emotional pain", "PROBLEM", 157, 171], ["insomnia", "PROBLEM", 173, 181], ["stress reactions", "PROBLEM", 183, 199], ["exhaustion", "PROBLEM", 204, 214]]], ["This increased the risk of illness in the staff themselves.", [["illness", "DISEASE", 27, 34], ["illness", "OBSERVATION", 27, 34]]], ["[2] [3] [4] [5] [6] [7] In addition, the medical workers became easily dissatisfied with their job.", [["[2] [3] [4] [5] [6] [7]", "SIMPLE_CHEMICAL", 0, 23]]], ["8 Due to the emergent nature of the epidemic, many doctors and nurses were not from the departments of infectious diseases, respiratory or intensive care units (ICU), so they lacked confidence in treating COVID-19, which also increased their stress.", [["infectious diseases", "DISEASE", 103, 122], ["COVID-19", "CHEMICAL", 205, 213], ["COVID-19", "CHEMICAL", 205, 213], ["COVID", "TEST", 205, 210], ["infectious", "OBSERVATION", 103, 113]]], ["In addition to maintaining the mental health of medical team members, this psychiatrist also provided psychological support for patients under the jurisdiction of this medical team.", [["patients", "ORGANISM", 128, 136], ["patients", "SPECIES", 128, 136], ["psychological support", "TREATMENT", 102, 123]]], ["Therefore, onsite mental health resources were minimal.INTRODUCTIONTo overcome these difficulties, a psychological health support programme was designed and implemented to reinforce the medical team sent to Leishenshan hospital in Wuhan,General PsychiatryChina.", [["these difficulties", "PROBLEM", 79, 97]]], ["12 Previous studies have demonstrated the effectiveness of peer support group approaches, such as Balint groups, on alleviating the exhaustion of healthcare workers.", [["Previous studies", "TEST", 3, 19], ["peer support group approaches", "TREATMENT", 59, 88]]], ["[13] [14] [15] [16] These activities have been validated both in face-to-face and online forms.", [["[13] [14] [15] [16]", "SIMPLE_CHEMICAL", 0, 19]]], ["Doctors and nurses tend not to accept the role of help-seeker, and they are more inclined to learn and solve problems by themselves, 5 18 bringing challenges to classical psychological interventions.", [["classical psychological interventions", "TREATMENT", 161, 198]]], ["Our programme thus emphasised motivating self-strengths by promoting positive self-feedback and coaching selfregulation exercises everyday.", [["coaching selfregulation exercises", "TREATMENT", 96, 129]]], ["This paper introduces the details of the psychological health support programme and presents data that reflect the effects of this programme.", [["this programme", "TREATMENT", 126, 140]]], ["We examined whether this programme can effectively promote positive emotions, maintain team work efficiency and prevent burnout.METHODS ParticipantsThere were 155 medical personnel in the medical team, including 59 doctors, 90 nurses and 6 administrative staff.", [["burnout", "DISEASE", 120, 127], ["Participants", "SPECIES", 136, 148], ["burnout", "PROBLEM", 120, 127]]], ["Mean age of the team was 35 years (24-54 years), with 49 men (31.6%).", [["men", "ORGANISM", 57, 60], ["men", "SPECIES", 57, 60]]], ["Figure 1 shows the details of the enrolment and follow-up of subjects in the study.", [["the study", "TEST", 73, 82]]], ["The information then inspires the daily mood broadcasts and the topics of the daily online themed chat.", [["the daily mood broadcasts", "TREATMENT", 30, 55]]], ["The after-work support team also provides assistance to medical team members based on the needs reflected in the psychometer module (blue lines in figure 2 ).", [["the psychometer module (blue lines", "TREATMENT", 109, 143]]], ["Details of each module are described below.PsychometerIn the psychometer module, we created an online, anonymously completed daily mood questionnaire, which includes an age-and-gender form, a Subjective Units of Feeling (SUF) scale and a Gain-and-Issue scale.", [["a Gain", "TEST", 236, 242]]], ["The scale was adapted from the subjective units of distress scale (Wolf, 1969) which changes the distress rating to a positive emotional rating.", [["distress scale", "PROBLEM", 51, 65], ["the distress rating", "PROBLEM", 93, 112]]], ["The Gain-and-Issue scale consists of two semi-open-ended questions that ask for answers to the question, 'What was your biggest gain today?'; 'What is the challenge you are experiencing today?'.", [["The Gain", "TEST", 0, 8]]], ["The results were used to capture individual impressions of gains and challenging issues.", [["challenging issues", "PROBLEM", 69, 87]]], ["The entire questionnaire was made into a web page that could be accessed via smartphone, and a QR code link was sent to the medical team's online General Psychiatry themed chat group daily.", [["QR", "PROTEIN", 95, 97], ["a QR code link", "TEST", 93, 107]]], ["The information collected in this questionnaire was summarised daily and used as valuable reference information for other intervention modules.", [["other intervention modules", "TREATMENT", 116, 142]]], ["At the same time, these data are one of the primary sources for later data analysis.PsychometerPositive self-affirmation training (in the form of a daily mood broadcast) Based on the level of positive emotions and positive self-reporting provided by the psychometer module, we composed a daily mood broadcast to report the mood index and convey positive feedback.", [["later data analysis", "TEST", 64, 83], ["PsychometerPositive self-affirmation training", "TREATMENT", 84, 129], ["a daily mood broadcast", "TREATMENT", 146, 168]]], ["In this way, we reinforced the selfaffirmation of the entire staff.PsychometerPeer-group psychological support, and education (in the form of a daily online themed chat) We conducted a daily 1 hour online themed chat group to invite people to share their experiences and thoughts.", [["people", "ORGANISM", 233, 239], ["people", "SPECIES", 233, 239], ["PsychometerPeer-group psychological support", "TREATMENT", 67, 110]]], ["The chat topics covered mood regulation, cognitive restructuring, problem-solving, pleasurable activities, relaxation meditation and positive mindfulness exercises (see online supplementary table 1 for specific daily chat topics).", [["mood regulation", "TREATMENT", 24, 39], ["cognitive restructuring", "PROBLEM", 41, 64], ["relaxation meditation", "TREATMENT", 107, 128], ["positive mindfulness exercises", "TREATMENT", 133, 163]]], ["Participants attended experiential learning from each other, tried to understand difficult emotions at work and shared solutions.After-work support teamAs an essential part of the psychological intervention programme, the after-work support team provided targeted materials based on the issues collected by the psychometer module and organised after-work activities, such as sports, cooking and photography.", [["Participants", "SPECIES", 0, 12], ["targeted materials", "TREATMENT", 255, 273], ["photography", "TEST", 395, 406]]], ["These efforts promoted relaxation and social supports among the medical team members.Follow-up investigationWe conducted a follow-up study of the effectiveness of our psychological health support programme after the medical team had finished their work assignment within 1 week after leaving Wuhan.", [["a follow-up study", "TEST", 121, 138]]], ["The subjective unit of feeling questionnaires asked the following information: (1) level of attention to the daily mood broadcast (0-10 scale; 0: never attention, 10: special attention); (2) subjective effectiveness rating of the Balint group (0-10 scale; 0: no effect, 10: a very significant effect), and (3) the most impressive topics in the daily online themed chat.Data analysesThe data collected in this study came partly from the follow-up study and partly from the psychometer data collected during the implementation of the psychological health support programme.", [["the daily mood broadcast", "TREATMENT", 105, 129], ["Data analyses", "TEST", 369, 382], ["The data", "TEST", 382, 390], ["this study", "TEST", 404, 414], ["the follow-up study", "TEST", 432, 451], ["the psychometer data", "TEST", 468, 488]]], ["We also calculated the percentage of 'impressive' topics in the daily online chat activity, that is, the number of individuals who were impressed with the daily topic divided by the sample size.", [["size", "OBSERVATION_MODIFIER", 189, 193]]], ["Through these analyses, we preliminarily examined the subjective effects of the intervention programme on the medical team members.Data analysesThe psychometer data collected during the implementation of the intervention programme included data from the Emotional SUF and the Gain-and-Issue scale.", [["these analyses", "TEST", 8, 22], ["Data analyses", "TEST", 131, 144], ["the intervention programme", "TREATMENT", 204, 230], ["the Gain", "TEST", 272, 280]]], ["Due to the intensive nature of emergency medical work, there were a few dates when these data could not be collected.", [["these data", "TEST", 83, 93]]], ["In data analysis, therefore, we ignored these missing values.", [["data analysis", "TEST", 3, 16]]], ["At the same time, we also obtained the total number of patients under the responsibility of the daily medical team and the number of cases in critical condition.Data analysesTo further investigate the effectiveness of the intervention programme, a stepwise regression analysis was used to examine how the DMI was affected by the total number of patients, the number of critical cases, the number of gains and the number of issues.", [["patients", "ORGANISM", 55, 63], ["DMI", "SIMPLE_CHEMICAL", 305, 308], ["patients", "ORGANISM", 345, 353], ["patients", "SPECIES", 55, 63], ["patients", "SPECIES", 345, 353], ["Data analyses", "TEST", 161, 174], ["the intervention programme", "TREATMENT", 218, 244], ["a stepwise regression analysis", "TEST", 246, 276]]], ["Further, we examined how the three different aspects of gains and issues affected the DMI.", [["DMI", "SIMPLE_CHEMICAL", 86, 89], ["the DMI", "PROBLEM", 82, 89]]], ["Since the main thrust of the intervention programme is positive self-feedback and regulation, testing the effect of the number of reports of gains and issues on the DMI would reflect the effectiveness of the intervention programme.Effects of group support and psychological educationOne hundred and twenty-four members of the medical team responded to the follow-up investigation, including 41 doctors, 79 nurses and 4 administrative staff.", [["DMI", "SIMPLE_CHEMICAL", 165, 168], ["the DMI", "PROBLEM", 161, 168], ["the intervention programme", "TREATMENT", 204, 230], ["group support", "TREATMENT", 242, 255], ["psychological education", "TREATMENT", 260, 283], ["main", "OBSERVATION_MODIFIER", 10, 14], ["thrust", "OBSERVATION_MODIFIER", 15, 21]]], ["There was also no significant difference between the General Psychiatry sex ratio of the sample and the entire medical team (see table 1 ).Effects of group support and psychological educationAccording to the survey, 99.2% of the participants followed the daily mood broadcast, 52.4% participated in daily themed chats and 27.4% participated in the Balint group.", [["participants", "SPECIES", 229, 241], ["group support", "TREATMENT", 150, 163], ["no", "UNCERTAINTY", 15, 17], ["significant", "OBSERVATION_MODIFIER", 18, 29], ["difference", "OBSERVATION_MODIFIER", 30, 40]]], ["Respondents rated this using an evaluation scale of 1-10.", [["an evaluation scale", "TEST", 29, 48]]], ["The distribution shows a significant leftward bias, with a median of 8, indicating that the daily mood broadcast received widespread attention from the medical staff.", [["a significant leftward bias", "PROBLEM", 23, 50], ["significant", "OBSERVATION_MODIFIER", 25, 36], ["leftward", "OBSERVATION_MODIFIER", 37, 45], ["bias", "OBSERVATION", 46, 50]]], ["Figure 3B shows the distribution of the evaluation scores of respondents who had participated in the Balint group.", [["the evaluation", "TEST", 36, 50], ["distribution", "OBSERVATION_MODIFIER", 20, 32]]], ["Similar to figure 3A , the distribution also showed a significant leftward bias, with a median of 9.", [["a significant leftward bias", "PROBLEM", 52, 79], ["significant", "OBSERVATION_MODIFIER", 54, 65], ["leftward bias", "OBSERVATION", 66, 79]]], ["The highest impression rate was 43.1%, the lowest 4.6% and the median 21.5%, suggesting that daily themed chat activities have some influence on medical team members.", [["The highest impression rate", "TEST", 0, 27]]], ["The above data show that several essential components of our programme received the attention and made the medical team members feel positive.DMI and its impacting factorsThe number of people who filled out a daily SUF scale while working at Leishenshan Hospital ranged from 3 to 48, depending on the days, with a median of 16.", [["DMI", "CHEMICAL", 142, 145], ["DMI", "SIMPLE_CHEMICAL", 142, 145], ["people", "ORGANISM", 185, 191], ["people", "SPECIES", 185, 191], ["The above data", "TEST", 0, 14], ["DMI", "PROBLEM", 142, 145], ["its impacting factors", "PROBLEM", 150, 171], ["a daily SUF scale", "TREATMENT", 207, 224], ["several", "OBSERVATION_MODIFIER", 25, 32], ["essential", "OBSERVATION_MODIFIER", 33, 42], ["components", "OBSERVATION_MODIFIER", 43, 53]]], ["Some data were missing (eg, [14] [15] [20] [21] [22] [24] [25] because of interruptions, such as the only psychiatrist had to deal with emergency of the patients or the medical team being busy with other things.", [["[14] [15] [20] [21] [22", "SIMPLE_CHEMICAL", 28, 51], ["patients", "ORGANISM", 153, 161], ["patients", "SPECIES", 153, 161], ["Some data", "TEST", 0, 9]]], ["Figure 4A General Psychiatry patients, including those in critical condition, were transferred to the wards, which broke the hope of going home for the team members ( figure 4B ).", [["patients", "ORGANISM", 29, 37], ["patients", "SPECIES", 29, 37]]], ["These changes in the DMI, which are strongly associated with external events, suggest that the DMI can sensitively portray mood states of the medical team.", [["DMI", "CHEMICAL", 95, 98], ["DMI", "SIMPLE_CHEMICAL", 21, 24], ["DMI", "SIMPLE_CHEMICAL", 95, 98], ["These changes in the DMI", "PROBLEM", 0, 24], ["external events", "PROBLEM", 61, 76], ["the DMI", "PROBLEM", 91, 98], ["DMI", "OBSERVATION", 21, 24]]], ["The DMI remained high (>8) most of the time compared with its initial level and the lowest point (30 March) and showed a gradual upward trend over time between 21 February and 13 March.", [["DMI", "SIMPLE_CHEMICAL", 4, 7], ["The DMI", "TEST", 0, 7], ["a gradual upward trend", "PROBLEM", 119, 141], ["high", "OBSERVATION", 17, 21], ["gradual", "OBSERVATION_MODIFIER", 121, 128], ["upward", "OBSERVATION_MODIFIER", 129, 135], ["trend", "OBSERVATION_MODIFIER", 136, 141]]], ["After experiencing a valley with a sudden spike in the number of patients, the DMI quickly returned to higher levels.", [["patients", "ORGANISM", 65, 73], ["DMI", "SIMPLE_CHEMICAL", 79, 82], ["patients", "SPECIES", 65, 73], ["a sudden spike", "PROBLEM", 33, 47], ["the DMI", "PROBLEM", 75, 82], ["spike", "OBSERVATION_MODIFIER", 42, 47]]], ["Perceiving gains and building positive attitudes are essential goals of our intervention programme.", [["our intervention programme", "TREATMENT", 72, 98]]], ["As shown in figure 4C , the average number of gains reported by medical team members increased rapidly from a starting point of 0.75 to 1.0 and subsequently above 1.0 with the implementation of the intervention programme, which means the members participating in the psychometer reported more than one gain per day on average.", [["the intervention programme", "TREATMENT", 194, 220], ["average", "OBSERVATION_MODIFIER", 28, 35], ["number", "OBSERVATION_MODIFIER", 36, 42]]], ["Conversely, the average number of issues reported fell rapidly from about 1.0 at the starting point to around 0.5.", [["average", "OBSERVATION_MODIFIER", 16, 23], ["number", "OBSERVATION_MODIFIER", 24, 30]]], ["Despite an increase between 6 March and 13 March, the ratio of issues to the number of gains remained mostly in a range of 0.25-0.75, after 25 February.", [["increase", "OBSERVATION_MODIFIER", 11, 19]]], ["This fact suggests that the intervention programme may help to increase awareness of the gains and to promote positive attitudes.DMI and its impacting factorsWe further classified three aspects of work, life and physiological factors according to the specific content of medical team members' reporting.", [["DMI", "CHEMICAL", 129, 132], ["DMI", "SIMPLE_CHEMICAL", 129, 132], ["the intervention programme", "TREATMENT", 24, 50], ["DMI", "PROBLEM", 129, 132], ["its impacting factors", "PROBLEM", 137, 158]]], ["The amount of reports on issues regarding work slightly decreased over time, while the amount of gains regarding life showed an upward trend.DMI and its impacting factorsWe used stepwise regression analysis to examine how the daily average of gains/issues, the number of patients and the number of severe cases affected the DMI.", [["DMI", "CHEMICAL", 141, 144], ["DMI", "SIMPLE_CHEMICAL", 141, 144], ["patients", "ORGANISM", 271, 279], ["DMI", "SIMPLE_CHEMICAL", 324, 327], ["patients", "SPECIES", 271, 279], ["an upward trend", "PROBLEM", 125, 140], ["DMI", "PROBLEM", 141, 144], ["its impacting factors", "PROBLEM", 149, 170], ["stepwise regression analysis", "TEST", 178, 206], ["the DMI", "PROBLEM", 320, 327], ["amount", "OBSERVATION_MODIFIER", 4, 10]]], ["Model 1 used the total number of patients, the number of severe cases, the daily average of gains and the daily average of issues as regressors to predict the variation of DMI.", [["DMI", "CHEMICAL", 172, 175], ["patients", "ORGANISM", 33, 41], ["DMI", "SIMPLE_CHEMICAL", 172, 175], ["patients", "SPECIES", 33, 41], ["severe cases", "PROBLEM", 57, 69], ["DMI", "PROBLEM", 172, 175], ["severe", "OBSERVATION_MODIFIER", 57, 63]]], ["Model 2 further broke down the gains and issues into three types, namely the total number of patients and the number of severe cases, gain-work, gain-life, gain-physiology, issuework, issue-life, issue-physiology were used as regressors to predict the variation of DMI.", [["DMI", "CHEMICAL", 265, 268], ["patients", "ORGANISM", 93, 101], ["DMI", "SIMPLE_CHEMICAL", 265, 268], ["patients", "SPECIES", 93, 101], ["DMI", "PROBLEM", 265, 268]]], ["The initial diagnosis of both models suggested that the data on 19 March andGeneral Psychiatry30 March affected the normality of the residuals, so they were eliminated.", [["the data", "TEST", 52, 60]]], ["The model showed that both the number of severe cases and the daily average of gains significantly explained the variation in DMI.", [["DMI", "CHEMICAL", 126, 129], ["DMI", "SIMPLE_CHEMICAL", 126, 129], ["severe cases", "PROBLEM", 41, 53], ["DMI", "PROBLEM", 126, 129], ["severe", "OBSERVATION_MODIFIER", 41, 47]]], ["The total number of patients and the daily average of issues did not reach significance.", [["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28], ["total", "OBSERVATION_MODIFIER", 4, 9], ["number", "OBSERVATION_MODIFIER", 10, 16]]], ["Model 2 also significantly explained the variance of DMI.", [["DMI", "CHEMICAL", 53, 56], ["DMI", "SIMPLE_CHEMICAL", 53, 56], ["DMI", "PROBLEM", 53, 56]]], ["The model showed that both the number of severe cases and the gain-life significantly explained the variation in DMI.", [["DMI", "SIMPLE_CHEMICAL", 113, 116], ["severe cases", "PROBLEM", 41, 53], ["DMI", "PROBLEM", 113, 116], ["severe", "OBSERVATION_MODIFIER", 41, 47]]], ["The total number of patients, gain-work, gain-physiology, issue-work, issue-life and issue-physiology did not show significant effects.General PsychiatryThe above results indicate that in addition to the significant impact of the number of severe cases on the DMI, the subjective gains reported by the medical team members, especially the daily average of life-related subjective gains, can also significantly explain the variation in DMI.", [["patients", "ORGANISM", 20, 28], ["DMI", "SIMPLE_CHEMICAL", 260, 263], ["DMI", "SIMPLE_CHEMICAL", 435, 438], ["patients", "SPECIES", 20, 28], ["the DMI", "PROBLEM", 256, 263], ["DMI", "PROBLEM", 435, 438], ["total", "OBSERVATION_MODIFIER", 4, 9], ["number", "OBSERVATION_MODIFIER", 10, 16], ["significant", "OBSERVATION_MODIFIER", 204, 215], ["severe", "OBSERVATION_MODIFIER", 240, 246], ["cases", "OBSERVATION", 247, 252]]], ["Therefore, our programme may improve DMI by improving the subjective sense of gain.Main findingsThe main finding of our study was that the entire medical team maintained an overall positive outlook with a DMI mainly between 7 and 9 out of 10 for nearly 6 weeks of continuous working.", [["DMI", "SIMPLE_CHEMICAL", 37, 40], ["DMI", "SIMPLE_CHEMICAL", 205, 208], ["DMI", "PROBLEM", 37, 40], ["our study", "TEST", 116, 125], ["a DMI", "PROBLEM", 203, 208], ["main", "OBSERVATION_MODIFIER", 100, 104], ["positive outlook", "OBSERVATION", 181, 197]]], ["The number of severe cases had a significant effect on the DMI of the medical team.", [["severe", "OBSERVATION_MODIFIER", 14, 20]]], ["Further analysis of the reported gains showed a significant effect of life-related gains on DMI.", [["DMI", "CHEMICAL", 92, 95], ["DMI", "SIMPLE_CHEMICAL", 92, 95], ["Further analysis", "TEST", 0, 16], ["DMI", "PROBLEM", 92, 95], ["significant", "OBSERVATION_MODIFIER", 48, 59]]], ["Since the primary feature of this psychological support programme was to promote self-strengths and positive self-affirmation, these findings support the effectiveness of this psychological support programme.", [["this psychological support programme", "TREATMENT", 171, 207]]], ["Meanwhile, the follow-up investigations also revealed that the modules of the programme, such as positive self-affirmation training (daily broadcast), peer psychological support and education (daily themed chat) and the Balint group, received high levels of attention and evaluation from staff, supporting the effectiveness of this programme.Main findingsA highlight of our psychological health support programme is that it reconciles the mental health needs of medical team members in extreme settings with the minimal resources available for mental health support.", [["the follow-up investigations", "TEST", 11, 39], ["peer psychological support", "TREATMENT", 151, 177], ["evaluation", "TEST", 272, 282], ["this programme", "TREATMENT", 327, 341], ["mental health support", "TREATMENT", 544, 565]]], ["Research has shown that exposure to a working environment where patients' conditions changed rapidly, were severe, urgent or even fatal could increase occupational exhaustion and trigger psychological trauma, thus adversely affecting the emotion and behaviour of healthcare workers.", [["trauma", "DISEASE", 201, 207], ["patients", "ORGANISM", 64, 72], ["patients", "SPECIES", 64, 72], ["psychological trauma", "PROBLEM", 187, 207]]], ["21 Furthermore, emotional burden, excessive workload and frustrations due to lack of control are potential risks for stress and burn-out.", [["emotional burden", "PROBLEM", 16, 32], ["excessive workload and frustrations", "PROBLEM", 34, 69], ["lack of control", "PROBLEM", 77, 92], ["stress and burn", "PROBLEM", 117, 132]]], ["22 Additionally, being away from home, inability to connect with family and lack of family support due to work are also significant risk factors for occupational exhaustion in healthcare workers.", [["family support", "TREATMENT", 84, 98]]], ["21 23 Given that these risk factors coincided together with medical teams in the midst of a disaster (the COVID-19 pandemic), it was necessary to apply a psychological support programme.Main findingsIndeed, as shown in this study, the DMI of medical team members was adversely impacted when the workload increased, as reflected in the number of severe cases.", [["DMI", "SIMPLE_CHEMICAL", 235, 238], ["a psychological support programme", "TREATMENT", 152, 185], ["this study", "TEST", 219, 229]]], ["On the other hand, positive events especially positive life experiences could enhance the DMI of medical team members.", [["positive events", "PROBLEM", 19, 34]]], ["Therefore, in the midst of major disasters, it is necessary and crucial to maintain the mental state of front-line healthcare workers to ensure their adequate working status and health, despite minimal resources for mental health support.", [["mental health support", "TREATMENT", 216, 237]]], ["24 The psychological support programme presented here is an effective and promising solution.Main findingsThe core ideas of this programme are resource-based learning, peer support and positive self-affirmation training.", [["peer support", "TREATMENT", 168, 180]]], ["The daily mood broadcasts, online themed chat groups and Balint group activities in the programme were all designed around these aims.", [["The daily mood broadcasts", "TREATMENT", 0, 25]]], ["Studies have shown that positive self-affirmation promotes healthy behaviours, better academic performance and more prosocial behaviours, [25] [26] [27] as well as improving psychological and physical well-being.", [["Studies", "TEST", 0, 7]]], ["28 Self-affirmation acts as a defence mechanism to help mobilise the individual's internal resources and enhance psychological openness and flexibility when facing external threatening events.", [["external threatening events", "PROBLEM", 164, 191]]], ["25 30 31 Research on healthcare workers has also found a significant relationship between self-efficacy and burn-out.", [["burn", "DISEASE", 108, 112]]], ["They were more likely to mobilise new resources when faced with difficulties and obstacles, such as seeking help from colleagues and supervisors.", [["more likely", "UNCERTAINTY", 10, 21]]], ["They were also more motivated, persistent and engaged in their work.", [["persistent", "OBSERVATION_MODIFIER", 31, 41]]], ["[33] [34] [35] [36] Social support is another powerful buffer against the adverse effects of emergency stressors and traumatic events, with better social support preventing and reducing the incidence and severity of post-traumatic stress disorder.", [["post-traumatic stress disorder", "DISEASE", 216, 246], ["traumatic events", "PROBLEM", 117, 133], ["post-traumatic stress disorder", "PROBLEM", 216, 246], ["post-traumatic stress disorder", "OBSERVATION", 216, 246]]], ["37 Moreover, both self-efficacy and social support play an essential role in reducing and ameliorating the adverse effects of traumatic events.", [["social support", "TREATMENT", 36, 50], ["traumatic events", "PROBLEM", 126, 142]]], ["38 The above arguments explain the effectiveness of the core ideas in this psychological health programme.Main findingsPrevious studies on psychological interventions for medical workers have mainly focused on long-term programmes to reduce burn-out.", [["burn", "DISEASE", 241, 245], ["Previous studies", "TEST", 119, 135], ["psychological interventions", "TREATMENT", 139, 166], ["long-term programmes", "TREATMENT", 210, 230]]], ["13 39 40 While a study has reported psychological intervention efforts, such as educational lectures and face-to-face psychotherapies for medical staff treating patients infected with severe acute respiratory syndrome, 41 the literature on psychological General Psychiatry intervention programmes for medical staff under highrisk continuous emergency work is sparse.", [["acute respiratory syndrome", "DISEASE", 191, 217], ["patients", "ORGANISM", 161, 169], ["patients", "SPECIES", 161, 169], ["a study", "TEST", 15, 22], ["psychological intervention efforts", "TREATMENT", 36, 70], ["severe acute respiratory syndrome", "PROBLEM", 184, 217], ["psychological General Psychiatry intervention programmes", "TREATMENT", 240, 296], ["severe", "OBSERVATION_MODIFIER", 184, 190], ["acute", "OBSERVATION_MODIFIER", 191, 196], ["respiratory syndrome", "OBSERVATION", 197, 217]]], ["In recent qualitative research, Jonker et al proposed a framework for psychological trauma management in high-risk occupations that highlights three levels of interventions for acute stress.", [["trauma", "DISEASE", 84, 90], ["psychological trauma management", "TREATMENT", 70, 101], ["interventions", "TREATMENT", 159, 172], ["acute stress", "PROBLEM", 177, 189]]], ["42 The primary interventions are a job-related resource, management support and immediate needs; the secondary intervention is psychoeducation and a team-based approach; and the tertiary interventions are onsite psychological support, psychological assessment and connection with social support.", [["management support", "TREATMENT", 57, 75], ["the tertiary interventions", "TREATMENT", 174, 200], ["psychological support", "TREATMENT", 212, 233], ["psychological assessment", "TEST", 235, 259], ["social support", "TREATMENT", 280, 294]]], ["The five modules in our psychological health support programme fit this framework.", [["five", "OBSERVATION_MODIFIER", 4, 8], ["modules", "OBSERVATION_MODIFIER", 9, 16]]], ["The support team tried to satisfy the needs of staff from food to life events (primary intervention), the Balint group and daily chat group provided psychoeducation and team-based psychological social support (secondary intervention), the daily broadcast promoted positive self-affirmation (secondary intervention) and the psychometer collected data on daily mood and needs of team members (tertiary intervention).", [["secondary intervention", "TREATMENT", 210, 232], ["secondary intervention", "TREATMENT", 291, 313], ["tertiary intervention", "TREATMENT", 391, 412]]], ["Therefore, our programme provided comprehensive coverage for the various aspects of preventing psychological issues.LimitationsConsidering the high working pressure of medical team members in Wuhan, we were worried that filling in standardised scales for evaluation of emotions and other conditions would increase their burden, which led to the lack of standardised scales for evaluation of intervention efficacy in this study.", [["comprehensive coverage", "TREATMENT", 34, 56], ["psychological issues", "PROBLEM", 95, 115], ["standardised scales", "TEST", 231, 250], ["evaluation", "TEST", 255, 265], ["emotions and other conditions", "PROBLEM", 269, 298], ["evaluation", "TEST", 377, 387], ["intervention efficacy", "TREATMENT", 391, 412], ["this study", "TEST", 416, 426]]], ["In addition this research lacks a control group to further demonstrate the effectiveness of interventions.ImplicationsAs the number of victims of global disasters continues to increase, the damage caused by disasters to humans will also increase.", [["humans", "ORGANISM", 220, 226], ["humans", "SPECIES", 220, 226], ["humans", "SPECIES", 220, 226], ["interventions", "TREATMENT", 92, 105], ["global disasters", "PROBLEM", 146, 162], ["the damage", "PROBLEM", 186, 196]]], ["The psychological support programme we designed in the practice of maintaining the mental health of medical staff can be used as part of the disaster prevention strategy.", [["the disaster prevention strategy", "TREATMENT", 137, 169]]]], "a105ffe0b3b61fb3a87bc85e3acf043af7e0163a": [["The exact relationship between the occurrence of arterial thrombotic events and SARS-CoV-2, 13 remains unclear.", [["arterial", "ANATOMY", 49, 57], ["arterial thrombotic", "DISEASE", 49, 68], ["SARS", "DISEASE", 80, 84], ["arterial", "MULTI-TISSUE_STRUCTURE", 49, 57], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 80, 90], ["arterial thrombotic events", "PROBLEM", 49, 75], ["SARS", "PROBLEM", 80, 84], ["CoV", "TEST", 85, 88], ["arterial", "ANATOMY", 49, 57], ["thrombotic", "OBSERVATION", 58, 68]]], ["We therefore set out to identify and characterize patients in the early stage of 14 the epidemic with arterial thromboembolic disease and its relationship to SARS-CoV-2 infection 15 at our institution.", [["arterial", "ANATOMY", 102, 110], ["arterial thromboembolic disease", "DISEASE", 102, 133], ["SARS-CoV-2 infection", "DISEASE", 158, 178], ["patients", "ORGANISM", 50, 58], ["arterial", "MULTI-TISSUE_STRUCTURE", 102, 110], ["CoV-2", "ORGANISM", 163, 168], ["patients", "SPECIES", 50, 58], ["SARS-CoV", "SPECIES", 158, 166], ["arterial thromboembolic disease", "PROBLEM", 102, 133], ["SARS", "PROBLEM", 158, 162], ["CoV-2 infection", "PROBLEM", 163, 178], ["arterial", "ANATOMY", 102, 110], ["thromboembolic disease", "OBSERVATION", 111, 133]]], ["7 imaging studies performed during the study period were reviewed.", [["7 imaging studies", "TEST", 0, 17], ["the study", "TEST", 35, 44]]], ["These studies included 1 computed tomography angiography (CTA), magnetic resonance angiography (MRA), and/or 2 arterial duplex.", [["arterial", "ANATOMY", 111, 119], ["These studies", "TEST", 0, 13], ["1 computed tomography angiography", "TEST", 23, 56], ["CTA", "TEST", 58, 61], ["magnetic resonance angiography", "TEST", 64, 94], ["MRA", "TEST", 96, 99], ["2 arterial duplex", "TEST", 109, 126]]], ["The choice of imaging modality (CTA, MRA or arterial duplex) was obtained at 3 the provider's discretion and was based on the presenting clinical complaints.", [["arterial duplex", "ANATOMY", 44, 59], ["arterial duplex", "MULTI-TISSUE_STRUCTURE", 44, 59], ["imaging modality", "TEST", 14, 30], ["CTA", "TEST", 32, 35], ["MRA", "TEST", 37, 40], ["arterial duplex)", "TEST", 44, 60]]], ["For patients 4 requiring duplex testing, the majority of these studies were conducted as portable bedside tests.5Patients presenting with neurologic events underwent MRA in addition to carotid duplex 6 evaluation as part of the stroke protocol.", [["neurologic", "ANATOMY", 138, 148], ["carotid", "ANATOMY", 185, 192], ["stroke", "DISEASE", 228, 234], ["patients", "ORGANISM", 4, 12], ["Patients", "ORGANISM", 113, 121], ["patients", "SPECIES", 4, 12], ["Patients", "SPECIES", 113, 121], ["duplex testing", "TEST", 25, 39], ["these studies", "TEST", 57, 70], ["portable bedside tests", "TEST", 89, 111], ["neurologic events", "PROBLEM", 138, 155], ["MRA", "TEST", 166, 169], ["carotid duplex 6 evaluation", "TEST", 185, 212], ["the stroke protocol", "TEST", 224, 243], ["carotid", "ANATOMY", 185, 192]]], ["SARS-CoV-2 status was obtained from the medical record.", [["SARS", "DISEASE", 0, 4]]], ["Patients were tested for SARS-CoV-9 2 based on clinical suspicion and in those requiring surgical treatment as part of their pre-10 procedural evaluation.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["SARS", "TEST", 25, 29], ["CoV", "TEST", 30, 33], ["surgical treatment", "TREATMENT", 89, 107], ["their pre-10 procedural evaluation", "TEST", 119, 153]]], ["Nasopharyngeal swab specimens were tested for SARS-CoV-2 by in-11 house polymerase chain reaction (PCR) testing.", [["Nasopharyngeal swab specimens", "ANATOMY", 0, 29], ["Nasopharyngeal swab specimens", "CANCER", 0, 29], ["SARS-CoV", "SPECIES", 46, 54], ["Nasopharyngeal swab specimens", "TEST", 0, 29], ["SARS", "TEST", 46, 50], ["CoV", "TEST", 51, 54], ["PCR) testing", "TEST", 99, 111]]], ["Confirmatory repeat testing was obtained in 12 patients with high clinical suspicion for COVID-19 and negative initial testing.", [["patients", "ORGANISM", 47, 55], ["patients", "SPECIES", 47, 55], ["Confirmatory repeat testing", "TEST", 0, 27], ["COVID", "TEST", 89, 94], ["initial testing", "TEST", 111, 126]]], ["Patients were 13 excluded if SARS-CoV-2 test results were pending at the time of data abstraction.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["SARS", "PROBLEM", 29, 33], ["CoV-2 test", "TEST", 34, 44]]], ["Patients were 14 divided into one of three groups: SARS-CoV-2 positive, SARS-CoV-2 negative, and patients not 15 tested.", [["Patients", "ORGANISM", 0, 8], ["SARS-CoV-2", "ORGANISM", 51, 61], ["patients", "ORGANISM", 97, 105], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 97, 105], ["SARS", "TEST", 51, 55], ["CoV", "TEST", 56, 59], ["SARS", "TEST", 72, 76], ["CoV", "TEST", 77, 80]]], ["The SARS-CoV-2 positive group included patients with a range of COVID-19 16 symptomatology (mild to severe) as well as those tested as part of routine preoperative 17 preparation.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 4, 14], ["patients", "ORGANISM", 39, 47], ["patients", "SPECIES", 39, 47], ["The SARS", "TEST", 0, 8], ["CoV", "TEST", 9, 12], ["COVID", "TEST", 64, 69], ["mild to severe)", "PROBLEM", 92, 107], ["routine preoperative 17 preparation", "TREATMENT", 143, 178], ["mild", "OBSERVATION_MODIFIER", 92, 96]]], ["The SARS-CoV-2 negative group included patients who presented with respiratory 18 symptoms or other influenza-like illness symptoms and who were found to have a negative PCR 19 result.", [["influenza-like illness symptoms", "DISEASE", 100, 131], ["CoV-2", "ORGANISM", 9, 14], ["patients", "ORGANISM", 39, 47], ["patients", "SPECIES", 39, 47], ["The SARS", "TEST", 0, 8], ["CoV", "TEST", 9, 12], ["respiratory 18 symptoms", "PROBLEM", 67, 90], ["other influenza-like illness symptoms", "PROBLEM", 94, 131], ["PCR", "TEST", 170, 173], ["respiratory", "ANATOMY", 67, 78]]], ["Patients admitted for other reasons and without suspicion for COVID-19 were not tested 20 and categorized as such.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["COVID", "TEST", 62, 67]]], ["Of the 25 patients who are SARS-CoV-2 negative or not tested 5 were 21 negative, 19 were not tested (admitted for unrelated reasons) and 1 patient was under Patients with imaging that confirmed acute thrombosis were further evaluated.", [["thrombosis", "DISEASE", 200, 210], ["patients", "ORGANISM", 10, 18], ["patient", "ORGANISM", 139, 146], ["Patients", "ORGANISM", 157, 165], ["patients", "SPECIES", 10, 18], ["patient", "SPECIES", 139, 146], ["Patients", "SPECIES", 157, 165], ["SARS-CoV", "TEST", 27, 35], ["imaging", "TEST", 171, 178], ["acute thrombosis", "PROBLEM", 194, 210], ["acute", "OBSERVATION_MODIFIER", 194, 199], ["thrombosis", "OBSERVATION", 200, 210]]], ["SARS-CoV-2 2 positive patients were compared to the combined SARS-CoV-2 negative and not tested groups.3Retrospective chart review abstracted demographic variables including age, race, body mass 4 index (BMI), gender, ethnicity, medical comorbidities and treatment for further evaluation.", [["body", "ANATOMY", 185, 189], ["SARS", "DISEASE", 0, 4], ["SARS", "DISEASE", 61, 65], ["SARS-CoV-2 2", "GENE_OR_GENE_PRODUCT", 0, 12], ["patients", "ORGANISM", 22, 30], ["body", "ORGANISM_SUBDIVISION", 185, 189], ["patients", "SPECIES", 22, 30], ["SARS", "TEST", 0, 4], ["CoV", "TEST", 5, 8], ["the combined SARS", "TEST", 48, 65], ["CoV", "TEST", 66, 69], ["demographic variables", "TEST", 142, 163], ["body mass", "PROBLEM", 185, 194], ["medical comorbidities", "PROBLEM", 229, 250], ["treatment", "TREATMENT", 255, 264], ["further evaluation", "TEST", 269, 287]]], ["The 5 presence of metabolic syndrome was defined as patients with three or more of the following: 6 BMI greater than 30, serum triglyceride level 150 mg/dL or greater within the last 6 months, 7 serum high-density lipoprotein (HDL) level less than 40 mg/dL in men or 50 mg/dL in women 8 within the last 6 months, systolic blood pressure greater than 130 mmHg or diastolic blood 9 pressure greater than 85 mmHg, and fasting serum glucose greater than 100 mg/dL.", [["serum", "ANATOMY", 121, 126], ["serum", "ANATOMY", 195, 200], ["blood", "ANATOMY", 322, 327], ["blood", "ANATOMY", 372, 377], ["serum", "ANATOMY", 423, 428], ["metabolic syndrome", "DISEASE", 18, 36], ["triglyceride", "CHEMICAL", 127, 139], ["glucose", "CHEMICAL", 429, 436], ["triglyceride", "CHEMICAL", 127, 139], ["glucose", "CHEMICAL", 429, 436], ["patients", "ORGANISM", 52, 60], ["serum", "ORGANISM_SUBSTANCE", 121, 126], ["triglyceride", "SIMPLE_CHEMICAL", 127, 139], ["serum", "ORGANISM_SUBSTANCE", 195, 200], ["high-density lipoprotein", "SIMPLE_CHEMICAL", 201, 225], ["HDL", "SIMPLE_CHEMICAL", 227, 230], ["men", "ORGANISM", 260, 263], ["women", "ORGANISM", 279, 284], ["blood", "ORGANISM_SUBSTANCE", 322, 327], ["blood", "ORGANISM_SUBSTANCE", 372, 377], ["serum", "ORGANISM_SUBSTANCE", 423, 428], ["glucose", "SIMPLE_CHEMICAL", 429, 436], ["HDL", "PROTEIN", 227, 230], ["patients", "SPECIES", 52, 60], ["men", "SPECIES", 260, 263], ["women", "SPECIES", 279, 284], ["metabolic syndrome", "PROBLEM", 18, 36], ["BMI", "TEST", 100, 103], ["serum triglyceride level", "TEST", 121, 145], ["serum high-density lipoprotein", "TEST", 195, 225], ["HDL", "TEST", 227, 230], ["systolic blood pressure", "TEST", 313, 336], ["diastolic blood 9 pressure", "TEST", 362, 388], ["fasting serum glucose", "TEST", 415, 436], ["metabolic syndrome", "OBSERVATION", 18, 36]]], ["Additional Missing data was assumed to be missing at random and excluded from the analysis for that 2 variable.", [["the analysis", "TEST", 78, 90]]], ["The odds ratio for acute arterial thrombosis in COVID-19 was evaluated with a two-3 tailed Fisher's exact test.", [["arterial", "ANATOMY", 25, 33], ["acute arterial thrombosis", "DISEASE", 19, 44], ["arterial", "MULTI-TISSUE_STRUCTURE", 25, 33], ["The odds ratio", "TEST", 0, 14], ["acute arterial thrombosis", "PROBLEM", 19, 44], ["COVID", "TEST", 48, 53], ["Fisher's exact test", "TEST", 91, 110], ["acute", "OBSERVATION_MODIFIER", 19, 24], ["arterial", "ANATOMY", 25, 33], ["thrombosis", "OBSERVATION", 34, 44]]], ["This study was approved by the Institutional Review Board of 4 MMC/AECOM with a waiver of informed consent for this observational review (#2020-11452).", [["MMC", "CHEMICAL", 63, 66], ["MMC", "CHEMICAL", 63, 66], ["This study", "TEST", 0, 10], ["this observational review", "TEST", 111, 136]]], ["(Table I) .3Patients positive for SARS-CoV-2 had significantly higher D-dimer levels at the time of imaging 4 (217.3 vs.1.8, p=0.038) and average in-hospital D-dimer levels (8.5 vs. 2.0, p=0.043) than 5 SARS-CoV-2 negative or not tested patients (Table II) .", [["SARS-CoV-2", "ORGANISM", 34, 44], ["D-dimer", "GENE_OR_GENE_PRODUCT", 70, 77], ["D-dimer", "GENE_OR_GENE_PRODUCT", 158, 165], ["patients", "ORGANISM", 237, 245], ["D-dimer", "PROTEIN", 70, 77], ["patients", "SPECIES", 237, 245], ["SARS-CoV", "SPECIES", 34, 42], ["SARS", "PROBLEM", 34, 38], ["CoV", "TEST", 39, 42], ["significantly higher D-dimer levels", "PROBLEM", 49, 84], ["imaging", "TEST", 100, 107], ["vs", "TEST", 117, 119], ["p", "TEST", 125, 126], ["average in-hospital D-dimer levels", "TEST", 138, 172], ["p", "TEST", 187, 188], ["5 SARS", "TEST", 201, 207], ["CoV", "TEST", 208, 211]]], ["SARS-CoV-2 positive patients exhibited 6 a higher white blood cell count (WBC) despite lack of statistical significance (14.5 vs. 9.9, 7 p=0.208).", [["white blood cell", "ANATOMY", 50, 66], ["WBC", "ANATOMY", 74, 77], ["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "ORGANISM", 0, 10], ["patients", "ORGANISM", 20, 28], ["white blood cell", "CELL", 50, 66], ["patients", "SPECIES", 20, 28], ["SARS", "TEST", 0, 4], ["CoV", "TEST", 5, 8], ["a higher white blood cell count", "PROBLEM", 41, 72], ["WBC", "TEST", 74, 77]]], ["There were no significant differences in prothrombin time (PT), aPTT, platelet count, (Table III) .", [["platelet", "ANATOMY", 70, 78], ["prothrombin", "GENE_OR_GENE_PRODUCT", 41, 52], ["platelet", "CELL", 70, 78], ["prothrombin", "PROTEIN", 41, 52], ["aPTT", "PROTEIN", 64, 68], ["significant differences", "PROBLEM", 14, 37], ["prothrombin time", "TEST", 41, 57], ["PT", "TEST", 59, 61], ["aPTT", "TEST", 64, 68], ["platelet count", "TEST", 70, 84], ["no", "UNCERTAINTY", 11, 13], ["significant", "OBSERVATION_MODIFIER", 14, 25], ["differences", "OBSERVATION_MODIFIER", 26, 37]]], ["The SARS-CoV-2 positive patients were treated with a left ventricular assist device.", [["left ventricular", "ANATOMY", 53, 69], ["SARS-CoV-2", "ORGANISM", 4, 14], ["patients", "ORGANISM", 24, 32], ["ventricular", "MULTI-TISSUE_STRUCTURE", 58, 69], ["patients", "SPECIES", 24, 32], ["The SARS", "TEST", 0, 8], ["a left ventricular assist device", "TREATMENT", 51, 83], ["left ventricular", "ANATOMY", 53, 69], ["assist device", "OBSERVATION", 70, 83]]], ["Amputation was required in 3 of the patients in the SARS-CoV-2 1 negative or untested group.3There were significantly more SARS-CoV-2 positive patients with aortoiliac involvement 4 compared to the SARS-CoV-2 negative or not tested patients (33.3% vs. 4.0%, p=0.040).", [["aortoiliac", "ANATOMY", 157, 167], ["SARS", "DISEASE", 52, 56], ["SARS", "DISEASE", 198, 202], ["patients", "ORGANISM", 36, 44], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 123, 133], ["patients", "ORGANISM", 143, 151], ["patients", "ORGANISM", 232, 240], ["patients", "SPECIES", 36, 44], ["patients", "SPECIES", 143, 151], ["patients", "SPECIES", 232, 240], ["SARS-CoV", "SPECIES", 198, 206], ["Amputation", "TREATMENT", 0, 10], ["the SARS", "TEST", 48, 56], ["CoV", "TEST", 57, 60], ["significantly more SARS", "PROBLEM", 104, 127], ["CoV", "TEST", 128, 131], ["aortoiliac involvement 4", "PROBLEM", 157, 181], ["the SARS", "TEST", 194, 202], ["CoV", "TEST", 203, 206], ["p", "TEST", 258, 259], ["aortoiliac", "ANATOMY", 157, 167]]], ["There 5 was a trend towards less tibial/pedal (13.3% vs. 40.0%, p=0.154) and more upper 6 extremity(20.0% vs. 8.0%, p=0.537) involvement in the SARS-CoV-2 positive patients when 7 compared to SARS-CoV-2 negative or not tested patients .", [["tibial/pedal", "ANATOMY", 33, 45], ["extremity", "ANATOMY", 90, 99], ["SARS", "DISEASE", 144, 148], ["SARS", "DISEASE", 192, 196], ["patients", "ORGANISM", 164, 172], ["patients", "ORGANISM", 226, 234], ["patients", "SPECIES", 164, 172], ["patients", "SPECIES", 226, 234], ["SARS-CoV", "SPECIES", 144, 152], ["SARS-CoV", "SPECIES", 192, 200], ["pedal", "TEST", 40, 45], ["p", "TEST", 64, 65], ["p", "TEST", 116, 117], ["the SARS", "TEST", 140, 148], ["CoV", "TEST", 149, 152], ["SARS", "TEST", 192, 196], ["CoV", "TEST", 197, 200], ["tibial", "ANATOMY", 33, 39], ["pedal", "ANATOMY", 40, 45], ["upper", "ANATOMY_MODIFIER", 82, 87], ["extremity", "ANATOMY", 90, 99], ["SARS", "ANATOMY", 144, 148]]], ["Carotid and femoropopliteal 8 involvement was relatively equal between the two groups (Table III) .10The COVID-19 specific severity of disease on presentation was documented (Table IV) .", [["Carotid", "ANATOMY", 0, 7], ["Carotid", "MULTI-TISSUE_STRUCTURE", 0, 7], ["The COVID", "TEST", 101, 110], ["disease", "PROBLEM", 135, 142], ["femoropopliteal", "ANATOMY", 12, 27], ["disease", "OBSERVATION", 135, 142]]], ["Most of 11 the patients with arterial thrombosis had critically severe disease (60.0 %).", [["arterial", "ANATOMY", 29, 37], ["arterial thrombosis", "DISEASE", 29, 48], ["patients", "ORGANISM", 15, 23], ["arterial", "MULTI-TISSUE_STRUCTURE", 29, 37], ["patients", "SPECIES", 15, 23], ["arterial thrombosis", "PROBLEM", 29, 48], ["critically severe disease", "PROBLEM", 53, 78], ["arterial", "ANATOMY", 29, 37], ["thrombosis", "OBSERVATION", 38, 48], ["severe", "OBSERVATION_MODIFIER", 64, 70], ["disease", "OBSERVATION", 71, 78]]], ["Three patients (20.0% 12 ) were asymptomatic, and one each had mild, moderate and severe COVID-19 presentation 13 (6.7% each).", [["COVID", "DISEASE", 89, 94], ["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14], ["mild, moderate and severe COVID", "PROBLEM", 63, 94], ["mild", "OBSERVATION_MODIFIER", 63, 67], ["moderate", "OBSERVATION_MODIFIER", 69, 77], ["severe", "OBSERVATION_MODIFIER", 82, 88]]], ["There was no observed correlation between the severity of COVID-19 disease and 14 the degree of arterial thrombosis.", [["arterial", "ANATOMY", 96, 104], ["arterial thrombosis", "DISEASE", 96, 115], ["arterial", "MULTI-TISSUE_STRUCTURE", 96, 104], ["COVID-19 disease", "PROBLEM", 58, 74], ["arterial thrombosis", "PROBLEM", 96, 115], ["no observed", "UNCERTAINTY", 10, 21], ["arterial", "ANATOMY", 96, 104], ["thrombosis", "OBSERVATION", 105, 115]]], ["None of the patients in the study had bleeding complications.", [["bleeding", "DISEASE", 38, 46], ["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20], ["the study", "TEST", 24, 33], ["bleeding complications", "PROBLEM", 38, 60]]], ["15 30 day outcomes resulted in 6 deaths due to COVID 19 complications, 4 major amputations, 3 16 patients were discharged to skilled nursing facilities (SNF) and one to home. ranged from mild to severe in intensity.", [["deaths", "DISEASE", 33, 39], ["COVID", "DISEASE", 47, 52], ["patients", "ORGANISM", 97, 105], ["patients", "SPECIES", 97, 105], ["COVID 19 complications", "PROBLEM", 47, 69], ["4 major amputations", "TREATMENT", 71, 90], ["mild to severe in intensity", "PROBLEM", 187, 214], ["mild", "OBSERVATION_MODIFIER", 187, 191], ["severe", "OBSERVATION_MODIFIER", 195, 201], ["intensity", "OBSERVATION_MODIFIER", 205, 214]]], ["Patients with arterial thrombosis who were SARS-CoV-10 2 positive had significantly higher D-dimer levels, BMI, were younger, and less often on 11 antiplatelet medications as compared to patients who were SARS-CoV-2 negative or not tested.12In addition, we noticed that SARS-CoV-2 positive patients with arterial thromboembolic 13 complications exhibited a trend towards higher WBC count and neutrophil to lymphocyte ratio 14 which may indicate an increased inflammatory response.", [["arterial", "ANATOMY", 14, 22], ["arterial", "ANATOMY", 304, 312], ["WBC", "ANATOMY", 378, 381], ["neutrophil", "ANATOMY", 392, 402], ["lymphocyte", "ANATOMY", 406, 416], ["arterial thrombosis", "DISEASE", 14, 33], ["SARS", "DISEASE", 270, 274], ["arterial thromboembolic", "DISEASE", 304, 327], ["Patients", "ORGANISM", 0, 8], ["arterial", "MULTI-TISSUE_STRUCTURE", 14, 22], ["D-dimer", "GENE_OR_GENE_PRODUCT", 91, 98], ["patients", "ORGANISM", 187, 195], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 205, 215], ["12In", "SIMPLE_CHEMICAL", 239, 243], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 270, 280], ["patients", "ORGANISM", 290, 298], ["arterial", "MULTI-TISSUE_STRUCTURE", 304, 312], ["WBC", "CELL", 378, 381], ["neutrophil", "CELL", 392, 402], ["lymphocyte", "CELL", 406, 416], ["neutrophil", "CELL_TYPE", 392, 402], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 187, 195], ["patients", "SPECIES", 290, 298], ["arterial thrombosis", "PROBLEM", 14, 33], ["SARS", "TEST", 43, 47], ["CoV", "TEST", 48, 51], ["significantly higher D-dimer levels", "PROBLEM", 70, 105], ["BMI", "PROBLEM", 107, 110], ["11 antiplatelet medications", "TREATMENT", 144, 171], ["SARS", "TEST", 205, 209], ["CoV", "TEST", 210, 213], ["SARS", "TEST", 270, 274], ["CoV", "TEST", 275, 278], ["arterial thromboembolic 13 complications", "PROBLEM", 304, 344], ["higher WBC count", "TEST", 371, 387], ["neutrophil", "TEST", 392, 402], ["lymphocyte ratio", "TEST", 406, 422], ["an increased inflammatory response", "PROBLEM", 445, 479], ["arterial", "ANATOMY", 14, 22], ["thrombosis", "OBSERVATION", 23, 33], ["arterial", "ANATOMY", 304, 312], ["thromboembolic", "OBSERVATION", 313, 327], ["may indicate", "UNCERTAINTY", 432, 444], ["increased", "OBSERVATION_MODIFIER", 448, 457], ["inflammatory response", "OBSERVATION", 458, 479]]], ["Other markers of increased 15 inflammation such as CRP and CPK were also greater in the SARS-CoV-2 positive group when 16 compared to their negative counterparts, but these did not reach statistical significance.", [["inflammation", "DISEASE", 30, 42], ["SARS", "DISEASE", 88, 92], ["CRP", "GENE_OR_GENE_PRODUCT", 51, 54], ["CPK", "GENE_OR_GENE_PRODUCT", 59, 62], ["SARS-CoV-2", "ORGANISM", 88, 98], ["CRP", "PROTEIN", 51, 54], ["CPK", "PROTEIN", 59, 62], ["SARS-CoV", "SPECIES", 88, 96], ["Other markers", "TEST", 0, 13], ["increased 15 inflammation", "PROBLEM", 17, 42], ["CRP", "TEST", 51, 54], ["CPK", "TEST", 59, 62], ["the SARS", "TEST", 84, 92], ["CoV", "TEST", 93, 96], ["increased", "OBSERVATION_MODIFIER", 17, 26], ["15 inflammation", "OBSERVATION_MODIFIER", 27, 42], ["greater", "OBSERVATION_MODIFIER", 73, 80]]], ["All 17 patients with acute arterial ischemia are placed on a heparin drip upon diagnosis.19We did not observe a typical cardioembolic pattern in the SARS-CoV-2 positive group but rather 20 a picture that was more consistent with in situ thrombosis.", [["arterial", "ANATOMY", 27, 35], ["acute arterial ischemia", "DISEASE", 21, 44], ["heparin", "CHEMICAL", 61, 68], ["cardioembolic", "DISEASE", 120, 133], ["SARS", "DISEASE", 149, 153], ["thrombosis", "DISEASE", 237, 247], ["patients", "ORGANISM", 7, 15], ["arterial", "MULTI-TISSUE_STRUCTURE", 27, 35], ["heparin", "SIMPLE_CHEMICAL", 61, 68], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 149, 159], ["patients", "SPECIES", 7, 15], ["acute arterial ischemia", "PROBLEM", 21, 44], ["a heparin drip", "TREATMENT", 59, 73], ["a typical cardioembolic pattern", "PROBLEM", 110, 141], ["the SARS", "TEST", 145, 153], ["CoV", "TEST", 154, 157], ["situ thrombosis", "PROBLEM", 232, 247], ["acute", "OBSERVATION_MODIFIER", 21, 26], ["arterial", "ANATOMY", 27, 35], ["ischemia", "OBSERVATION", 36, 44], ["typical", "OBSERVATION_MODIFIER", 112, 119], ["cardioembolic", "OBSERVATION", 120, 133], ["more consistent with", "UNCERTAINTY", 208, 228], ["situ", "OBSERVATION_MODIFIER", 232, 236], ["thrombosis", "OBSERVATION", 237, 247]]], ["The arterial thrombotic events Figure 1C ).12The majority of arterial emboli originate in the heart and travel to the extremities, with the lower 13 extremities being affected more frequently than the upper extremities and carotid arteries.", [["arterial", "ANATOMY", 4, 12], ["arterial emboli", "ANATOMY", 61, 76], ["heart", "ANATOMY", 94, 99], ["extremities", "ANATOMY", 118, 129], ["extremities", "ANATOMY", 149, 160], ["upper extremities", "ANATOMY", 201, 218], ["carotid arteries", "ANATOMY", 223, 239], ["arterial thrombotic", "DISEASE", 4, 23], ["arterial emboli", "DISEASE", 61, 76], ["arterial", "MULTI-TISSUE_STRUCTURE", 4, 12], ["arterial emboli", "MULTI-TISSUE_STRUCTURE", 61, 76], ["heart", "ORGAN", 94, 99], ["extremities", "ORGANISM_SUBDIVISION", 118, 129], ["extremities", "ORGANISM_SUBDIVISION", 149, 160], ["upper extremities", "ORGANISM_SUBDIVISION", 201, 218], ["carotid arteries", "MULTI-TISSUE_STRUCTURE", 223, 239], ["The arterial thrombotic events", "PROBLEM", 0, 30], ["arterial emboli", "PROBLEM", 61, 76], ["arterial", "ANATOMY", 4, 12], ["thrombotic", "OBSERVATION", 13, 23], ["majority", "OBSERVATION_MODIFIER", 49, 57], ["arterial", "ANATOMY", 61, 69], ["emboli", "OBSERVATION", 70, 76], ["heart", "ANATOMY", 94, 99], ["extremities", "ANATOMY", 118, 129], ["lower", "ANATOMY_MODIFIER", 140, 145], ["upper extremities", "ANATOMY", 201, 218], ["carotid arteries", "ANATOMY", 223, 239]]], ["There remains much to learn about the SARS CoV-2 and the disease it causes.", [["SARS", "DISEASE", 38, 42], ["SARS CoV", "SPECIES", 38, 46], ["the SARS CoV", "TEST", 34, 46], ["the disease", "PROBLEM", 53, 64], ["disease", "OBSERVATION", 57, 64]]], ["In addition to an 2 early lack of comprehensive testing for both active disease as well as prior infection, the 3 reliability of many of these tests have been called into question.", [["infection", "DISEASE", 97, 106], ["comprehensive testing", "TEST", 34, 55], ["both active disease", "PROBLEM", 60, 79], ["prior infection", "PROBLEM", 91, 106], ["these tests", "TEST", 137, 148], ["active", "OBSERVATION_MODIFIER", 65, 71], ["disease", "OBSERVATION", 72, 79], ["infection", "OBSERVATION", 97, 106]]], ["False negative rates ranging 4 from 20% to as high as 50% for diagnostic tests have been quoted and more recently it has been 5 suggested that antibody tests may not be as indicative of prior infection as first believed.", [["infection", "DISEASE", 192, 201], ["diagnostic tests", "TEST", 62, 78], ["antibody tests", "TEST", 143, 157], ["prior infection", "PROBLEM", 186, 201], ["negative", "OBSERVATION", 6, 14], ["rates", "OBSERVATION_MODIFIER", 15, 20], ["infection", "OBSERVATION", 192, 201]]], ["11,12 6 Whether these are issues with the tests themselves or a peculiarity of the virus is unclear.", [["the tests", "TEST", 38, 47], ["the virus", "PROBLEM", 79, 88], ["virus", "OBSERVATION", 83, 88]]], ["We do 7 not know whether the virus can remain dormant and \"reactivate\" in an individual nor whether 8 individuals develop immunity and if so to what degree and for how long.", [["the virus", "PROBLEM", 25, 34], ["virus", "OBSERVATION", 29, 34]]], ["We also do not know 9 whether the impact of inflammatory changes and possible endothelial damage will resolve with 10 convalescence or whether the changes may persist and lead to symptomatic vascular disease in 11 the future at an undetermined time point.", [["endothelial", "ANATOMY", 78, 89], ["vascular", "ANATOMY", 191, 199], ["endothelial damage", "DISEASE", 78, 96], ["vascular disease", "DISEASE", 191, 207], ["endothelial", "TISSUE", 78, 89], ["vascular", "MULTI-TISSUE_STRUCTURE", 191, 199], ["inflammatory changes", "PROBLEM", 44, 64], ["endothelial damage", "PROBLEM", 78, 96], ["symptomatic vascular disease", "PROBLEM", 179, 207], ["inflammatory", "OBSERVATION", 44, 56], ["possible", "UNCERTAINTY", 69, 77], ["endothelial", "ANATOMY", 78, 89], ["damage", "OBSERVATION", 90, 96], ["vascular", "ANATOMY", 191, 199], ["disease", "OBSERVATION", 200, 207]]], ["If the latter is the case, we will need to anticipate this 12 eventuality and investigate therapies to help delay or prevent these occurrences.", [["therapies", "TREATMENT", 90, 99]]]], "b3c467f9f62239840dec279d104765bfe5d112a6": [["IntroductionViral respiratory tract infections are a leading cause of morbidity and mortality worldwide, representing an enormous economic and disease burden [1] .", [["respiratory tract", "ANATOMY", 18, 35], ["respiratory tract infections", "DISEASE", 18, 46], ["IntroductionViral respiratory tract", "ORGANISM", 0, 35], ["IntroductionViral respiratory tract infections", "PROBLEM", 0, 46], ["morbidity", "PROBLEM", 70, 79], ["an enormous economic and disease burden", "PROBLEM", 118, 157], ["respiratory tract", "ANATOMY", 18, 35], ["infections", "OBSERVATION", 36, 46], ["enormous", "OBSERVATION_MODIFIER", 121, 129], ["economic", "OBSERVATION_MODIFIER", 130, 138], ["disease", "OBSERVATION", 143, 150]]], ["Respiratory viruses replicate in the respiratory tract from where they are subsequently shed and transmitted via respiratory secretions.", [["respiratory tract", "ANATOMY", 37, 54], ["respiratory secretions", "ANATOMY", 113, 135], ["Respiratory viruses", "ORGANISM", 0, 19], ["respiratory tract", "ORGANISM_SUBDIVISION", 37, 54], ["Respiratory viruses", "PROBLEM", 0, 19], ["viruses", "OBSERVATION", 12, 19], ["respiratory tract", "ANATOMY", 37, 54], ["respiratory", "ANATOMY", 113, 124], ["secretions", "OBSERVATION", 125, 135]]], ["Respiratory tract infections may range from asymptomatic to acute live threating disease thereby posing a major health threat to young children, elderly, and immunocompromised people.", [["Respiratory tract", "ANATOMY", 0, 17], ["Respiratory tract infections", "DISEASE", 0, 28], ["children", "ORGANISM", 135, 143], ["people", "ORGANISM", 176, 182], ["children", "SPECIES", 135, 143], ["people", "SPECIES", 176, 182], ["Respiratory tract infections", "PROBLEM", 0, 28], ["acute live threating disease", "PROBLEM", 60, 88], ["tract", "OBSERVATION_MODIFIER", 12, 17], ["infections", "OBSERVATION", 18, 28], ["acute", "OBSERVATION_MODIFIER", 60, 65]]], ["Respiratory viruses spread via three different transmission routes: contact (direct or indirect), droplet and aerosol transmission (Table 1) [2, 3] .", [["Respiratory viruses spread", "PROBLEM", 0, 26], ["viruses", "OBSERVATION", 12, 19]]], ["Contact transmission refers to direct virus transfer from an infected person to a susceptible individual (e.g. via contaminated hands) or indirect virus transfer via intermediate objects (fomites).", [["hands", "ORGANISM_SUBDIVISION", 128, 133], ["person", "SPECIES", 70, 76]]], ["Transmission of virus through the air can occur via droplets or aerosols.", [["virus", "PROBLEM", 16, 21], ["virus", "OBSERVATION", 16, 21], ["air", "OBSERVATION", 34, 37], ["aerosols", "OBSERVATION", 64, 72]]], ["The commonly accepted cut-off size between the large droplets and small aerosols is 5 mm, although this varies considerably between studies, ranging up to 12 mm [4] [5] [6] [7] [8] .", [["5] [6] [7] [8]", "SIMPLE_CHEMICAL", 166, 180], ["the large droplets and small aerosols", "PROBLEM", 43, 80], ["studies", "TEST", 132, 139], ["cut", "OBSERVATION_MODIFIER", 22, 25], ["off size", "OBSERVATION_MODIFIER", 26, 34], ["large", "OBSERVATION_MODIFIER", 47, 52], ["droplets", "OBSERVATION_MODIFIER", 53, 61], ["small", "OBSERVATION_MODIFIER", 66, 71], ["aerosols", "OBSERVATION", 72, 80], ["5 mm", "OBSERVATION_MODIFIER", 84, 88]]], ["Droplets generated during coughing, sneezing or talking do not remain suspended in air and travel less than 1 m before settling on the mucosa of close contacts or environmental surfaces.", [["mucosa", "ANATOMY", 135, 141], ["coughing", "DISEASE", 26, 34], ["mucosa", "MULTI-TISSUE_STRUCTURE", 135, 141], ["Droplets", "TREATMENT", 0, 8], ["coughing", "PROBLEM", 26, 34], ["sneezing", "PROBLEM", 36, 44], ["air", "OBSERVATION", 83, 86], ["mucosa", "ANATOMY", 135, 141]]], ["Aerosols have a slow settling velocity, thus they remain suspended in the air longer and can travel further [5, 9, 10] .IntroductionTransmission via each of these three routes is complex and depends on many variables such as environmental factors (e.g. humidity and temperature), crowding of people, but also on host factors such as receptor distribution throughout the respiratory tract.", [["respiratory tract", "ANATOMY", 370, 387], ["respiratory tract", "ORGANISM_SUBDIVISION", 370, 387], ["people", "SPECIES", 292, 298], ["a slow settling velocity", "PROBLEM", 14, 38], ["crowding of people", "PROBLEM", 280, 298], ["slow", "OBSERVATION_MODIFIER", 16, 20], ["settling velocity", "OBSERVATION_MODIFIER", 21, 38], ["respiratory tract", "ANATOMY", 370, 387]]], ["The fact that all these variables affect the different transmission routes of the different respiratory viruses in a dissimilar way, makes it very difficult to investigate them experimentally [9, 11] .", [["the different respiratory viruses", "PROBLEM", 78, 111], ["respiratory viruses", "OBSERVATION", 92, 111]]], ["Here, we summarize the evidence from experimental and observational studies on inter-human transmission routes of important respiratory viruses (summarized in Table 2 ).", [["respiratory viruses", "DISEASE", 124, 143], ["observational studies", "TEST", 54, 75], ["important respiratory viruses", "PROBLEM", 114, 143], ["respiratory viruses", "OBSERVATION", 124, 143]]], ["A literature search was conducted for each respiratory virus using 'human transmission experiments' and 'transmission (routes)' of the virus of interest as search criteria in PubMed and Google Scholar.", [["human", "ORGANISM", 68, 73], ["human", "SPECIES", 68, 73], ["human", "SPECIES", 68, 73], ["A literature search", "TEST", 0, 19], ["each respiratory virus", "PROBLEM", 38, 60]]], ["Subsequently, the backward snowball method was applied in which additional papers were identified based on the reference list of a paper of interest.", [["the backward snowball method", "TREATMENT", 14, 42]]], ["As this review focuses on the evidence on inter-human transmission routes, data from animal studies were excluded.", [["animal studies", "TEST", 85, 99]]], ["In addition, intervention studies, (aircraft) outbreak reports and household studies were excluded if the transmission route was not specifically investigated.", [["intervention studies", "TEST", 13, 33], ["household studies", "TEST", 67, 84]]], ["The strengths and weaknesses of the different methods employed in transmission studies are summarized in Table 3 .", [["transmission studies", "TEST", 66, 86]]], ["Finally, we discuss our findings in the light of several available (inter)national guidelines on infection control.", [["infection", "DISEASE", 97, 106], ["infection control", "TREATMENT", 97, 114]]], ["Our observations underscore the urgent need for new knowledge on respiratory virus transmission routes and the implementation of this knowledge in infection control guidelines to advance intervention strategies for currently circulating and newly emerging viruses and to improve public health.Measles virus (MV)Measles is one of the most contagious viral diseases in humans that has been associated with aerosol transmission for a long time [12,13,14 ,15-17,18 ].", [["infection", "DISEASE", 147, 156], ["Measles virus (MV)Measles", "DISEASE", 293, 318], ["viral diseases", "DISEASE", 349, 363], ["Measles virus", "ORGANISM", 293, 306], ["humans", "ORGANISM", 367, 373], ["Measles virus", "SPECIES", 293, 306], ["humans", "SPECIES", 367, 373], ["Measles virus", "SPECIES", 293, 306], ["MV", "SPECIES", 308, 310], ["humans", "SPECIES", 367, 373], ["respiratory virus transmission routes", "TREATMENT", 65, 102], ["infection control guidelines", "TREATMENT", 147, 175], ["intervention strategies", "TREATMENT", 187, 210], ["newly emerging viruses", "PROBLEM", 241, 263], ["Measles virus", "PROBLEM", 293, 306], ["the most contagious viral diseases in humans", "PROBLEM", 329, 373], ["most", "OBSERVATION_MODIFIER", 333, 337], ["contagious", "OBSERVATION_MODIFIER", 338, 348], ["viral diseases", "OBSERVATION", 349, 363]]], ["However, it should be noted that MV also replicates systemically, and that there is a role for dead cell debris-associated virus spread via fomites.", [["cell", "ANATOMY", 100, 104], ["dead cell debris-associated virus", "ORGANISM", 95, 128], ["MV", "SPECIES", 33, 35], ["MV", "TEST", 33, 35], ["dead cell debris-associated virus spread", "PROBLEM", 95, 135], ["dead cell", "OBSERVATION", 95, 104], ["debris-associated virus", "OBSERVATION", 105, 128]]], ["In the late 1970s and early 1980s, data from retrospective observational studies obtained during outbreaks in pediatric practices, a school, and a sporting event suggested transmission through aerosols [14 ,15-17,18 ] .", [["retrospective observational studies", "TEST", 45, 80]]], ["Indeed, those studies showed that most secondary cases never came in direct contact with the index patient and some were never even simultaneously present in the same area as the index case [14 ,18 ] .", [["patient", "ORGANISM", 99, 106], ["patient", "SPECIES", 99, 106], ["those studies", "TEST", 8, 21]]], ["Examination of airflow in the pediatricians' offices showed that aerosols were not only dispersed over the entire examination room but also accumulated in the hallway and other areas [14 ,18 ] .", [["Examination", "TEST", 0, 11]]], ["Furthermore, based on the investigation of air circulation in a sport stadium, in which a MV outbreak occurred, authors suggested that MV had been dispersed through the ventilation system [16] .", [["MV", "SPECIES", 90, 92], ["MV", "SPECIES", 135, 137], ["a MV outbreak", "PROBLEM", 88, 101], ["air circulation", "OBSERVATION", 43, 58]]], ["Thus it was concluded that MV can be transmitted via aerosols.", [["MV", "SPECIES", 27, 29]]], ["Although coughing is a common symptom associated with measles disease, index patients were described to cough Inter-human transmission of respiratory viruses Kutter et al. 143 Table 1 Commonly accepted respiratory routes of transmission [18 ] .", [["coughing", "DISEASE", 9, 17], ["measles disease", "DISEASE", 54, 69], ["cough", "DISEASE", 104, 109], ["respiratory viruses", "DISEASE", 138, 157], ["patients", "ORGANISM", 77, 85], ["human", "ORGANISM", 116, 121], ["patients", "SPECIES", 77, 85], ["human", "SPECIES", 116, 121], ["human", "SPECIES", 116, 121], ["coughing", "PROBLEM", 9, 17], ["a common symptom", "PROBLEM", 21, 37], ["measles disease", "PROBLEM", 54, 69], ["cough", "PROBLEM", 104, 109], ["respiratory viruses", "PROBLEM", 138, 157], ["respiratory viruses", "OBSERVATION", 138, 157]]], ["Superspreaders are individuals who are able to infect a disproportionally large number of susceptible contacts when compared to a typical individual [19] [20] [21] [22] , which may contribute to the efficient transmission of MV.", [["20] [21] [22]", "SIMPLE_CHEMICAL", 155, 168], ["MV", "SPECIES", 225, 227]]], ["Table 3 Overview of the methods to study human-to-human transmission and their respective pro's and con'sRetrospective.Usually not conclusive on transmission route or relative importance of transmission routes.", [["human", "ORGANISM", 41, 46], ["human", "ORGANISM", 50, 55], ["human", "SPECIES", 41, 46], ["human", "SPECIES", 50, 55], ["human", "SPECIES", 41, 46], ["human", "SPECIES", 50, 55]]], ["[120] [121] [122] [123] Outbreak reportaircraftRetrospective.Relatively easy to perform Outbreak in closed settingRetrospective.Retrospective which can result in recall-bias and hard to trace back passenger movements.Retrospective.Inconclusive.Retrospective.Only reported in case of secondary infections and in these cases infections may also occur before or after the flight.", [["infections", "DISEASE", 293, 303], ["infections", "DISEASE", 323, 333], ["secondary infections", "PROBLEM", 283, 303], ["these cases infections", "PROBLEM", 311, 333], ["back", "ANATOMY", 192, 196], ["secondary", "OBSERVATION_MODIFIER", 283, 292], ["infections", "OBSERVATION", 293, 303]]], ["[118, [124] [125] [126] [127] Non-pharmaceutical InterventionRetrospective.Can help to discriminate between transmission routes if performed properly.Retrospective.Usually no controlled environment.", [["Non-pharmaceutical InterventionRetrospective", "TREATMENT", 30, 74], ["no", "UNCERTAINTY", 172, 174], ["controlled", "OBSERVATION_MODIFIER", 175, 185], ["environment", "OBSERVATION", 186, 197]]], ["Difficult to determine ideal time-point of the intervention.Retrospective.Risk of drop-out or perseverance.Retrospective.[35, [128] [129] [130] [131] Pharmaceutical intervention Characterization of droplet/ aerosol size.Retrospective.Can be used in parallel with human studies or outbreaks.Retrospective.Can gain information on possible aerosol spread.Retrospective.In a nosocomial setting aerosol-generating procedures can play a major role.Retrospective.Frequently only detection by PCR.Retrospective.Direct human-to-human transmission is not studied (circumstantial).Retrospective.Technical issues (procedure may affect virus viability) or false interpretation.", [["human", "ORGANISM", 263, 268], ["human", "ORGANISM", 510, 515], ["human", "ORGANISM", 519, 524], ["human", "SPECIES", 263, 268], ["human", "SPECIES", 510, 515], ["human", "SPECIES", 519, 524], ["human", "SPECIES", 263, 268], ["human", "SPECIES", 510, 515], ["human", "SPECIES", 519, 524], ["the intervention", "TREATMENT", 43, 59], ["drop-out", "PROBLEM", 82, 90], ["perseverance", "PROBLEM", 94, 106], ["Pharmaceutical intervention", "TREATMENT", 150, 177], ["droplet/ aerosol size", "TREATMENT", 198, 219], ["human studies", "TEST", 263, 276], ["aerosol spread", "PROBLEM", 337, 351], ["aerosol-generating procedures", "TREATMENT", 390, 419], ["PCR", "TEST", 485, 488], ["Technical issues", "PROBLEM", 584, 600], ["procedure", "TREATMENT", 602, 611], ["false interpretation", "TEST", 643, 663], ["drop", "OBSERVATION", 82, 86], ["perseverance", "OBSERVATION", 94, 106], ["size", "OBSERVATION_MODIFIER", 215, 219], ["possible", "UNCERTAINTY", 328, 336], ["aerosol spread", "OBSERVATION", 337, 351]]], ["Visualize airstreamRetrospective.Usually performed retrospectively and not during outbreaks [134, 135] ComputationalRetrospective.Modeling/SimulationRetrospective.Describes transmission in a greater context.Retrospective.Can account for heterogeneity of transmission within a population.Retrospective.Human mannequins can be used as replacement for humans Theoretical (for mathematical modeling).", [["Human", "ORGANISM", 301, 306], ["humans", "ORGANISM", 349, 355], ["Human", "SPECIES", 301, 306], ["humans", "SPECIES", 349, 355], ["Human", "SPECIES", 301, 306], ["humans", "SPECIES", 349, 355], ["Human mannequins", "TREATMENT", 301, 317], ["replacement", "TREATMENT", 333, 344]]], ["Artificial setting.", [["Artificial setting", "TREATMENT", 0, 18]]], ["[82, [136] [137] [138] [139] [140] [141]Parainfluenza (PIV) and human metapneumovirus (HMPV)There is a substantial lack of (experimental) evidence on the transmission routes of PIV (types 1-4) and HMPV.", [["[136] [137] [138] [139] [140] [141]Parainfluenza", "SIMPLE_CHEMICAL", 5, 53], ["human", "ORGANISM", 64, 69], ["metapneumovirus", "ORGANISM", 70, 85], ["HMPV", "ORGANISM", 87, 91], ["HMPV", "ORGANISM", 197, 201], ["human", "SPECIES", 64, 69], ["metapneumovirus", "SPECIES", 70, 85], ["human metapneumovirus", "SPECIES", 64, 85], ["HMPV", "SPECIES", 87, 91], ["HMPV", "SPECIES", 197, 201], ["Parainfluenza (PIV", "TREATMENT", 40, 58], ["human metapneumovirus (HMPV", "PROBLEM", 64, 91], ["PIV (types", "TREATMENT", 177, 187], ["HMPV", "PROBLEM", 197, 201], ["metapneumovirus", "OBSERVATION", 70, 85], ["substantial", "OBSERVATION_MODIFIER", 103, 114], ["HMPV", "OBSERVATION", 197, 201]]], ["For both viruses, contact and droplet transmission are commonly accepted transmission routes [23] [24] [25] .", [["viruses", "OBSERVATION", 9, 16]]], ["However, only virus stability on various surfaces has been investigated so far and it has been shown that PIV and HMPV are stable on non-absorptive surfaces and can barely be recovered from absorptive surfaces [26-30].Respiratory syncytial virus (RSV)Transmission of RSV among humans is thought to occur via droplets and fomites [1, 7] .", [["Respiratory syncytial virus", "DISEASE", 218, 245], ["RSV", "DISEASE", 267, 270], ["HMPV", "ORGANISM", 114, 118], ["Respiratory syncytial virus", "ORGANISM", 218, 245], ["RSV", "ORGANISM", 247, 250], ["RSV", "ORGANISM", 267, 270], ["humans", "ORGANISM", 277, 283], ["Respiratory syncytial virus", "SPECIES", 218, 245], ["RSV", "SPECIES", 267, 270], ["humans", "SPECIES", 277, 283], ["HMPV", "SPECIES", 114, 118], ["Respiratory syncytial virus", "SPECIES", 218, 245], ["RSV", "SPECIES", 247, 250], ["RSV", "SPECIES", 267, 270], ["humans", "SPECIES", 277, 283], ["virus stability on various surfaces", "PROBLEM", 14, 49], ["PIV", "TREATMENT", 106, 109], ["HMPV", "PROBLEM", 114, 118], ["non-absorptive surfaces", "TREATMENT", 133, 156], ["absorptive surfaces", "TEST", 190, 209], ["Respiratory syncytial virus", "PROBLEM", 218, 245], ["RSV", "PROBLEM", 267, 270], ["virus stability", "OBSERVATION", 14, 29], ["PIV", "OBSERVATION", 106, 109], ["HMPV", "OBSERVATION", 114, 118], ["stable", "OBSERVATION_MODIFIER", 123, 129], ["syncytial virus", "OBSERVATION", 230, 245]]], ["In the 1980s three potential transmission routes of RSV were studied in humans by dividing infected infants and healthy volunteers into three groups, representing: Firstly, all transmission routes, secondly, transmission via fomites and finally, airborne transmission by allowing the volunteers to have either, firstly, direct contact with infants (cuddlers), secondly, touching potential fomites (touchers) or finally, sitting next to the infant (sitters).", [["RSV", "ORGANISM", 52, 55], ["humans", "ORGANISM", 72, 78], ["infants", "ORGANISM", 100, 107], ["volunteers", "ORGANISM", 284, 294], ["infants", "ORGANISM", 340, 347], ["humans", "SPECIES", 72, 78], ["infants", "SPECIES", 100, 107], ["infants", "SPECIES", 340, 347], ["infant", "SPECIES", 440, 446], ["RSV", "SPECIES", 52, 55], ["humans", "SPECIES", 72, 78], ["RSV", "PROBLEM", 52, 55]]], ["Volunteers in the group of the cuddlers and touchers but not the sitters became infected, suggesting that direct contact and droplet transmission were the probable routes for efficient infection of the volunteers and that transmission via aerosols was less likely [31] .", [["cuddlers", "ANATOMY", 31, 39], ["infection", "DISEASE", 185, 194], ["volunteers", "ORGANISM", 202, 212], ["infected", "PROBLEM", 80, 88], ["direct contact and droplet transmission", "PROBLEM", 106, 145], ["efficient infection of the volunteers", "PROBLEM", 175, 212], ["infection", "OBSERVATION", 185, 194]]], ["Another study on the transmission via fomites showed that RSV could be recovered from countertops for several hours, but only for several minutes from absorptive surfaces such as paper tissue and skin [32 ] .", [["tissue", "ANATOMY", 185, 191], ["skin", "ANATOMY", 196, 200], ["RSV", "ORGANISM", 58, 61], ["tissue", "TISSUE", 185, 191], ["skin", "ORGAN", 196, 200], ["RSV", "SPECIES", 58, 61], ["Another study", "TEST", 0, 13], ["the transmission", "TEST", 17, 33], ["RSV", "PROBLEM", 58, 61], ["absorptive surfaces", "TREATMENT", 151, 170], ["RSV", "OBSERVATION", 58, 61], ["skin", "ANATOMY", 196, 200]]], ["Later on, in the late 1990s, Aintablian et al. detected RSV RNA in the air up to 7 m away from a patient's head [33] .", [["head", "ANATOMY", 107, 111], ["RSV", "ORGANISM", 56, 59], ["patient", "ORGANISM", 97, 104], ["head", "ORGANISM_SUBDIVISION", 107, 111], ["RSV RNA", "RNA", 56, 63], ["patient", "SPECIES", 97, 104], ["RSV", "SPECIES", 56, 59], ["RSV RNA", "PROBLEM", 56, 63], ["RSV RNA", "OBSERVATION", 56, 63], ["air", "OBSERVATION_MODIFIER", 71, 74], ["head", "ANATOMY", 107, 111]]], ["In spite of that, since virus infectivity could not be demonstrated, potential airborne transmission of RSV has been considered negligible and transmission of RSV was thought to occur mainly through contact and droplet transmission.", [["RSV", "DISEASE", 104, 107], ["RSV", "DISEASE", 159, 162], ["RSV", "ORGANISM", 104, 107], ["RSV", "ORGANISM", 159, 162], ["RSV", "SPECIES", 104, 107], ["RSV", "SPECIES", 159, 162], ["virus infectivity", "PROBLEM", 24, 41], ["RSV", "PROBLEM", 104, 107], ["RSV", "PROBLEM", 159, 162], ["RSV", "OBSERVATION", 104, 107], ["RSV", "OBSERVATION", 159, 162]]], ["However, in a recent study authors were able to collect aerosols that contained viable virus from the air around RSV infected children [34 ] .", [["RSV infected", "DISEASE", 113, 125], ["RSV", "ORGANISM", 113, 116], ["children", "ORGANISM", 126, 134], ["children", "SPECIES", 126, 134], ["RSV", "SPECIES", 113, 116], ["a recent study", "TEST", 12, 26], ["viable virus", "PROBLEM", 80, 92], ["viable virus", "OBSERVATION", 80, 92], ["air", "ANATOMY", 102, 105]]], ["Although the detection of viable virus in the air is by itself not enough to confirm aerosol transmission, the general presumption that RSV exclusively transmits via droplets should be reconsidered and explored further. .", [["RSV", "ORGANISM", 136, 139], ["RSV", "SPECIES", 136, 139], ["viable virus in the air", "PROBLEM", 26, 49], ["RSV", "PROBLEM", 136, 139], ["viable", "OBSERVATION_MODIFIER", 26, 32], ["virus", "OBSERVATION", 33, 38], ["air", "OBSERVATION", 46, 49]]], ["In a three-day rhinovirus experiment with healthy volunteers different exposure modes were used to investigate the rhinovirus transmission route: Firsrtly, smallparticle exposure (separating donor and recipients by wire mesh), secondly, large particle exposure (encouraging contact, coughing and sneezing while wearing gloves) and finally, direct contact exposure (hand contact followed by self-inoculation).", [["hand", "ANATOMY", 365, 369], ["smallparticle", "CHEMICAL", 156, 169], ["coughing", "DISEASE", 283, 291], ["rhinovirus", "ORGANISM", 15, 25], ["volunteers", "ORGANISM", 50, 60], ["rhinovirus", "ORGANISM", 115, 125], ["hand", "ORGANISM_SUBDIVISION", 365, 369], ["donor and recipients by wire mesh", "TREATMENT", 191, 224], ["coughing", "PROBLEM", 283, 291], ["sneezing", "PROBLEM", 296, 304], ["large", "OBSERVATION_MODIFIER", 237, 242], ["particle exposure", "OBSERVATION", 243, 260]]], ["Furthermore, rhinovirus RNA was detected in offices by air sampling studies and subsequent sequencing resulted in a matched air-mucus pair [37] .", [["rhinovirus", "ORGANISM", 13, 23], ["rhinovirus RNA", "RNA", 13, 27], ["rhinovirus", "SPECIES", 13, 23], ["rhinovirus RNA", "PROBLEM", 13, 27], ["air sampling studies", "TEST", 55, 75], ["subsequent sequencing", "TEST", 80, 101], ["rhinovirus", "OBSERVATION", 13, 23]]], ["In a miniature field trail, experimentally infected donors with severe colds participated in a card game with susceptible recipients for 12 hours [38 ,39 ,40].", [["colds", "DISEASE", 71, 76], ["donors", "ORGANISM", 52, 58], ["recipients", "ORGANISM", 122, 132], ["severe colds", "PROBLEM", 64, 76], ["severe", "OBSERVATION_MODIFIER", 64, 70]]], ["A restraining device, preventing touching of the head and face, was used in the aerosol condition and heavily contaminated cards and exaggerated hand-to-face movements in the fomite condition.", [["head", "ANATOMY", 49, 53], ["face", "ANATOMY", 58, 62], ["hand", "ANATOMY", 145, 149], ["head", "ORGANISM_SUBDIVISION", 49, 53], ["A restraining device", "TREATMENT", 0, 20], ["restraining device", "OBSERVATION", 2, 20], ["head", "ANATOMY", 49, 53], ["face", "ANATOMY", 58, 62]]], ["In these experiments aerosol transmission was suggested [40] .RhinovirusIn general, transmission rates and exposure time varied between studies, which may contribute to the different routes of transmission that were observed.", [["Rhinovirus", "PROBLEM", 62, 72], ["studies", "TEST", 136, 143]]], ["Therefore, the donor-hours of exposure was determined using donors with severe rhinovirus infections.", [["rhinovirus infections", "DISEASE", 79, 100], ["donors", "ORGANISM", 60, 66], ["rhinovirus", "ORGANISM", 79, 89], ["severe rhinovirus infections", "PROBLEM", 72, 100], ["severe", "OBSERVATION_MODIFIER", 72, 78], ["rhinovirus", "OBSERVATION", 79, 89]]], ["At 200 hours of exposure to donors, transmission had occurred to 50% of the susceptible recipients, though the transmission route itself was not investigated [38 ].Influenza A virusDue to the severity of the yearly influenza epidemics and the potential of zoonotic influenza A viruses to cause severe outbreaks, there have been many studies on influenza A virus transmission among humans.", [["influenza epidemics", "DISEASE", 215, 234], ["zoonotic influenza A viruses", "DISEASE", 256, 284], ["influenza A virus transmission", "DISEASE", 344, 374], ["donors", "ORGANISM", 28, 34], ["recipients", "ORGANISM", 88, 98], ["influenza A viruses", "ORGANISM", 265, 284], ["influenza A virus", "ORGANISM", 344, 361], ["humans", "ORGANISM", 381, 387], ["influenza A viruses", "SPECIES", 265, 284], ["influenza A virus", "SPECIES", 344, 361], ["humans", "SPECIES", 381, 387], ["zoonotic influenza A viruses", "SPECIES", 256, 284], ["influenza A virus", "SPECIES", 344, 361], ["humans", "SPECIES", 381, 387], ["Influenza", "PROBLEM", 164, 173], ["the yearly influenza epidemics", "PROBLEM", 204, 234], ["zoonotic influenza A viruses", "PROBLEM", 256, 284], ["severe outbreaks", "PROBLEM", 294, 310], ["influenza", "PROBLEM", 344, 353]]], ["Different kinds of studies, such as air sampling and intervention studies, as well as human challenge studies have been conducted.", [["human", "ORGANISM", 86, 91], ["human", "SPECIES", 86, 91], ["human", "SPECIES", 86, 91], ["studies", "TEST", 19, 26], ["air sampling", "TEST", 36, 48], ["intervention studies", "TEST", 53, 73], ["human challenge studies", "TEST", 86, 109]]], ["However, until today, results on the relative importance of droplet and aerosol transmission of influenza viruses stay inconclusive and hence, there are many reviews intensively discussing this issue [10, [45] [46] [47] [48] [49] [50] .Influenza A virusAlready in the mid-1900s human challenge models were used to assess the transmission route of influenza virus [51 ,52-54].", [["influenza viruses", "DISEASE", 96, 113], ["influenza", "DISEASE", 347, 356], ["[45] [46] [47] [48] [49] [50]", "SIMPLE_CHEMICAL", 205, 234], ["Influenza A virusAlready", "ORGANISM", 236, 260], ["human", "ORGANISM", 278, 283], ["influenza virus", "ORGANISM", 347, 362], ["Influenza", "SPECIES", 236, 245], ["human", "SPECIES", 278, 283], ["influenza virus", "SPECIES", 347, 362], ["human", "SPECIES", 278, 283], ["droplet", "TREATMENT", 60, 67], ["influenza viruses", "PROBLEM", 96, 113], ["Influenza", "PROBLEM", 236, 245], ["influenza virus", "PROBLEM", 347, 362]]], ["It was shown that illness outcome is dependent on the inoculation route and tends to be milder in intranasally infected volunteers in comparison to inoculation through inhalation [52, 53] .", [["illness", "DISEASE", 18, 25], ["volunteers", "ORGANISM", 120, 130], ["illness outcome", "PROBLEM", 18, 33], ["the inoculation route", "TREATMENT", 50, 71], ["milder in intranasally infected volunteers", "PROBLEM", 88, 130], ["illness", "OBSERVATION", 18, 25], ["dependent", "OBSERVATION_MODIFIER", 37, 46]]], ["Furthermore, illness seemed to be milder in experimentally infected volunteers than in naturally infected individuals [51 ] .", [["illness", "DISEASE", 13, 20], ["naturally infected", "DISEASE", 87, 105], ["volunteers", "ORGANISM", 68, 78], ["illness", "PROBLEM", 13, 20], ["experimentally infected volunteers", "PROBLEM", 44, 78], ["infected", "OBSERVATION", 59, 67]]], ["Increasing numbers of studies focused on the detection and quantification of influenza viruses contained in droplets and aerosols expelled into the air through breathing, sneezing and coughing of infected individuals The SARS outbreak was primarily linked to healthcare settings, with 49% of the cases linked to hospitals [71] , most probably caused by aerosol-generating procedures on severely ill patients [72, 73] .", [["influenza viruses", "DISEASE", 77, 94], ["sneezing", "DISEASE", 171, 179], ["coughing of infected", "DISEASE", 184, 204], ["SARS", "DISEASE", 221, 225], ["influenza viruses", "ORGANISM", 77, 94], ["patients", "ORGANISM", 399, 407], ["patients", "SPECIES", 399, 407], ["studies", "TEST", 22, 29], ["the detection", "TEST", 41, 54], ["influenza viruses", "PROBLEM", 77, 94], ["aerosols", "TREATMENT", 121, 129], ["the air through breathing", "PROBLEM", 144, 169], ["sneezing", "PROBLEM", 171, 179], ["coughing of infected individuals", "PROBLEM", 184, 216], ["influenza viruses", "OBSERVATION", 77, 94], ["air", "ANATOMY", 148, 151], ["most probably caused", "UNCERTAINTY", 329, 349]]], ["Aerosol-generating procedures like intubation, the use of continuous positivepressure ventilation and drug delivery via nebulizers are likely to produce 'fine infectious droplets', which travel further than droplets from coughs [74] .", [["coughs", "DISEASE", 221, 227], ["Aerosol", "TREATMENT", 0, 7], ["generating procedures", "TREATMENT", 8, 29], ["intubation", "TREATMENT", 35, 45], ["continuous positivepressure ventilation", "TREATMENT", 58, 97], ["drug delivery via nebulizers", "TREATMENT", 102, 130], ["coughs", "PROBLEM", 221, 227]]], ["Additionally, superspreading events contributed to the dispersion of the SARS outbreak [73, [75] [76] [77] , particularly in the Hotel Metropole and the Prince of Wales Hospital in Hong Kong [76] .", [["SARS", "DISEASE", 73, 77], ["superspreading events", "PROBLEM", 14, 35], ["the SARS outbreak", "PROBLEM", 69, 86]]], ["Moreover, a link with transmission to healthcare workers was observed when they were in close proximity (<1 m) to an index patient, suggesting direct contact or droplet transmission [73,78 ,79 ] .", [["patient", "ORGANISM", 123, 130], ["patient", "SPECIES", 123, 130]]], ["Air samples and swabs from frequently touched surfaces in a room occupied by a SARS patient tested positive by PCR, although no virus could be cultured from these samples [80] .", [["Air samples", "ANATOMY", 0, 11], ["swabs", "ANATOMY", 16, 21], ["samples", "ANATOMY", 163, 170], ["SARS", "DISEASE", 79, 83], ["Air samples", "TISSUE", 0, 11], ["patient", "ORGANISM", 84, 91], ["patient", "SPECIES", 84, 91], ["Air samples", "TEST", 0, 11], ["swabs", "TEST", 16, 21], ["a SARS", "PROBLEM", 77, 83], ["PCR", "TEST", 111, 114], ["virus", "PROBLEM", 128, 133], ["these samples", "TEST", 157, 170]]], ["In the Amoy gardens outbreak fecal droplet transmission was suggested [81, 82] .Influenza A virusTo date, there is little data on the human-to-human MERS-CoV transmission route [83] .", [["fecal droplet", "ANATOMY", 29, 42], ["fecal droplet", "MULTI-TISSUE_STRUCTURE", 29, 42], ["Influenza A virus", "ORGANISM", 80, 97], ["human", "ORGANISM", 134, 139], ["human", "ORGANISM", 143, 148], ["MERS-CoV", "ORGANISM", 149, 157], ["Influenza A virus", "SPECIES", 80, 97], ["human", "SPECIES", 134, 139], ["human", "SPECIES", 143, 148], ["Influenza A virus", "SPECIES", 80, 97], ["human", "SPECIES", 134, 139], ["human MERS-CoV", "SPECIES", 143, 157], ["fecal droplet transmission", "TEST", 29, 55], ["Influenza", "PROBLEM", 80, 89], ["fecal droplet", "OBSERVATION", 29, 42]]], ["MERS-CoV remained stable on non-absorptive for 8 up to 48 hours and for 10 min at 20 C and 40% relative humidity in aerosols [84] .", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 0, 8], ["MERS-CoV", "SPECIES", 0, 8], ["stable", "OBSERVATION_MODIFIER", 18, 24]]], ["MERS-CoV outbreaks in humans are, like those with SARS-CoV, primarily linked to healthcare settings, with a link to hospitals in 31% of the cases [71, 85, 86] and healthcare associated human-to-human transmission was observed [87, 88] .", [["SARS-CoV", "DISEASE", 50, 58], ["human-to-human transmission", "DISEASE", 185, 212], ["MERS-CoV", "ORGANISM", 0, 8], ["humans", "ORGANISM", 22, 28], ["SARS-CoV", "ORGANISM", 50, 58], ["human", "ORGANISM", 185, 190], ["human", "ORGANISM", 194, 199], ["humans", "SPECIES", 22, 28], ["human", "SPECIES", 185, 190], ["human", "SPECIES", 194, 199], ["MERS-CoV", "SPECIES", 0, 8], ["humans", "SPECIES", 22, 28], ["SARS-CoV", "SPECIES", 50, 58], ["human", "SPECIES", 185, 190], ["human", "SPECIES", 194, 199]]], ["Superspreader events were shown to play an important role in nosocomial outbreaks [71, 89] .", [["Superspreader events", "PROBLEM", 0, 20]]], ["Virus was isolated from environmental samples in hospital rooms, suggesting direct contact or fomite transmission.", [["samples", "ANATOMY", 38, 45], ["Virus", "ORGANISM", 0, 5], ["Virus", "PROBLEM", 0, 5]]], ["Moreover, the airborne potential of MERS was investigated by air sample analysis [90, 91 ] .", [["MERS", "PROBLEM", 36, 40], ["air sample analysis", "TEST", 61, 80]]], ["Viral RNA was detected on the inlet of air ventilation equipment [90] and virus was isolated from air samples and surfaces from inaccessible areas like the ventilator exit, implicating potential aerosol transmission [91 ] .AdenovirusHuman adenoviruses can cause respiratory disease (mainly type 1-5, 7, 14 and 21) [92, 93] , conjunctivitis or infantile gastroenteritis (type 40 and 41) [94] .", [["air samples", "ANATOMY", 98, 109], ["respiratory", "ANATOMY", 262, 273], ["respiratory disease", "DISEASE", 262, 281], ["conjunctivitis", "DISEASE", 325, 339], ["infantile gastroenteritis", "DISEASE", 343, 368], ["Viral", "ORGANISM", 0, 5], ["air samples", "ORGANISM_SUBSTANCE", 98, 109], ["AdenovirusHuman adenoviruses", "ORGANISM", 223, 251], ["Viral RNA", "RNA", 0, 9], ["Viral RNA", "PROBLEM", 0, 9], ["air ventilation equipment", "TREATMENT", 39, 64], ["virus", "PROBLEM", 74, 79], ["air samples", "TEST", 98, 109], ["AdenovirusHuman adenoviruses", "TREATMENT", 223, 251], ["respiratory disease", "PROBLEM", 262, 281], ["conjunctivitis", "PROBLEM", 325, 339], ["infantile gastroenteritis", "PROBLEM", 343, 368], ["RNA", "OBSERVATION", 6, 9], ["ventilator exit", "OBSERVATION", 156, 171], ["respiratory disease", "OBSERVATION", 262, 281], ["conjunctivitis", "OBSERVATION", 325, 339], ["gastroenteritis", "OBSERVATION", 353, 368]]], ["They are a common cause of respiratory illness and pneumonia in children [95, 96] , whereas infections are generally asymptomatic in adults [92] .", [["respiratory", "ANATOMY", 27, 38], ["respiratory illness", "DISEASE", 27, 46], ["pneumonia", "DISEASE", 51, 60], ["infections", "DISEASE", 92, 102], ["children", "ORGANISM", 64, 72], ["children", "SPECIES", 64, 72], ["respiratory illness", "PROBLEM", 27, 46], ["pneumonia", "PROBLEM", 51, 60], ["respiratory", "ANATOMY", 27, 38], ["illness", "OBSERVATION", 39, 46], ["pneumonia", "OBSERVATION", 51, 60]]], ["Adenoviruses cause nosocomial outbreaks, especially in pediatric care facilities, where they spread rapidly [95, 97, 98] .", [["Adenoviruses", "DISEASE", 0, 12], ["Adenoviruses", "PROBLEM", 0, 12], ["nosocomial outbreaks", "PROBLEM", 19, 39], ["nosocomial", "OBSERVATION_MODIFIER", 19, 29], ["outbreaks", "OBSERVATION", 30, 39]]], ["Moreover, adenovirus type 4 and 7 are responsible for large outbreaks of acute respiratory disease, especially in crowded conditions.", [["respiratory", "ANATOMY", 79, 90], ["acute respiratory disease", "DISEASE", 73, 98], ["adenovirus type 4", "ORGANISM", 10, 27], ["acute respiratory disease", "PROBLEM", 73, 98], ["responsible for", "UNCERTAINTY", 38, 53], ["large", "OBSERVATION_MODIFIER", 54, 59], ["outbreaks", "OBSERVATION_MODIFIER", 60, 69], ["acute", "OBSERVATION_MODIFIER", 73, 78], ["respiratory disease", "OBSERVATION", 79, 98]]], ["It is difficult to eliminate adenovirus from skin, fomites and environmental surfaces [100] .", [["skin", "ANATOMY", 45, 49], ["fomites", "ANATOMY", 51, 58], ["adenovirus", "ORGANISM", 29, 39], ["skin", "ORGAN", 45, 49], ["adenovirus", "SPECIES", 29, 39], ["adenovirus", "PROBLEM", 29, 39], ["adenovirus", "OBSERVATION", 29, 39], ["skin", "ANATOMY", 45, 49]]], ["An outbreak in a mental care facility was probably enhanced by spending the day mainly in a crowded room while sharing cigarettes and soda cans, suggesting indirect fomite spread [101] .", [["outbreak", "OBSERVATION_MODIFIER", 3, 11]]], ["In a study published in 1966, experimental infections with adenovirus administered as aerosols (0.3-2.5 mm) or droplets (15 mm) to healthy, male inmates, resulted in infection of all volunteers, although the resulting illness resembled a natural infection only in the aerosol group [102] .", [["droplets", "ANATOMY", 111, 119], ["infections", "DISEASE", 43, 53], ["infection", "DISEASE", 166, 175], ["illness", "DISEASE", 218, 225], ["infection", "DISEASE", 246, 255], ["adenovirus", "ORGANISM", 59, 69], ["volunteers", "ORGANISM", 183, 193], ["adenovirus", "SPECIES", 59, 69], ["a study", "TEST", 3, 10], ["experimental infections", "PROBLEM", 30, 53], ["adenovirus", "TREATMENT", 59, 69], ["infection of all volunteers", "PROBLEM", 166, 193], ["the resulting illness", "PROBLEM", 204, 225], ["a natural infection", "PROBLEM", 236, 255], ["infections", "OBSERVATION", 43, 53], ["infection", "OBSERVATION", 166, 175], ["natural", "OBSERVATION_MODIFIER", 238, 245], ["infection", "OBSERVATION", 246, 255]]], ["During a military training period, increased numbers of adenovirus infections occurred over time, which correlated with an increased detection of PCR-positive air filters.", [["adenovirus infections", "DISEASE", 56, 77], ["adenovirus", "ORGANISM", 56, 66], ["adenovirus", "SPECIES", 56, 66], ["a military training period", "TREATMENT", 7, 33], ["adenovirus infections", "PROBLEM", 56, 77], ["PCR", "TEST", 146, 149], ["positive air filters", "PROBLEM", 150, 170], ["increased", "OBSERVATION_MODIFIER", 35, 44], ["numbers", "OBSERVATION_MODIFIER", 45, 52], ["adenovirus", "OBSERVATION_MODIFIER", 56, 66], ["infections", "OBSERVATION", 67, 77], ["increased", "OBSERVATION_MODIFIER", 123, 132], ["air filters", "OBSERVATION", 159, 170]]], ["Additionally, a correlation between disease and the extent of ventilation was observed, with more ventilation resulting in fewer disease cases [103 ] .", [["disease", "PROBLEM", 36, 43], ["ventilation", "TREATMENT", 62, 73], ["fewer disease cases", "PROBLEM", 123, 142], ["ventilation", "OBSERVATION", 62, 73]]], ["In a more recent study in military recruits, positive viral DNA samples were mainly obtained from pillows, lockers and rifles, although adenovirus DNA was also detected in air samples.", [["samples", "ANATOMY", 64, 71], ["air samples", "ANATOMY", 172, 183], ["adenovirus", "ORGANISM", 136, 146], ["DNA", "CELLULAR_COMPONENT", 147, 150], ["air samples", "CANCER", 172, 183], ["adenovirus DNA", "DNA", 136, 150], ["adenovirus", "SPECIES", 136, 146], ["positive viral DNA samples", "PROBLEM", 45, 71], ["pillows", "TREATMENT", 98, 105], ["lockers", "TREATMENT", 107, 114], ["rifles", "TREATMENT", 119, 125], ["adenovirus DNA", "PROBLEM", 136, 150], ["viral DNA", "OBSERVATION", 54, 63]]], ["No consistent correlation between increased positive environmental samples and disease was observed [104] .DiscussionStudies on the transmission routes of respiratory viruses have been performed since the beginning of the 20th century [105] .", [["samples", "ANATOMY", 67, 74], ["respiratory viruses", "DISEASE", 155, 174], ["increased positive environmental samples", "PROBLEM", 34, 74], ["disease", "PROBLEM", 79, 86], ["respiratory viruses", "PROBLEM", 155, 174], ["increased", "OBSERVATION_MODIFIER", 34, 43], ["positive", "OBSERVATION_MODIFIER", 44, 52], ["environmental samples", "OBSERVATION", 53, 74]]], ["Despite this, the relative importance of transmission routes of respiratory viruses is still unclear, depending on the heterogeneity of many factors like the environment (e.g. temperature and humidity), pathogen and host [5, 19] .", [["respiratory viruses", "DISEASE", 64, 83], ["respiratory viruses", "PROBLEM", 64, 83], ["pathogen", "PROBLEM", 203, 211], ["respiratory viruses", "OBSERVATION", 64, 83]]], ["Differences in virus shedding between individuals can contribute to the transmissibility rate, especially in the case of superspreaders [75, 106] .", [["the transmissibility rate", "TEST", 68, 93], ["virus", "OBSERVATION", 15, 20]]], ["In addition, the SARS-CoV outbreak highlighted the impact of aerosol-generating procedures on the increased risk of human-to-human transmission [74, 107] , demonstrating that for these procedures additional containment measures are necessary.DiscussionInter-human transmission has been studied under many different (experimental) conditions.", [["SARS", "DISEASE", 17, 21], ["human", "ORGANISM", 116, 121], ["human", "ORGANISM", 125, 130], ["human", "ORGANISM", 258, 263], ["human", "SPECIES", 116, 121], ["human", "SPECIES", 125, 130], ["human", "SPECIES", 258, 263], ["SARS-CoV", "SPECIES", 17, 25], ["human", "SPECIES", 116, 121], ["human", "SPECIES", 125, 130], ["human", "SPECIES", 258, 263], ["the SARS", "PROBLEM", 13, 21], ["aerosol-generating procedures", "TREATMENT", 61, 90], ["these procedures additional containment measures", "TREATMENT", 179, 227]]], ["A summary of the advantages and disadvantages of the different study designs (Table 3 ) highlights the difficulty of human transmission experiments.", [["human", "ORGANISM", 117, 122], ["human", "SPECIES", 117, 122], ["human", "SPECIES", 117, 122], ["the different study", "TEST", 49, 68]]], ["As a consequence, contrasting results have been obtained for many viruses.", [["many viruses", "PROBLEM", 61, 73]]], ["Besides the difficulty of performing studies under well-controlled conditions, another key issue is that often (attenuated) laboratory strains are studied in healthy adults, which does not reflect the natural circumstances and target group and hence influence the outcome of the studies.DiscussionRespiratory viruses are an important cause of nosocomial infections, especially in children.", [["nosocomial infections", "DISEASE", 343, 364], ["children", "ORGANISM", 380, 388], ["children", "SPECIES", 380, 388], ["performing studies", "TEST", 26, 44], ["the studies", "TEST", 275, 286], ["DiscussionRespiratory viruses", "PROBLEM", 287, 316], ["nosocomial infections", "PROBLEM", 343, 364], ["viruses", "OBSERVATION", 309, 316], ["nosocomial", "OBSERVATION_MODIFIER", 343, 353], ["infections", "OBSERVATION", 354, 364]]], ["Therefore, we consulted the guidelines on infection prevention from National [108] , European [109] , American [3, 110] and International [111]) organizations for their information on transmission routes (Table 2 ) and associated isolation guidelines (Figure 1) .", [["infection", "DISEASE", 42, 51], ["infection prevention", "TREATMENT", 42, 62]]], ["Unfortunately, terms and definitions of respiratory transmission routes and isolation guidelines are not always used in a uniform way, leaving room for personal interpretation.", [["respiratory", "ANATOMY", 40, 51], ["respiratory transmission routes", "TREATMENT", 40, 71], ["isolation guidelines", "TREATMENT", 76, 96]]], ["But more importantly, information on the transmission route does not always reflect the isolation guidelines (e.g. for PIV and rhinovirus, Figure 1) .", [["rhinovirus", "ORGANISM", 127, 137], ["PIV", "TREATMENT", 119, 122], ["rhinovirus", "PROBLEM", 127, 137]]], ["As a proxy for transmission route, virus stability is often referred to in the guidelines, however, this can only imply a role for indirect contact transmission but is by no means conclusive on the transmission route.In hospital settings, prevention of contact transmission is generally implemented in standard infection preventionInter-human transmission of respiratory viruses Kutter et al. 147 precautions such as strict hand hygiene and cough etiquette.", [["hand", "ANATOMY", 424, 428], ["infection", "DISEASE", 311, 320], ["respiratory viruses", "DISEASE", 359, 378], ["cough", "DISEASE", 441, 446], ["human", "ORGANISM", 337, 342], ["hand", "ORGANISM_SUBDIVISION", 424, 428], ["human", "SPECIES", 337, 342], ["human", "SPECIES", 337, 342], ["virus stability", "PROBLEM", 35, 50], ["standard infection prevention", "TREATMENT", 302, 331], ["respiratory viruses", "PROBLEM", 359, 378], ["strict hand hygiene", "TREATMENT", 417, 436], ["cough etiquette", "PROBLEM", 441, 456], ["infection", "OBSERVATION", 311, 320], ["respiratory", "ANATOMY", 359, 370]]], ["It is important to note differences in isolation guidelines between different organizations and the lack of correlation to scientific data.", [["isolation guidelines", "TREATMENT", 39, 59], ["scientific data", "TEST", 123, 138]]], ["The variation in described transmission routes and associated isolation guidelines among the different organizations underscores the lack of convincing data.In hospital settings, prevention of contact transmission is generally implemented in standard infection preventionWell-designed human infection studies could be employed to investigate the role of transmission routes of respiratory viruses among humans [112 ] .", [["infection", "DISEASE", 251, 260], ["infection", "DISEASE", 291, 300], ["respiratory viruses", "DISEASE", 377, 396], ["human", "ORGANISM", 285, 290], ["humans", "ORGANISM", 403, 409], ["human", "SPECIES", 285, 290], ["humans", "SPECIES", 403, 409], ["human", "SPECIES", 285, 290], ["humans", "SPECIES", 403, 409], ["associated isolation guidelines", "TREATMENT", 51, 82], ["human infection studies", "TEST", 285, 308], ["respiratory viruses", "PROBLEM", 377, 396], ["variation", "OBSERVATION_MODIFIER", 4, 13], ["infection", "OBSERVATION", 251, 260]]], ["However, since human transmission experiments are very challenging, animal transmission models can provide an attractive alternative and should be explored and developed for all respiratory viruses.", [["respiratory viruses", "DISEASE", 178, 197], ["human", "ORGANISM", 15, 20], ["human", "SPECIES", 15, 20], ["human", "SPECIES", 15, 20], ["all respiratory viruses", "PROBLEM", 174, 197], ["respiratory", "ANATOMY", 178, 189], ["viruses", "OBSERVATION", 190, 197]]], ["However, before extrapolating experimentally generated data to humans, it is important to understand the limitations of these models, and appreciate the heterogeneity of experimental setups employed in laboratories [114] .", [["humans", "ORGANISM", 63, 69], ["humans", "SPECIES", 63, 69], ["humans", "SPECIES", 63, 69], ["these models", "TEST", 120, 132]]], ["Furthermore, quantitative data such as viral load in the air can be obtained by air sampling methods in various environments, such as hospital settings.", [["quantitative data", "TEST", 13, 30], ["viral load in the air", "PROBLEM", 39, 60]]], ["Air sampling of viruses is an increasingly used technology in animal and human experiments.", [["human", "ORGANISM", 73, 78], ["human", "SPECIES", 73, 78], ["human", "SPECIES", 73, 78], ["Air sampling of viruses", "PROBLEM", 0, 23], ["viruses", "OBSERVATION", 16, 23]]], ["However, whereas most studies rely on the detection of viral genome copies, viability assays such as plaque assays or virus titration should be included to gain information on virus infectivity.In hospital settings, prevention of contact transmission is generally implemented in standard infection preventionUltimately, the knowledge gap on inter-human transmission should be filled by developing and performing stateof-the art experiments in a natural setting.", [["plaque", "ANATOMY", 101, 107], ["infection", "DISEASE", 288, 297], ["viral genome copies", "DNA", 55, 74], ["viral genome copies", "PROBLEM", 55, 74], ["viability assays", "TEST", 76, 92], ["plaque assays", "PROBLEM", 101, 114], ["virus titration", "TREATMENT", 118, 133], ["virus infectivity", "PROBLEM", 176, 193], ["inter-human transmission", "TREATMENT", 341, 365], ["infection", "OBSERVATION", 288, 297]]], ["Combined with animal transmission models and air sampling in different (health care and experimental) settings, these data should result in a thorough scientific understanding of the inter-human transmission routes of respiratory viruses.", [["respiratory viruses", "DISEASE", 218, 237], ["animal transmission models", "TREATMENT", 14, 40], ["air sampling", "TEST", 45, 57], ["respiratory viruses", "PROBLEM", 218, 237], ["air sampling", "OBSERVATION", 45, 57], ["respiratory viruses", "OBSERVATION", 218, 237]]], ["Eventually, this knowledge will help with an evidence-based risk assessment of the different transmission routes to improve existing infection prevention strategies.", [["infection", "DISEASE", 133, 142], ["based risk assessment", "TEST", 54, 75], ["the different transmission routes", "TREATMENT", 79, 112], ["existing infection prevention strategies", "TREATMENT", 124, 164], ["infection", "OBSERVATION", 133, 142]]]], "PMC7300505": [["In early 2020, the UK Otolaryngology \u2010 Head and Neck Surgery national body (ENT UK) became aware from experience in China and Italy that coronavirus disease 2019 (COVID\u201019) posed a special threat to otolaryngologists\u2013head and neck surgeons.1 This risk was not recognized at the time by Public Health England (PHE), the body charged with directing health and safety policy throughout the UK's National Health Service (NHS).", [["otolaryngologists\u2013head", "ANATOMY", 199, 221], ["neck", "ANATOMY", 226, 230], ["body", "ANATOMY", 319, 323], ["coronavirus disease", "DISEASE", 137, 156], ["PHE", "CHEMICAL", 309, 312], ["neck", "ORGAN", 226, 230], ["body", "ORGANISM_SUBDIVISION", 319, 323], ["coronavirus disease", "PROBLEM", 137, 156], ["Head", "ANATOMY", 39, 43], ["Neck", "ANATOMY", 48, 52], ["neck", "ANATOMY", 226, 230]]], ["It initially had not been appreciated that routine endoscopic procedures of the upper airway as well as other interventions were aerosol\u2010generating procedures (AGPs) transmitting high viral loads to clinicians.", [["upper airway", "ANATOMY", 80, 92], ["upper airway", "ORGANISM_SUBDIVISION", 80, 92], ["routine endoscopic procedures of the upper airway", "TREATMENT", 43, 92], ["other interventions", "TREATMENT", 104, 123], ["aerosol\u2010generating procedures", "TREATMENT", 129, 158], ["transmitting high viral loads", "PROBLEM", 166, 195], ["upper", "ANATOMY_MODIFIER", 80, 85], ["airway", "ANATOMY", 86, 92]]], ["An urgent change of policy was needed.", [["An urgent change of policy", "TREATMENT", 0, 26]]], ["We entered into dialogue with PHE to ensure that recognition of interventions on the upper airway were considered high risk, thus obliging hospitals to make full personal protective equipment (PPE) available to otolaryngologists\u2014a radical change in policy with major resource implications.", [["upper airway", "ANATOMY", 85, 97], ["PHE", "CHEMICAL", 30, 33], ["upper airway", "ORGANISM_SUBDIVISION", 85, 97], ["otolaryngologists\u2014a radical change", "TREATMENT", 211, 245], ["upper", "ANATOMY_MODIFIER", 85, 90], ["airway", "ANATOMY", 91, 97]]], ["The tragic death of an otolaryngologist to COVID\u201019 recorded in March 2020 was a sober reminder of our concerns.", [["death", "DISEASE", 11, 16]]]], "e55d8bed8c37794b13574060d2803f3bb18dbbf6": [["Severe delayed hypersensitivity reactions (DHR) are observed to various drugs that are otherwise highly efficacious.", [["hypersensitivity", "DISEASE", 15, 31], ["DHR", "DISEASE", 43, 46], ["Severe delayed hypersensitivity reactions", "PROBLEM", 0, 41], ["various drugs", "TREATMENT", 64, 77], ["delayed", "OBSERVATION_MODIFIER", 7, 14], ["hypersensitivity reactions", "OBSERVATION", 15, 41]]], ["Particular human leukocyte antigen (HLA) class I and/or class II alleles are associated with DHR risk for particular drugs, allowing screening of patients to inform clinical decision making.", [["human leukocyte antigen", "GENE_OR_GENE_PRODUCT", 11, 34], ["HLA) class I", "GENE_OR_GENE_PRODUCT", 36, 48], ["DHR", "SIMPLE_CHEMICAL", 93, 96], ["patients", "ORGANISM", 146, 154], ["human leukocyte antigen (HLA) class I and/or class II alleles", "DNA", 11, 72], ["human", "SPECIES", 11, 16], ["patients", "SPECIES", 146, 154], ["human", "SPECIES", 11, 16], ["particular drugs", "TREATMENT", 106, 122]]]], "7fafc7d8eae5dc2162c27ffdb640047f2fe73ea7": [["RT-PCR.", [["RT-PCR", "TEST", 0, 6]]], ["An immunochromatography-based COVID-19 immunoglobulin G (IgG)/immunoglobulin M (IgM) rapid test on the sera of the study population was applied to measure the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and receiver operating characteristic (ROC) curve compared to RT-PCR, with a 95% confidence interval (CI).", [["sera", "ANATOMY", 103, 107], ["immunoglobulin G", "GENE_OR_GENE_PRODUCT", 39, 55], ["IgG", "GENE_OR_GENE_PRODUCT", 57, 60], ["immunoglobulin M", "GENE_OR_GENE_PRODUCT", 62, 78], ["IgM", "GENE_OR_GENE_PRODUCT", 80, 83], ["sera", "ORGANISM_SUBSTANCE", 103, 107], ["COVID", "PROTEIN", 30, 35], ["immunoglobulin G", "PROTEIN", 39, 55], ["IgG", "PROTEIN", 57, 60], ["immunoglobulin M", "PROTEIN", 62, 78], ["IgM", "PROTEIN", 80, 83], ["An immunochromatography", "TEST", 0, 23], ["COVID", "TEST", 30, 35], ["immunoglobulin G", "TEST", 39, 55], ["IgG", "TEST", 57, 60], ["immunoglobulin M (IgM", "TEST", 62, 83], ["rapid test", "TEST", 85, 95], ["the sera", "TEST", 99, 107], ["the study population", "TEST", 111, 131], ["PPV", "TEST", 212, 215], ["NPV", "TEST", 245, 248], ["RT-PCR", "TEST", 313, 319], ["CI", "TEST", 353, 355]]], ["IgM or IgG antibodies were detected in 65 subjects (SARS-CoV-2).", [["IgM", "GENE_OR_GENE_PRODUCT", 0, 3], ["IgG", "GENE_OR_GENE_PRODUCT", 7, 10], ["IgM", "PROTEIN", 0, 3], ["IgG antibodies", "PROTEIN", 7, 21], ["SARS-CoV", "SPECIES", 52, 60], ["IgM", "TEST", 0, 3], ["IgG antibodies", "TEST", 7, 21], ["SARS", "TEST", 52, 56], ["CoV", "TEST", 57, 60]]], ["2 The disease is also referred to as coronavirus disease 2019 .", [["coronavirus disease", "DISEASE", 37, 56], ["The disease", "PROBLEM", 2, 13], ["coronavirus disease", "PROBLEM", 37, 56], ["disease", "OBSERVATION", 6, 13]]], ["3 The global mortality rate of COVID-19 was reported to range from 1.5% to 3.6%.", [["COVID-19", "CHEMICAL", 31, 39], ["The global mortality rate", "TEST", 2, 27], ["COVID", "TEST", 31, 36], ["global", "OBSERVATION_MODIFIER", 6, 12], ["mortality", "OBSERVATION_MODIFIER", 13, 22]]], ["4 Currently, the diagnosis of COVID-19 has been confirmed using next-generation sequencing or real-time reverse| RESULTSBaseline characteristics of the study population were described at and headache in positive COVID-19 group was higher than that of the negative group (P = .009, P < .001, P < .001, and P = .031, respectively).| RESULTSIn the analysis of immmunochromatography for COVID -19, there were no subjects in the RT-PCR positive group and two subjects (2.5%)| RESULTSin the RT-PCR negative group who only produced the IgM antibody (Table 2 ).", [["headache", "DISEASE", 191, 199], ["IgM antibody", "PROTEIN", 529, 541], ["COVID", "TEST", 30, 35], ["the study population", "TEST", 148, 168], ["headache", "PROBLEM", 191, 199], ["positive COVID", "TEST", 203, 217], ["P", "TEST", 271, 272], ["P", "TEST", 281, 282], ["P", "TEST", 291, 292], ["P", "TEST", 305, 306], ["the analysis", "TEST", 341, 353], ["immmunochromatography", "TEST", 357, 378], ["COVID", "TEST", 383, 388], ["the RT-PCR", "TEST", 420, 430], ["the RT-PCR", "TEST", 481, 491], ["the IgM antibody", "TEST", 525, 541]]], ["In addition, 19 patients ( Figure 1A) .", [["patients", "ORGANISM", 16, 24], ["patients", "SPECIES", 16, 24]]], ["A gradual decrease in NPV of either IgM or IgG positivity from 99.9% to 95.3% was observed with increasing from 1% to 50% disease prevalence ( Figure 1B The WHO announced that Chinese authorities had identified a novel type of coronavirus on 7 January 2020.", [["coronavirus", "DISEASE", 227, 238], ["IgM", "GENE_OR_GENE_PRODUCT", 36, 39], ["IgG", "GENE_OR_GENE_PRODUCT", 43, 46], ["coronavirus", "ORGANISM", 227, 238], ["IgM", "PROTEIN", 36, 39], ["IgG", "PROTEIN", 43, 46], ["A gradual decrease", "PROBLEM", 0, 18], ["NPV", "TEST", 22, 25], ["IgM", "TEST", 36, 39], ["IgG positivity", "TEST", 43, 57], ["coronavirus", "PROBLEM", 227, 238], ["gradual", "OBSERVATION_MODIFIER", 2, 9], ["decrease", "OBSERVATION_MODIFIER", 10, 18]]], ["9 Presently, RT-PCR, a nucleic acid amplification test (NAAT), has been routinely used to detect COVID-19 infection in many countries around the world.", [["nucleic acid", "CHEMICAL", 23, 35], ["infection", "DISEASE", 106, 115], ["COVID-19", "CELL", 97, 105], ["COVID-19", "SPECIES", 97, 105], ["RT-PCR", "TEST", 13, 19], ["a nucleic acid amplification test", "TEST", 21, 54], ["COVID-19 infection", "PROBLEM", 97, 115], ["infection", "OBSERVATION", 106, 115]]], ["1, 2, 5, 6 In this study, we assessed the diagnostic value of a new immunochromatography assay to detect IgM and IgG antibodies for However, there are some limitations or weaknesses in the areas of confirmation of COVID-19 diagnosis by RT-PCR testing alone, such as the inability to distinguish virus viability and production of indeterminate or false-negative results due to low numbers of target cells in specimens, although RT-PCR remains a powerful technique for microbial diagnostics.", [["cells", "ANATOMY", 398, 403], ["specimens", "ANATOMY", 407, 416], ["IgM", "GENE_OR_GENE_PRODUCT", 105, 108], ["IgG antibodies", "GENE_OR_GENE_PRODUCT", 113, 127], ["cells", "CELL", 398, 403], ["specimens", "CELL", 407, 416], ["IgM", "PROTEIN", 105, 108], ["IgG antibodies", "PROTEIN", 113, 127], ["target cells", "CELL_TYPE", 391, 403], ["this study", "TEST", 14, 24], ["a new immunochromatography assay", "TEST", 62, 94], ["IgM", "TEST", 105, 108], ["IgG antibodies", "TEST", 113, 127], ["weaknesses", "PROBLEM", 171, 181], ["COVID", "TEST", 214, 219], ["RT-PCR testing", "TEST", 236, 250], ["virus viability", "PROBLEM", 295, 310], ["low numbers of target cells in specimens", "PROBLEM", 376, 416], ["RT-PCR", "TEST", 427, 433], ["microbial diagnostics", "TEST", 467, 488], ["indeterminate", "OBSERVATION_MODIFIER", 329, 342]]], ["14 Laboratory assays such as ELISA and immunochromatography that use serum or blood sampled from suspected or established patients with COVID-19 infection have been proposed to overcome or supplement these limitations.| RESULTSOne study using In-house anti-SARSr-CoV IgG and IgM ELISA to target the N gene showed that the IgM antibody level increased rapidly in the early stages of COVID-19 infection and then decreased in the later stages.", [["serum", "ANATOMY", 69, 74], ["blood", "ANATOMY", 78, 83], ["infection", "DISEASE", 145, 154], ["infection", "DISEASE", 391, 400], ["serum", "ORGANISM_SUBSTANCE", 69, 74], ["blood", "ORGANISM_SUBSTANCE", 78, 83], ["patients", "ORGANISM", 122, 130], ["IgM", "GENE_OR_GENE_PRODUCT", 275, 278], ["IgM antibody", "GENE_OR_GENE_PRODUCT", 322, 334], ["anti-SARSr-CoV IgG", "PROTEIN", 252, 270], ["IgM", "PROTEIN", 275, 278], ["N gene", "DNA", 299, 305], ["IgM antibody", "PROTEIN", 322, 334], ["patients", "SPECIES", 122, 130], ["Laboratory assays", "TEST", 3, 20], ["ELISA", "TEST", 29, 34], ["immunochromatography", "TEST", 39, 59], ["serum", "TEST", 69, 74], ["blood sampled", "TEST", 78, 91], ["COVID-19 infection", "PROBLEM", 136, 154], ["RESULTSOne study", "TEST", 220, 236], ["IgM ELISA", "TEST", 275, 284], ["the N gene", "TEST", 295, 305], ["the IgM antibody level", "TEST", 318, 340], ["COVID-19 infection", "PROBLEM", 382, 400], ["early stages", "OBSERVATION_MODIFIER", 366, 378], ["infection", "OBSERVATION", 391, 400], ["decreased", "OBSERVATION_MODIFIER", 410, 419]]], ["13 Furthermore, the IgG antibody was insignificantly expressed in the early stages of infection but increased rapidly in the later stages.", [["infection", "DISEASE", 86, 95], ["IgG antibody", "GENE_OR_GENE_PRODUCT", 20, 32], ["IgG antibody", "PROTEIN", 20, 32], ["the IgG antibody", "TEST", 16, 32], ["infection", "PROBLEM", 86, 95], ["early stages", "OBSERVATION_MODIFIER", 70, 82], ["infection", "OBSERVATION", 86, 95], ["increased", "OBSERVATION_MODIFIER", 100, 109], ["rapidly", "OBSERVATION_MODIFIER", 110, 117]]], ["Interestingly, titers of both IgM and IgG antibodies in COVID-19 patients were significantly higher than those assessed in healthy subjects.", [["IgM", "GENE_OR_GENE_PRODUCT", 30, 33], ["IgG antibodies", "GENE_OR_GENE_PRODUCT", 38, 52], ["patients", "ORGANISM", 65, 73], ["IgM", "PROTEIN", 30, 33], ["IgG antibodies", "PROTEIN", 38, 52], ["patients", "SPECIES", 65, 73], ["titers", "TEST", 15, 21], ["both IgM", "TEST", 25, 33], ["IgG antibodies", "TEST", 38, 52], ["COVID", "TEST", 56, 61]]], ["Infections have been reported to be reactivated in patients and confirmed by RT-PCR testing.", [["Infections", "DISEASE", 0, 10], ["patients", "ORGANISM", 51, 59], ["patients", "SPECIES", 51, 59], ["Infections", "PROBLEM", 0, 10], ["RT-PCR testing", "TEST", 77, 91]]], ["15 Therefore, serial quantitative results using ELISA may help not only confirm the diagnosis but also predict the clinical course of a patient.| RESULTSImmunochromatography is another diagnostic alternative that has been proposed to detect COVID-19 infection.", [["infection", "DISEASE", 250, 259], ["patient", "ORGANISM", 136, 143], ["COVID-19", "GENE_OR_GENE_PRODUCT", 241, 249], ["patient", "SPECIES", 136, 143], ["COVID-19", "SPECIES", 241, 249], ["ELISA", "TEST", 48, 53], ["COVID", "TEST", 241, 246], ["infection", "PROBLEM", 250, 259], ["infection", "OBSERVATION", 250, 259]]], ["This technique was developed in the late 1960s to detect antigens in the blood and has recently been used as a rapid diagnostic method for various viral infections, such as Norovirus and influenza.", [["blood", "ANATOMY", 73, 78], ["viral infections", "DISEASE", 147, 163], ["Norovirus", "DISEASE", 173, 182], ["influenza", "DISEASE", 187, 196], ["blood", "ORGANISM_SUBSTANCE", 73, 78], ["antigens", "PROTEIN", 57, 65], ["antigens in the blood", "PROBLEM", 57, 78], ["a rapid diagnostic method", "TREATMENT", 109, 134], ["various viral infections", "PROBLEM", 139, 163], ["Norovirus", "PROBLEM", 173, 182], ["influenza", "PROBLEM", 187, 196], ["viral infections", "OBSERVATION", 147, 163]]], ["16, 17 The benefits or advantages of immunochromatography include its ability to be performed at bedside without special laboratory equipment, its ease of performance, its simple interpretation, and its rapid time to produce results, which may compare favorably to other diagnostic tools, such as RT-PCR and ELISA methods.", [["immunochromatography", "TEST", 37, 57], ["diagnostic tools", "TEST", 271, 287], ["RT-PCR", "TEST", 297, 303], ["ELISA methods", "TEST", 308, 321]]], ["There are some limitations to this study.", [["this study", "TEST", 30, 40]]], ["First, it was not possible to observe changes in antibodies from the time of patient diagnosis to the time of participation in the study because this study was conducted in a cross-sectional manner.", [["patient", "ORGANISM", 77, 84], ["antibodies", "PROTEIN", 49, 59], ["patient", "SPECIES", 77, 84], ["changes in antibodies", "PROBLEM", 38, 59], ["the study", "TEST", 127, 136], ["this study", "TEST", 145, 155], ["not possible", "UNCERTAINTY", 14, 26]]], ["Second, the quantitative titer for each antibody expressed in the test kit could not be confirmed and is, therefore, a methodological limitation of immunochromatography.| RESULTSThird, it may be difficult to fully represent the diagnostic values, especially the sensitivity and specificity, of the diagnostic kit due to the small size of the study population.| RESULTSIn conclusion, immunochromatography demonstrated higher", [["each antibody", "TEST", 35, 48], ["the test kit", "TEST", 62, 74], ["immunochromatography", "TEST", 148, 168], ["the diagnostic kit", "TEST", 294, 312], ["the study population", "TEST", 338, 358], ["immunochromatography", "TEST", 383, 403], ["small", "OBSERVATION_MODIFIER", 324, 329], ["size", "OBSERVATION_MODIFIER", 330, 334], ["higher", "OBSERVATION_MODIFIER", 417, 423]]]], "PMC7242893": [["BackgroundCirculating miRNAs have emerged as new disease-biomarkers in human cancer [1], and in animals [2\u20134].", [["cancer", "ANATOMY", 77, 83], ["cancer", "DISEASE", 77, 83], ["human", "ORGANISM", 71, 76], ["cancer", "CANCER", 77, 83], ["human", "SPECIES", 71, 76], ["human", "SPECIES", 71, 76], ["BackgroundCirculating miRNAs", "PROBLEM", 0, 28], ["new disease", "PROBLEM", 45, 56], ["human cancer", "PROBLEM", 71, 83], ["cancer", "OBSERVATION", 77, 83]]], ["The goals of this study were to identify PBMCs miRNAs profiles in Indian water buffalo associated with economically devastating diseases, namely, brucellosis and paratuberculosis (Johne\u2019s disease or JD).", [["PBMCs", "ANATOMY", 41, 46], ["brucellosis and paratuberculosis", "DISEASE", 146, 178], ["Johne\u2019s disease", "DISEASE", 180, 195], ["JD", "DISEASE", 199, 201], ["PBMCs", "CELL", 41, 46], ["PBMCs", "CELL_TYPE", 41, 46], ["paratuberculosis", "SPECIES", 162, 178], ["buffalo", "SPECIES", 79, 86], ["paratuberculosis", "SPECIES", 162, 178], ["Johne", "SPECIES", 180, 185], ["this study", "TEST", 13, 23], ["economically devastating diseases", "PROBLEM", 103, 136], ["brucellosis", "PROBLEM", 146, 157], ["paratuberculosis (Johne\u2019s disease", "PROBLEM", 162, 195], ["devastating", "OBSERVATION_MODIFIER", 116, 127], ["diseases", "OBSERVATION", 128, 136], ["brucellosis", "OBSERVATION", 146, 157], ["paratuberculosis", "OBSERVATION", 162, 178]]], ["Brucellosis an important zoonotic disease of livestock is caused by facultative, gram-negative bacteria of Brucella genus.", [["Brucellosis", "DISEASE", 0, 11], ["zoonotic disease of livestock", "DISEASE", 25, 54], ["Brucella genus", "ORGANISM", 107, 121], ["Brucellosis", "PROBLEM", 0, 11], ["gram", "TEST", 81, 85], ["Brucella genus", "PROBLEM", 107, 121], ["important", "UNCERTAINTY", 15, 24], ["zoonotic disease", "OBSERVATION", 25, 41], ["facultative", "OBSERVATION_MODIFIER", 68, 79], ["negative bacteria", "OBSERVATION_MODIFIER", 86, 103], ["Brucella genus", "OBSERVATION", 107, 121]]], ["This intracellular organism generally enters the host via the nasal and oral routes followed by invasion and proliferation within monocytic phagocytes [5].", [["intracellular", "ANATOMY", 5, 18], ["nasal", "ANATOMY", 62, 67], ["oral", "ANATOMY", 72, 76], ["monocytic phagocytes", "ANATOMY", 130, 150], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 5, 18], ["nasal", "ORGANISM_SUBDIVISION", 62, 67], ["oral", "ORGANISM_SUBDIVISION", 72, 76], ["monocytic phagocytes", "CELL", 130, 150], ["monocytic phagocytes", "CELL_TYPE", 130, 150], ["This intracellular organism", "PROBLEM", 0, 27], ["the nasal and oral routes", "TREATMENT", 58, 83], ["invasion and proliferation within monocytic phagocytes", "PROBLEM", 96, 150], ["organism", "OBSERVATION", 19, 27], ["nasal", "ANATOMY", 62, 67], ["invasion", "OBSERVATION", 96, 104], ["monocytic phagocytes", "OBSERVATION", 130, 150]]], ["It spreads via macrophages to the lymph nodes, spleen, liver, bone marrow, mammary glands, and reproductive organs.", [["macrophages", "ANATOMY", 15, 26], ["lymph nodes", "ANATOMY", 34, 45], ["spleen", "ANATOMY", 47, 53], ["liver", "ANATOMY", 55, 60], ["bone marrow", "ANATOMY", 62, 73], ["mammary glands", "ANATOMY", 75, 89], ["reproductive organs", "ANATOMY", 95, 114], ["macrophages", "CELL", 15, 26], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 34, 45], ["spleen", "ORGAN", 47, 53], ["liver", "ORGAN", 55, 60], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 62, 73], ["mammary glands", "ORGAN", 75, 89], ["reproductive organs", "ORGAN", 95, 114], ["macrophages", "CELL_TYPE", 15, 26], ["macrophages", "OBSERVATION", 15, 26], ["lymph nodes", "OBSERVATION", 34, 45], ["spleen", "ANATOMY", 47, 53], ["liver", "ANATOMY", 55, 60], ["bone marrow", "ANATOMY", 62, 73], ["mammary glands", "ANATOMY", 75, 89]]], ["Another important disease that has been encountered in dairy animals is the paratuberculosis (Johne\u2019s disease or JD) caused by Mycobacterium avium subspecies paratuberculosis (MAP).", [["Johne\u2019s disease", "DISEASE", 94, 109], ["JD", "DISEASE", 113, 115], ["Mycobacterium avium subspecies paratuberculosis", "DISEASE", 127, 174], ["Mycobacterium avium subspecies paratuberculosis", "ORGANISM", 127, 174], ["MAP", "GENE_OR_GENE_PRODUCT", 176, 179], ["Mycobacterium avium", "SPECIES", 127, 146], ["subspecies paratuberculosis", "SPECIES", 147, 174], ["paratuberculosis", "SPECIES", 76, 92], ["Johne", "SPECIES", 94, 99], ["Mycobacterium avium subspecies paratuberculosis", "SPECIES", 127, 174], ["Another important disease", "PROBLEM", 0, 25], ["the paratuberculosis (Johne\u2019s disease", "PROBLEM", 72, 109], ["Mycobacterium avium subspecies paratuberculosis", "PROBLEM", 127, 174], ["disease", "OBSERVATION", 18, 25], ["paratuberculosis", "OBSERVATION", 76, 92], ["Mycobacterium", "OBSERVATION_MODIFIER", 127, 140], ["avium", "OBSERVATION_MODIFIER", 141, 146], ["subspecies", "OBSERVATION_MODIFIER", 147, 157], ["paratuberculosis", "OBSERVATION", 158, 174]]], ["Calves mainly acquire the infection through oral route by uptake of MAP via colostrum, milk or feed contaminated with fecal matter [6] or via intrauterine route [7].", [["oral", "ANATOMY", 44, 48], ["colostrum", "ANATOMY", 76, 85], ["milk", "ANATOMY", 87, 91], ["fecal matter", "ANATOMY", 118, 130], ["intrauterine", "ANATOMY", 142, 154], ["infection", "DISEASE", 26, 35], ["MAP", "CHEMICAL", 68, 71], ["Calves", "ORGANISM", 0, 6], ["oral", "ORGANISM_SUBDIVISION", 44, 48], ["MAP", "GENE_OR_GENE_PRODUCT", 68, 71], ["colostrum", "ORGANISM_SUBSTANCE", 76, 85], ["milk", "ORGANISM_SUBSTANCE", 87, 91], ["Calves", "SPECIES", 0, 6], ["the infection", "PROBLEM", 22, 35], ["fecal matter", "TREATMENT", 118, 130], ["infection", "OBSERVATION", 26, 35]]], ["Following the invasion, the bacteria primarily resides in the mucosal tissues of gut and its associated lymph nodes and spreads to bloodstream, milk and other peripheral tissues [8].", [["mucosal tissues", "ANATOMY", 62, 77], ["gut", "ANATOMY", 81, 84], ["lymph nodes", "ANATOMY", 104, 115], ["bloodstream", "ANATOMY", 131, 142], ["milk", "ANATOMY", 144, 148], ["peripheral tissues", "ANATOMY", 159, 177], ["mucosal tissues", "TISSUE", 62, 77], ["gut", "ORGAN", 81, 84], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 104, 115], ["milk", "ORGANISM_SUBSTANCE", 144, 148], ["peripheral tissues", "TISSUE", 159, 177], ["the invasion", "PROBLEM", 10, 22], ["the bacteria", "PROBLEM", 24, 36], ["its associated lymph nodes", "PROBLEM", 89, 115], ["invasion", "OBSERVATION", 14, 22], ["bacteria", "OBSERVATION", 28, 36], ["mucosal tissues", "ANATOMY", 62, 77], ["gut", "ANATOMY", 81, 84], ["lymph nodes", "OBSERVATION", 104, 115], ["bloodstream", "OBSERVATION_MODIFIER", 131, 142], ["peripheral", "ANATOMY_MODIFIER", 159, 169], ["tissues", "ANATOMY", 170, 177]]], ["MAP being an obligate intracellular pathogen resides in host macrophages and enhance its survival by inhibiting intracellular phagosomal activation and maturation [9, 10].", [["intracellular", "ANATOMY", 22, 35], ["macrophages", "ANATOMY", 61, 72], ["intracellular", "ANATOMY", 112, 125], ["MAP", "GENE_OR_GENE_PRODUCT", 0, 3], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 22, 35], ["macrophages", "CELL", 61, 72], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 112, 125], ["host macrophages", "CELL_TYPE", 56, 72], ["MAP", "TEST", 0, 3], ["an obligate intracellular pathogen", "PROBLEM", 10, 44], ["host macrophages", "OBSERVATION", 56, 72], ["phagosomal activation", "OBSERVATION", 126, 147]]], ["Thus, Brucellosis and JD, causes substantial economic losses to livestock worldwide and hence scientific research has been focused on their diagnosis, prevention, and control.BackgroundThe currently available diagnostic tests of MAP infection, which are based on assays of IFN-\u03b3 and PCR, have the limitation of sensitivity and specificity, particularly in detecting early stage of infection [11, 12].", [["Brucellosis", "DISEASE", 6, 17], ["JD", "DISEASE", 22, 24], ["MAP infection", "DISEASE", 229, 242], ["infection", "DISEASE", 381, 390], ["MAP", "GENE_OR_GENE_PRODUCT", 229, 232], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 273, 278], ["IFN", "PROTEIN", 273, 276], ["Brucellosis", "PROBLEM", 6, 17], ["JD", "PROBLEM", 22, 24], ["substantial economic losses", "PROBLEM", 33, 60], ["diagnostic tests", "TEST", 209, 225], ["MAP infection", "PROBLEM", 229, 242], ["assays", "TEST", 263, 269], ["IFN", "TEST", 273, 276], ["PCR", "TEST", 283, 286], ["sensitivity", "TEST", 311, 322], ["specificity", "TEST", 327, 338], ["infection", "PROBLEM", 381, 390], ["Brucellosis", "OBSERVATION", 6, 17], ["substantial", "OBSERVATION_MODIFIER", 33, 44], ["economic losses", "OBSERVATION", 45, 60], ["infection", "OBSERVATION", 233, 242], ["infection", "OBSERVATION", 381, 390]]], ["Therefore search for novel and alternative diagnostic biomarkers such as microRNAs for early stages of MAP infection would be beneficial.BackgroundThe microRNAs (miRNAs) are short (~ 22 nt), non-coding RNAs that regulate post-transcriptional expression of mRNAs of at least one-third of known mammalian genes.", [["MAP infection", "DISEASE", 103, 116], ["MAP", "GENE_OR_GENE_PRODUCT", 103, 106], ["microRNAs", "DNA", 151, 160], ["miRNAs", "DNA", 162, 168], ["~ 22 nt), non-coding RNAs", "RNA", 181, 206], ["mRNAs", "RNA", 256, 261], ["mammalian genes", "DNA", 293, 308], ["alternative diagnostic biomarkers", "TEST", 31, 64], ["MAP infection", "PROBLEM", 103, 116], ["non-coding RNAs", "PROBLEM", 191, 206], ["infection", "OBSERVATION", 107, 116], ["microRNAs", "OBSERVATION", 151, 160], ["mammalian genes", "OBSERVATION", 293, 308]]], ["These miniature RNAs play an instrumental role in immune regulation and disease pathogenesis [13\u201315].", [["miniature RNAs", "RNA", 6, 20], ["These miniature RNAs", "PROBLEM", 0, 20], ["disease pathogenesis", "PROBLEM", 72, 92]]], ["Moreover, circulating miRNAs in the serum or plasma has also been reported.", [["serum", "ANATOMY", 36, 41], ["plasma", "ANATOMY", 45, 51], ["serum", "ORGANISM_SUBSTANCE", 36, 41], ["plasma", "ORGANISM_SUBSTANCE", 45, 51], ["the serum", "TEST", 32, 41], ["circulating miRNAs", "OBSERVATION", 10, 28]]], ["De-regulation of certain miRNAs indicates their utilization as potential biomarkers for various types of cardiovascular, nervous system diseases and cancer [16\u201318].", [["cardiovascular", "ANATOMY", 105, 119], ["nervous system", "ANATOMY", 121, 135], ["cancer", "ANATOMY", 149, 155], ["cardiovascular, nervous system diseases", "DISEASE", 105, 144], ["cancer", "DISEASE", 149, 155], ["cardiovascular", "ANATOMICAL_SYSTEM", 105, 119], ["nervous", "ANATOMICAL_SYSTEM", 121, 128], ["system", "ANATOMICAL_SYSTEM", 129, 135], ["cancer", "CANCER", 149, 155], ["potential biomarkers", "TEST", 63, 83], ["cardiovascular, nervous system diseases", "PROBLEM", 105, 144], ["cancer", "PROBLEM", 149, 155], ["certain miRNAs", "OBSERVATION", 17, 31], ["cardiovascular", "ANATOMY", 105, 119]]], ["However, their possible association with the diseases in livestock species, particularly in buffalo, is the least studied.BackgroundA plethora of reports are available on immune and cytokine responses of Brucella infected peripheral blood mononuclear cells (PBMC) which have been exploited either for diagnosis or for vaccine development [19\u201322].", [["peripheral blood mononuclear cells", "ANATOMY", 222, 256], ["PBMC", "ANATOMY", 258, 262], ["buffalo", "ORGANISM", 92, 99], ["Brucella", "ORGANISM", 204, 212], ["peripheral blood mononuclear cells", "CELL", 222, 256], ["PBMC", "CELL", 258, 262], ["cytokine", "PROTEIN", 182, 190], ["Brucella infected peripheral blood mononuclear cells", "CELL_TYPE", 204, 256], ["PBMC", "CELL_TYPE", 258, 262], ["buffalo", "SPECIES", 92, 99], ["the diseases in livestock species", "PROBLEM", 41, 74], ["cytokine responses", "TEST", 182, 200], ["Brucella infected peripheral blood mononuclear cells", "PROBLEM", 204, 256], ["vaccine development", "PROBLEM", 318, 337], ["diseases", "OBSERVATION", 45, 53], ["livestock species", "OBSERVATION", 57, 74], ["mononuclear cells", "OBSERVATION", 239, 256]]], ["Similarly, recent studies on transcriptional profiling of PBMCs in cattle suffering from Johne\u2019s disease have identified upregulated expression of genes (such as IL-5 & transcription factor GATA-3) promoting growth and differentiation of hematopoietic progenitor cells and T-lymphocytes genes as well as activation of neutrophils and macrophages.", [["PBMCs", "ANATOMY", 58, 63], ["hematopoietic progenitor cells", "ANATOMY", 238, 268], ["T-lymphocytes", "ANATOMY", 273, 286], ["neutrophils", "ANATOMY", 318, 329], ["macrophages", "ANATOMY", 334, 345], ["Johne\u2019s disease", "DISEASE", 89, 104], ["PBMCs", "CELL", 58, 63], ["cattle", "ORGANISM", 67, 73], ["IL-5", "GENE_OR_GENE_PRODUCT", 162, 166], ["GATA-3", "GENE_OR_GENE_PRODUCT", 190, 196], ["hematopoietic progenitor cells", "CELL", 238, 268], ["T-lymphocytes", "CELL", 273, 286], ["neutrophils", "CELL", 318, 329], ["macrophages", "CELL", 334, 345], ["PBMCs", "CELL_TYPE", 58, 63], ["IL-5 & transcription factor GATA-3", "PROTEIN", 162, 196], ["hematopoietic progenitor cells", "CELL_TYPE", 238, 268], ["T-lymphocytes genes", "DNA", 273, 292], ["neutrophils", "CELL_TYPE", 318, 329], ["macrophages", "CELL_TYPE", 334, 345], ["cattle", "SPECIES", 67, 73], ["cattle", "SPECIES", 67, 73], ["Johne", "SPECIES", 89, 94], ["recent studies", "TEST", 11, 25], ["disease", "PROBLEM", 97, 104], ["upregulated expression of genes", "PROBLEM", 121, 152], ["transcription factor GATA", "TEST", 169, 194], ["promoting growth", "PROBLEM", 198, 214], ["hematopoietic progenitor cells", "PROBLEM", 238, 268], ["T-lymphocytes genes", "PROBLEM", 273, 292], ["neutrophils", "TEST", 318, 329], ["hematopoietic progenitor cells", "OBSERVATION", 238, 268], ["macrophages", "ANATOMY", 334, 345]]], ["Further, infection with M. paratuberculosis is shown to be associated with upregulated expression of genes (Bad, CIDE-A, Fas, TNFRI) responsible for promoting apoptosis as well as genes (tissue inhibitors of matrix metalloproteinases, TIMP-1 and TIMP-2) having role in modeling extracellular matrix and tissue [23].", [["tissue", "ANATOMY", 187, 193], ["extracellular matrix", "ANATOMY", 278, 298], ["tissue", "ANATOMY", 303, 309], ["infection", "DISEASE", 9, 18], ["M. paratuberculosis", "ORGANISM", 24, 43], ["Bad", "GENE_OR_GENE_PRODUCT", 108, 111], ["CIDE-A", "GENE_OR_GENE_PRODUCT", 113, 119], ["Fas", "GENE_OR_GENE_PRODUCT", 121, 124], ["TNFRI", "GENE_OR_GENE_PRODUCT", 126, 131], ["tissue inhibitors of matrix metalloproteinases", "GENE_OR_GENE_PRODUCT", 187, 233], ["TIMP-1", "GENE_OR_GENE_PRODUCT", 235, 241], ["TIMP-2", "GENE_OR_GENE_PRODUCT", 246, 252], ["extracellular matrix", "CELLULAR_COMPONENT", 278, 298], ["tissue", "TISSUE", 303, 309], ["Bad", "DNA", 108, 111], ["CIDE", "DNA", 113, 117], ["Fas", "DNA", 121, 124], ["TNFRI", "DNA", 126, 131], ["matrix metalloproteinases", "PROTEIN", 208, 233], ["TIMP", "PROTEIN", 235, 239], ["TIMP", "PROTEIN", 246, 250], ["M. paratuberculosis", "SPECIES", 24, 43], ["M. paratuberculosis", "SPECIES", 24, 43], ["infection", "PROBLEM", 9, 18], ["M. paratuberculosis", "PROBLEM", 24, 43], ["CIDE", "TEST", 113, 117], ["promoting apoptosis", "PROBLEM", 149, 168], ["matrix metalloproteinases", "TEST", 208, 233], ["TIMP", "TEST", 235, 239], ["TIMP", "TEST", 246, 250], ["infection", "OBSERVATION", 9, 18], ["paratuberculosis", "OBSERVATION", 27, 43], ["apoptosis", "OBSERVATION", 159, 168]]], ["Additionally, natural infection of cattle with M. avium paratuberculosis (MAP) resulted in upregulated expression of the CD40 receptor and its ligand in PBMC [24].BackgroundSome immune-related miRNAs were up-regulated in various cells in response to intracellular pathogens, viz. mycobacterium infections [25, 26].", [["PBMC", "ANATOMY", 153, 157], ["cells", "ANATOMY", 229, 234], ["intracellular", "ANATOMY", 250, 263], ["infection", "DISEASE", 22, 31], ["mycobacterium infections", "DISEASE", 280, 304], ["cattle", "ORGANISM", 35, 41], ["M. avium paratuberculosis", "ORGANISM", 47, 72], ["MAP", "GENE_OR_GENE_PRODUCT", 74, 77], ["CD40 receptor", "GENE_OR_GENE_PRODUCT", 121, 134], ["PBMC", "CELL", 153, 157], ["cells", "CELL", 229, 234], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 250, 263], ["CD40 receptor", "PROTEIN", 121, 134], ["PBMC", "CELL_TYPE", 153, 157], ["cattle", "SPECIES", 35, 41], ["M. avium", "SPECIES", 47, 55], ["paratuberculosis", "SPECIES", 56, 72], ["cattle", "SPECIES", 35, 41], ["M. avium paratuberculosis", "SPECIES", 47, 72], ["natural infection of cattle", "PROBLEM", 14, 41], ["M. avium paratuberculosis", "PROBLEM", 47, 72], ["the CD40 receptor", "TREATMENT", 117, 134], ["related miRNAs", "PROBLEM", 185, 199], ["intracellular pathogens", "PROBLEM", 250, 273], ["mycobacterium infections", "PROBLEM", 280, 304], ["natural", "OBSERVATION_MODIFIER", 14, 21], ["infection", "OBSERVATION", 22, 31], ["avium paratuberculosis", "OBSERVATION", 50, 72], ["intracellular pathogens", "OBSERVATION", 250, 273]]], ["Further, some studies conducted in human have revealed significantly altered circulating miRNA profiles in serum of patients affected by tuberculosis than their respective healthy controls [27, 28].", [["serum", "ANATOMY", 107, 112], ["tuberculosis", "DISEASE", 137, 149], ["human", "ORGANISM", 35, 40], ["serum", "ORGANISM_SUBSTANCE", 107, 112], ["patients", "ORGANISM", 116, 124], ["human", "SPECIES", 35, 40], ["patients", "SPECIES", 116, 124], ["human", "SPECIES", 35, 40], ["some studies", "TEST", 9, 21], ["significantly altered circulating miRNA profiles", "PROBLEM", 55, 103], ["tuberculosis", "PROBLEM", 137, 149], ["significantly", "OBSERVATION_MODIFIER", 55, 68], ["altered", "OBSERVATION_MODIFIER", 69, 76], ["circulating miRNA profiles", "OBSERVATION", 77, 103], ["tuberculosis", "OBSERVATION", 137, 149]]], ["Therefore, corroborating the possiblity that other intracellular mycobacterial and Gram-negative bacterial infections including Johne\u2019s disease and Brucellosis of cattle may also alter the miRNA profiles of PBMCs.", [["intracellular", "ANATOMY", 51, 64], ["PBMCs", "ANATOMY", 207, 212], ["infections", "DISEASE", 107, 117], ["Johne\u2019s disease", "DISEASE", 128, 143], ["Brucellosis", "DISEASE", 148, 159], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 51, 64], ["Gram", "GENE_OR_GENE_PRODUCT", 83, 87], ["cattle", "ORGANISM", 163, 169], ["PBMCs", "CELL", 207, 212], ["PBMCs", "CELL_TYPE", 207, 212], ["cattle", "SPECIES", 163, 169], ["Johne", "SPECIES", 128, 133], ["cattle", "SPECIES", 163, 169], ["other intracellular mycobacterial and Gram-negative bacterial infections", "PROBLEM", 45, 117], ["Johne\u2019s disease", "PROBLEM", 128, 143], ["Brucellosis of cattle", "PROBLEM", 148, 169], ["mycobacterial", "OBSERVATION", 65, 78], ["negative bacterial", "OBSERVATION_MODIFIER", 88, 106], ["infections", "OBSERVATION", 107, 117]]], ["Very limited reports are available on the bubaline miRNA repertoire in context to disease.", [["bubaline miRNA repertoire", "PROTEIN", 42, 67], ["the bubaline miRNA repertoire", "TREATMENT", 38, 67], ["disease", "PROBLEM", 82, 89]]], ["Only one such recent study characterized the serum and vaginal fluids miRNAs involved in Brucella infection in water buffaloes and implicated its use as potential disease prognostic biomarkers [29].", [["serum", "ANATOMY", 45, 50], ["vaginal fluids", "ANATOMY", 55, 69], ["Brucella infection", "DISEASE", 89, 107], ["serum", "ORGANISM_SUBSTANCE", 45, 50], ["vaginal fluids", "MULTI-TISSUE_STRUCTURE", 55, 69], ["Brucella", "ORGANISM", 89, 97], ["recent study", "TEST", 14, 26], ["the serum and vaginal fluids miRNAs", "TEST", 41, 76], ["Brucella infection", "PROBLEM", 89, 107], ["potential disease prognostic biomarkers", "PROBLEM", 153, 192], ["vaginal", "ANATOMY", 55, 62], ["Brucella infection", "OBSERVATION", 89, 107]]], ["Recently our lab also identified isomiRs related to Brucellosis and Jhone\u2019s disease in Indian water buffaloes and classified their predicted targets based on their biological and immune functions [30, 31].BackgroundIn this study, we hypothesized that intracellular bacterial infections with MAP and Brucella causes significant changes in the miRNA profiles of bubaline PBMCs and profiling the repertoire of those miRNAs could help in identifying biomarker(s) for the diagnosis as well as disease resistance/susceptibility of animals.", [["intracellular", "ANATOMY", 251, 264], ["PBMCs", "ANATOMY", 369, 374], ["Brucellosis", "DISEASE", 52, 63], ["Jhone\u2019s disease", "DISEASE", 68, 83], ["bacterial infections", "DISEASE", 265, 285], ["isomiRs", "GENE_OR_GENE_PRODUCT", 33, 40], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 251, 264], ["MAP", "GENE_OR_GENE_PRODUCT", 291, 294], ["bubaline PBMCs", "CELL", 360, 374], ["bubaline PBMCs", "CELL_TYPE", 360, 374], ["isomiRs", "PROBLEM", 33, 40], ["Brucellosis", "PROBLEM", 52, 63], ["Jhone\u2019s disease", "PROBLEM", 68, 83], ["this study", "TEST", 218, 228], ["intracellular bacterial infections", "PROBLEM", 251, 285], ["MAP", "TEST", 291, 294], ["Brucella", "PROBLEM", 299, 307], ["significant changes", "PROBLEM", 315, 334], ["bubaline PBMCs", "TREATMENT", 360, 374], ["disease resistance/susceptibility of animals", "PROBLEM", 488, 532], ["Brucellosis", "OBSERVATION", 52, 63], ["bacterial", "OBSERVATION_MODIFIER", 265, 274], ["infections", "OBSERVATION", 275, 285]]], ["We performed next-generation sequencing of small-RNAs (sRNAs) extracted from the PBMCs of diseased (Johne\u2019s disease and Brucella infected) and healthy buffaloes.", [["PBMCs", "ANATOMY", 81, 86], ["Johne\u2019s disease and Brucella infected", "DISEASE", 100, 137], ["PBMCs", "CELL", 81, 86], ["buffaloes", "ORGANISM", 151, 160], ["small-RNAs", "RNA", 43, 53], ["sRNAs", "DNA", 55, 60], ["PBMCs", "CELL_TYPE", 81, 86], ["buffaloes", "SPECIES", 151, 160], ["buffaloes", "SPECIES", 151, 160], ["small-RNAs (sRNAs)", "PROBLEM", 43, 61], ["diseased (Johne\u2019s disease", "PROBLEM", 90, 115], ["Brucella infected", "PROBLEM", 120, 137], ["small", "OBSERVATION_MODIFIER", 43, 48], ["-RNAs", "OBSERVATION_MODIFIER", 48, 53], ["PBMCs", "ANATOMY", 81, 86], ["diseased", "OBSERVATION_MODIFIER", 90, 98]]], ["The comparison of the catalogued-miRNAs between the diseased and healthy animals further provided a reference for future studies aimed to identify disease biomarkers and to modulate the expression of specific miRNAs for the disease therapeutics.", [["future studies", "TEST", 114, 128], ["disease biomarkers", "TEST", 147, 165], ["the disease therapeutics", "PROBLEM", 220, 244], ["diseased", "OBSERVATION", 52, 60]]], ["The identified differentially expressed miRNAs and their predicted target genes were validated using real-time PCR.Animals ::: Materials and methodsDiseased vis-a-vis healthy water buffaloes (Bubalus bubalis) included in the study were from the dairy farm of our institution i.e. Guru Anagad Dev Veterinary and animal Sciences University (GADVASU), Ludhiana as well as other dairy farms situated in Punjab, based on the history of occurrences of Johne\u2019s disease and Brucellosis (abbreviated as \u201cJD\u201d and \u201cBr\u201d, respectively).", [["Johne\u2019s disease", "DISEASE", 446, 461], ["Brucellosis", "DISEASE", 466, 477], ["buffaloes", "ORGANISM", 181, 190], ["Bubalus bubalis", "ORGANISM", 192, 207], ["target genes", "DNA", 67, 79], ["buffaloes", "SPECIES", 181, 190], ["Bubalus bubalis", "SPECIES", 192, 207], ["Bubalus bubalis", "SPECIES", 192, 207], ["Johne", "SPECIES", 446, 451], ["the study", "TEST", 221, 230], ["Johne\u2019s disease", "PROBLEM", 446, 461], ["Brucellosis", "PROBLEM", 466, 477], ["Brucellosis", "OBSERVATION", 466, 477]]], ["The experimental animals were adult (3 years age) male or female buffaloes of Murrah (abbreviated as \u201cMu\u201d) breed.Diagnosis of disease ::: Materials and methodsAnimal Disease Research Centre (ADRC), GADVASU performed the disease diagnosis (Brucellosis, and Johne\u2019s disease).", [["Brucellosis", "DISEASE", 239, 250], ["Johne\u2019s disease", "DISEASE", 256, 271], ["buffaloes", "ORGANISM", 65, 74], ["Johne", "SPECIES", 256, 261], ["disease", "PROBLEM", 126, 133], ["Brucellosis", "PROBLEM", 239, 250], ["disease", "OBSERVATION", 126, 133], ["Brucellosis", "OBSERVATION", 239, 250]]], ["The Brucellosis-infected animals were diagnosed by the Rose Bengal plate test (RBPT), a rapid slide based agglutination test that detects antibodies against the smooth Brucella species particularly B. abortus, B. melitensis and B. suis [32].", [["Brucellosis-infected", "DISEASE", 4, 24], ["animals", "ORGANISM", 25, 32], ["smooth Brucella species", "ORGANISM", 161, 184], ["B. abortus", "ORGANISM", 198, 208], ["B. melitensis", "ORGANISM", 210, 223], ["B. suis", "ORGANISM", 228, 235], ["antibodies", "PROTEIN", 138, 148], ["B. abortus", "SPECIES", 198, 208], ["B. melitensis", "SPECIES", 210, 223], ["B. suis", "SPECIES", 228, 235], ["B. abortus", "SPECIES", 198, 208], ["B. melitensis", "SPECIES", 210, 223], ["B. suis", "SPECIES", 228, 235], ["The Brucellosis", "PROBLEM", 0, 15], ["infected animals", "PROBLEM", 16, 32], ["the Rose Bengal plate test", "TEST", 51, 77], ["a rapid slide based agglutination test", "TEST", 86, 124], ["antibodies", "PROBLEM", 138, 148], ["the smooth Brucella species", "PROBLEM", 157, 184], ["Brucellosis", "OBSERVATION", 4, 15], ["infected", "OBSERVATION_MODIFIER", 16, 24], ["Brucella species", "OBSERVATION", 168, 184]]], ["The RBPT results were further confirmed by competitive ELISA (cELISA) using Brucella-Ab C-Elisa (Bovine) Kit (Svanova).", [["Bovine", "ORGANISM", 97, 103], ["Kit", "ORGANISM", 105, 108], ["Bovine", "SPECIES", 97, 103], ["Bovine", "SPECIES", 97, 103], ["The RBPT", "TEST", 0, 8], ["cELISA", "TEST", 62, 68], ["Brucella-Ab C-Elisa (Bovine) Kit (Svanova)", "TREATMENT", 76, 118]]], ["The diagnosis of Johne\u2019s disease was done by PCR using primers (IS900/150C: CCGCTAATTGAGAGATGCGATTGG; IS900/921: AATCAACTCC AGCAGCGCGGCCTCG) specifically amplifying 229 bp of target insertion sequence IS900 (i.e. present in multiple genomic copies in all M. paratuberculosis strains) [33].", [["Johne\u2019s disease", "DISEASE", 17, 32], ["M. paratuberculosis strains", "ORGANISM", 255, 282], ["target insertion sequence IS900", "DNA", 175, 206], ["M. paratuberculosis", "SPECIES", 255, 274], ["Johne", "SPECIES", 17, 22], ["M. paratuberculosis", "SPECIES", 255, 274], ["Johne\u2019s disease", "PROBLEM", 17, 32], ["bp", "TEST", 169, 171], ["target insertion sequence IS900", "TREATMENT", 175, 206]]], ["The animals diagnosed positive for the diseases were segregated in different sheds of the respective herds.", [["animals", "ORGANISM", 4, 11], ["the diseases", "PROBLEM", 35, 47], ["diseases", "OBSERVATION", 39, 47]]], ["The experimental animals were divided into three diseased and one healthy control group:Brucellosis-positive Murrah buffaloes (Br-Mu; n = 2).Johne\u2019s disease- positive Murrah buffaloes (JD-Mu; n = 5).Healthy Murrah buffaloes (Ctrl-Mu; n = 4) as a control group.Collection of blood samples and isolation of PBMCs ::: Materials and methodsPeripharal blood samples (15 ml each) were aseptically collected from the jugular vein in an anticoagulant (0.5 M EDTA, 100 \u03bcl) containing collection tube (50 ml) and were kept at 4 \u00b0C using ice packs before further processing in the laboratory.", [["blood samples", "ANATOMY", 274, 287], ["PBMCs", "ANATOMY", 305, 310], ["Peripharal blood samples", "ANATOMY", 336, 360], ["jugular vein", "ANATOMY", 410, 422], ["Brucellosis", "DISEASE", 88, 99], ["Johne\u2019s disease", "DISEASE", 141, 156], ["EDTA", "CHEMICAL", 450, 454], ["animals", "ORGANISM", 17, 24], ["buffaloes", "ORGANISM", 116, 125], ["blood samples", "ORGANISM_SUBSTANCE", 274, 287], ["PBMCs", "CELL", 305, 310], ["blood samples", "ORGANISM_SUBSTANCE", 347, 360], ["jugular vein", "MULTI-TISSUE_STRUCTURE", 410, 422], ["tube", "TISSUE", 486, 490], ["PBMCs", "CELL_TYPE", 305, 310], ["Johne", "SPECIES", 141, 146], ["Johne", "SPECIES", 141, 146], ["Brucellosis", "TEST", 88, 99], ["Johne\u2019s disease", "PROBLEM", 141, 156], ["blood samples", "TEST", 274, 287], ["Peripharal blood samples", "TEST", 336, 360], ["an anticoagulant", "TREATMENT", 426, 442], ["EDTA", "TREATMENT", 450, 454], ["collection tube", "TREATMENT", 475, 490], ["ice packs", "TREATMENT", 527, 536], ["Brucellosis", "OBSERVATION", 88, 99], ["blood", "ANATOMY", 274, 279], ["jugular vein", "ANATOMY", 410, 422]]], ["The density-based gradient centrifugation method, using Hisep 1077 (HiMedia, Mumbai, India), was foolowed for PBMC isolation.", [["PBMC", "ANATOMY", 110, 114], ["Hisep 1077", "CHEMICAL", 56, 66], ["PBMC", "CELL", 110, 114], ["PBMC", "CELL_TYPE", 110, 114], ["PBMC isolation", "TREATMENT", 110, 124], ["density", "OBSERVATION", 4, 11], ["gradient", "OBSERVATION_MODIFIER", 18, 26], ["centrifugation method", "OBSERVATION", 27, 48]]], ["The extracted PBMCs belonging to each of the specific experimental groups (i.e. biological replicates) were pooled into one sample.", [["PBMCs", "ANATOMY", 14, 19], ["PBMCs", "CELL", 14, 19], ["PBMCs", "CELL_TYPE", 14, 19], ["The extracted PBMCs", "TREATMENT", 0, 19], ["PBMCs", "OBSERVATION", 14, 19]]], ["Since only two animal was tested positive for Brucellosis, about 30 ml of blood was collected from these animals in order to get approximately the same PBMCs count for all for the experimental groups.", [["blood", "ANATOMY", 74, 79], ["PBMCs", "ANATOMY", 152, 157], ["Brucellosis", "DISEASE", 46, 57], ["blood", "ORGANISM_SUBSTANCE", 74, 79], ["PBMCs", "CELL", 152, 157], ["PBMCs", "CELL_TYPE", 152, 157], ["Brucellosis", "PROBLEM", 46, 57], ["blood", "TEST", 74, 79], ["the same PBMCs count", "TEST", 143, 163], ["Brucellosis", "OBSERVATION", 46, 57]]], ["The three pooled samples of PBMCs were further processed separately for sRNA extraction and miRNA-sequencing [34].Small-RNA isolation and library preparation ::: Materials and methodsThe pooled PBMCs pellets were further processed for small-RNA extraction using mirVana\u2122 miRNA Isolation Kit (Ambion, Life Technologies, CA, USA).", [["samples", "ANATOMY", 17, 24], ["PBMCs", "ANATOMY", 28, 33], ["PBMCs", "ANATOMY", 194, 199], ["PBMCs", "CELL", 28, 33], ["PBMCs", "CELL", 194, 199], ["PBMCs", "CELL_TYPE", 28, 33], ["PBMCs", "CELL_TYPE", 194, 199], ["PBMCs", "TEST", 28, 33], ["sRNA extraction", "TREATMENT", 72, 87], ["miRNA", "TEST", 92, 97], ["The pooled PBMCs pellets", "TREATMENT", 183, 207], ["small-RNA extraction", "TREATMENT", 235, 255], ["mirVana\u2122 miRNA Isolation", "TREATMENT", 262, 286], ["-", "OBSERVATION_MODIFIER", 119, 120], ["RNA isolation", "OBSERVATION", 120, 133]]], ["The steps included organic phase extraction and RNA immobilization on glass-fiber filters to yield enriched miRNA-fraction.", [["organic phase extraction", "TREATMENT", 19, 43], ["RNA immobilization", "TREATMENT", 48, 66], ["glass-fiber filters", "TREATMENT", 70, 89], ["organic phase", "OBSERVATION", 19, 32], ["enriched miRNA", "OBSERVATION", 99, 113]]], ["The sRNA samples were quantified and tested for quality on Agilent\u2019s Bioanalyzer (Agilent, CA, USA) before further processing.", [["samples", "ANATOMY", 9, 16], ["The sRNA samples", "TEST", 0, 16]]], ["The electropherogram profile of each sRNA sample was obtained and the presence of degraded sRNA, as well as concentrations (pg/\u03bcl) of sRNA, was checked.Small-RNA isolation and library preparation ::: Materials and methodsThe extracted sRNA samples were transported in dry ice to GCC Biotech Pvt. Ltd., Kolkata for next-generation sequencing (NGS).", [["sample", "ANATOMY", 42, 48], ["samples", "ANATOMY", 240, 247], ["sRNA sample", "RNA", 37, 48], ["degraded sRNA", "RNA", 82, 95], ["The electropherogram profile", "TEST", 0, 28], ["each sRNA sample", "TEST", 32, 48], ["degraded sRNA", "PROBLEM", 82, 95], ["sRNA", "PROBLEM", 134, 138], ["The extracted sRNA samples", "PROBLEM", 221, 247], ["next-generation sequencing", "TREATMENT", 314, 340], ["sRNA", "OBSERVATION", 91, 95], ["sRNA", "ANATOMY", 134, 138], ["-", "OBSERVATION_MODIFIER", 157, 158], ["RNA isolation", "OBSERVATION", 158, 171]]], ["The cDNA libraries were prepared using Ion Total RNA-Seq Kit v2 and assessed for quality on an Agilent 2100 Bioanalyzer with DNA 1000 Kit (Agilent Technologies, USA).", [["DNA", "CELLULAR_COMPONENT", 125, 128], ["cDNA libraries", "DNA", 4, 18], ["The cDNA libraries", "TREATMENT", 0, 18], ["Ion Total RNA", "TREATMENT", 39, 52]]], ["Smear analysis was carried out by utilizing 2100 expert program (Agilent Technologies, CA, USA), to determine the size distribution of the amplified DNA.", [["DNA", "CELLULAR_COMPONENT", 149, 152], ["amplified DNA", "DNA", 139, 152], ["Smear analysis", "TEST", 0, 14], ["the amplified DNA", "PROBLEM", 135, 152], ["size", "OBSERVATION_MODIFIER", 114, 118], ["amplified DNA", "OBSERVATION", 139, 152]]], ["For template preparation, equal molar concentration (nM) each cDNA library were immobilized on Ion Sphere Particles for sequencing on Ion PGM\u2122 Sequencer (Life Technologies, USA).", [["cDNA library", "DNA", 62, 74], ["template preparation", "TREATMENT", 4, 24], ["equal molar concentration (nM) each cDNA library", "TREATMENT", 26, 74], ["Ion Sphere Particles", "TREATMENT", 95, 115]]], ["The library workflow uses a proprietary technology to inhibits by-product synthesis and thus eliminating the need of the gel purification to select suitable size range.", [["-product", "SIMPLE_CHEMICAL", 65, 73], ["a proprietary technology", "TREATMENT", 26, 50], ["the gel purification", "TREATMENT", 117, 137], ["size", "OBSERVATION_MODIFIER", 157, 161]]], ["For better coverage and depth analysis, the samples were multiplexed on to two separate Ion Torrent chips (318 chip and 316 chip) .Pre-processing of the raw reads ::: Bioinformatics analysis of miRNA-Seq data ::: Materials and methodsThe three cDNA libraries were sequenced and the raw sequencing data were subjected to pre-processing steps to remove low quality reads containing too many missing nucleotides or reads of inappropriate length (i.e. either less than 18 nucleotides or more than 30 nucleotides).", [["samples", "ANATOMY", 44, 51], ["nucleotides", "CHEMICAL", 468, 479], ["nucleotides", "CHEMICAL", 496, 507], ["cDNA libraries", "DNA", 244, 258], ["depth analysis", "TEST", 24, 38], ["the samples", "TEST", 40, 51], ["Ion Torrent chips", "TREATMENT", 88, 105], ["Bioinformatics analysis", "TEST", 167, 190], ["The three cDNA libraries", "PROBLEM", 234, 258], ["the raw sequencing data", "TEST", 278, 301], ["low quality reads", "PROBLEM", 351, 368], ["too many missing nucleotides", "PROBLEM", 380, 408], ["inappropriate length", "PROBLEM", 421, 441], ["inappropriate length", "OBSERVATION_MODIFIER", 421, 441]]], ["Clean reads were further obtained by trimming adaptor sequences and saved as fastq files which records the unique sequence and its count.", [["trimming adaptor sequences", "DNA", 37, 63], ["trimming adaptor sequences", "TEST", 37, 63], ["the unique sequence", "TEST", 103, 122], ["its count", "TEST", 127, 136]]], ["Further quality control check of filtered reads was performed by K-mer analyisis.Alignment to bovine genome and identification of mature as well as novel miRNAs ::: Bioinformatics analysis of miRNA-Seq data ::: Materials and methodsSince Bubalus bubalis complete genome was not sequenced, all the filtered sequences were mapped to the cattle reference genome (Btau_4.0 assembly), which is the most closely related species to buffalo.", [["bovine", "ORGANISM", 94, 100], ["Bubalus bubalis", "ORGANISM", 238, 253], ["buffalo", "ORGANISM", 425, 432], ["bovine genome", "DNA", 94, 107], ["cattle reference genome", "DNA", 335, 358], ["bovine", "SPECIES", 94, 100], ["Bubalus bubalis", "SPECIES", 238, 253], ["cattle", "SPECIES", 335, 341], ["Bubalus bubalis", "SPECIES", 238, 253], ["cattle", "SPECIES", 335, 341], ["buffalo", "SPECIES", 425, 432], ["filtered reads", "TEST", 33, 47], ["Bioinformatics analysis", "TEST", 165, 188], ["methods", "TREATMENT", 225, 232], ["Btau_", "TEST", 360, 365], ["bovine genome", "OBSERVATION", 94, 107]]], ["Moreover, sRNA sequencing data generally covers sequences of tRNAs, piRNAs, snRNAs and snoRNAs and repeat sequences.", [["snoRNAs", "CELLULAR_COMPONENT", 87, 94], ["tRNAs", "RNA", 61, 66], ["piRNAs", "RNA", 68, 74], ["snRNAs", "RNA", 76, 82], ["snoRNAs", "DNA", 87, 94], ["repeat sequences", "DNA", 99, 115], ["sRNA sequencing data", "TEST", 10, 30], ["tRNAs, piRNAs", "TEST", 61, 74], ["repeat sequences", "TEST", 99, 115]]], ["So to filter out such sequences, the quality-checked reads were then aligned to different libraries viz.", [["such sequences", "TEST", 17, 31]]], ["Rfam database (http://rfam.xfam.org/), Repbase database (http://www.girinst.org/server/RepBase/), tRNA, hairpins and piRNA database (http://pirnabank.ibab.ac.in/about.html).", [["Repbase database", "DNA", 39, 55], ["piRNA database", "DNA", 117, 131], ["Repbase database", "TEST", 39, 55], ["tRNA", "TREATMENT", 98, 102], ["hairpins", "TREATMENT", 104, 112]]], ["To identify to known miRNAs and predict novel miRNAs, filtered reads were aligned to miRNA database i.e. miRBase Release 20 (http://www.mirbase.org/) and categorized with respect to the previously known miRNAs of Bos taurus species.", [["Bos taurus species", "ORGANISM", 213, 231], ["miRNAs", "DNA", 21, 27], ["miRNAs", "DNA", 46, 52], ["Bos taurus", "SPECIES", 213, 223], ["Bos taurus", "SPECIES", 213, 223], ["miRNA database", "TEST", 85, 99], ["miRBase Release", "TREATMENT", 105, 120], ["Bos taurus species", "PROBLEM", 213, 231], ["Bos taurus species", "OBSERVATION", 213, 231]]], ["For attributing imperfect Dicer processing of precursor miRNAs, certain short nucleotide extensions at 3\u2032 and 5\u2032 terminal were taken into account.", [["nucleotide", "CHEMICAL", 78, 88], ["nucleotide", "CHEMICAL", 78, 88], ["Dicer", "GENE_OR_GENE_PRODUCT", 26, 31], ["Dicer", "PROTEIN", 26, 31], ["precursor miRNAs", "RNA", 46, 62], ["3\u2032 and 5\u2032 terminal", "DNA", 103, 121], ["precursor miRNAs", "PROBLEM", 46, 62], ["certain short nucleotide extensions", "PROBLEM", 64, 99], ["precursor miRNAs", "OBSERVATION", 46, 62]]], ["Moreover, mutations and RNA editing sites were identified within the miRNAs by aligning the reads to pre-miRNA.", [["miRNAs", "DNA", 69, 75], ["pre-miRNA", "RNA", 101, 110], ["mutations and RNA editing sites", "PROBLEM", 10, 41], ["miRNAs", "ANATOMY", 69, 75]]], ["Normalized read counts were calculated by taking the ratio of miRNA read counts times one million to the total number reads for each experimental group and then transformed to natural log scale:", [["Normalized read counts", "TEST", 0, 22]]]], "PMC7086623": [["IntroductionAvian infectious bronchitis virus (AIBV), a member of the single-stranded, positive-sense RNA virus family Coronaviridae, infects domestic chickens and causes major economic losses to the poultry industry worldwide [1\u20135].", [["infectious bronchitis virus", "DISEASE", 18, 45], ["IntroductionAvian infectious bronchitis virus", "ORGANISM", 0, 45], ["AIBV", "ORGANISM", 47, 51], ["chickens", "ORGANISM", 151, 159], ["infectious bronchitis virus", "SPECIES", 18, 45], ["chickens", "SPECIES", 151, 159], ["infectious bronchitis virus", "SPECIES", 18, 45], ["AIBV", "SPECIES", 47, 51], ["chickens", "SPECIES", 151, 159], ["IntroductionAvian infectious bronchitis virus", "PROBLEM", 0, 45], ["Coronaviridae", "TREATMENT", 119, 132], ["infectious", "OBSERVATION_MODIFIER", 18, 28]]], ["AIBV causes disease in the upper respiratory tract, but it can also infect other organs such as the kidney and gonads [2].", [["upper respiratory tract", "ANATOMY", 27, 50], ["organs", "ANATOMY", 81, 87], ["kidney", "ANATOMY", 100, 106], ["gonads", "ANATOMY", 111, 117], ["AIBV", "CHEMICAL", 0, 4], ["disease in the upper respiratory tract", "DISEASE", 12, 50], ["AIBV", "GENE_OR_GENE_PRODUCT", 0, 4], ["upper respiratory", "ORGANISM_SUBDIVISION", 27, 44], ["tract", "ORGANISM_SUBDIVISION", 45, 50], ["organs", "ORGAN", 81, 87], ["kidney", "ORGAN", 100, 106], ["gonads", "ORGAN", 111, 117], ["AIBV", "SPECIES", 0, 4], ["disease in the upper respiratory tract", "PROBLEM", 12, 50], ["disease", "OBSERVATION", 12, 19], ["upper", "ANATOMY_MODIFIER", 27, 32], ["respiratory tract", "ANATOMY", 33, 50], ["kidney", "ANATOMY", 100, 106], ["gonads", "ANATOMY", 111, 117]]], ["Turkey coronavirus (TCoV), which causes acute enteric disease in turkeys and consequent economic loss, is closely related to AIBV [6].", [["enteric disease", "DISEASE", 46, 61], ["Turkey coronavirus", "ORGANISM", 0, 18], ["TCoV", "ORGANISM", 20, 24], ["Turkey coronavirus", "SPECIES", 0, 18], ["turkeys", "SPECIES", 65, 72], ["Turkey coronavirus", "SPECIES", 0, 18], ["TCoV", "SPECIES", 20, 24], ["turkeys", "SPECIES", 65, 72], ["AIBV", "SPECIES", 125, 129], ["acute enteric disease in turkeys", "PROBLEM", 40, 72], ["consequent economic loss", "PROBLEM", 77, 101], ["acute", "OBSERVATION_MODIFIER", 40, 45], ["enteric disease", "OBSERVATION", 46, 61], ["economic loss", "OBSERVATION", 88, 101]]], ["Sequence analysis has suggested that recombination may have played a key role in the evolutionary origin of TCoV.", [["TCoV", "GENE_OR_GENE_PRODUCT", 108, 112], ["TCoV", "DNA", 108, 112], ["TCoV", "SPECIES", 108, 112], ["Sequence analysis", "TEST", 0, 17]]], ["Because the spike proteins of TCoV isolates were much more divergent from those of AIBV than were other TCoV proteins, Jackwood and colleagues [7] proposed that TCoV arose through a recombination event involving replacement of the S gene (encoding the spike or S protein) of an AIBV genome with one derived from a more distant, unidentified coronavirus.IntroductionLargely because of interest in the origin of SARS coronavirus, numerous studies have addressed the role of recombination in coronavirus evolution [8].", [["coronavirus", "DISEASE", 341, 352], ["SARS coronavirus", "DISEASE", 410, 426], ["TCoV", "GENE_OR_GENE_PRODUCT", 30, 34], ["AIBV", "GENE_OR_GENE_PRODUCT", 83, 87], ["TCoV", "GENE_OR_GENE_PRODUCT", 104, 108], ["TCoV", "GENE_OR_GENE_PRODUCT", 161, 165], ["AIBV", "GENE_OR_GENE_PRODUCT", 278, 282], ["coronavirus", "ORGANISM", 341, 352], ["SARS coronavirus", "ORGANISM", 410, 426], ["coronavirus", "ORGANISM", 489, 500], ["spike proteins", "PROTEIN", 12, 26], ["AIBV", "PROTEIN", 83, 87], ["TCoV proteins", "PROTEIN", 104, 117], ["TCoV", "PROTEIN", 161, 165], ["S gene", "DNA", 231, 237], ["spike or S protein", "PROTEIN", 252, 270], ["AIBV genome", "DNA", 278, 289], ["SARS coronavirus", "SPECIES", 410, 426], ["TCoV isolates", "PROBLEM", 30, 43], ["replacement of the S gene", "TREATMENT", 212, 237], ["an AIBV genome", "TREATMENT", 275, 289], ["SARS coronavirus", "PROBLEM", 410, 426], ["numerous studies", "TEST", 428, 444], ["coronavirus", "OBSERVATION", 341, 352]]], ["In the case of AIBV, there has been long-standing interest in recombination among free-living strains [7, 9\u201312], and the occurrence of recombination among genotypes has been demonstrated experimentally in vitro [13].", [["AIBV", "DISEASE", 15, 19], ["AIBV", "CANCER", 15, 19]]], ["As the genomes of AIBV isolates have been sequenced, several naturally occurring genomes have been reported with novel gene sets and/or gene orders compared to those seen in classic AIBV isolates [14, 15].", [["AIBV isolates", "ORGANISM", 18, 31], ["novel gene sets", "DNA", 113, 128], ["AIBV", "SPECIES", 18, 22], ["AIBV", "SPECIES", 182, 186], ["AIBV isolates", "TREATMENT", 18, 31]]], ["The sequences of these genomes show the effects of gene deletion and rearrangement, processes to which recombination may have contributed.IntroductionHere I applied phylogenetic methods to sequences of protein-coding genes of 11 classic AIBV genomes and 6 TCoV genomes in order to reconstruct past recombination events among members of these two taxa.", [["protein-coding genes", "DNA", 202, 222], ["AIBV genomes", "DNA", 237, 249], ["TCoV genomes", "DNA", 256, 268], ["gene deletion", "PROBLEM", 51, 64], ["protein", "TEST", 202, 209], ["classic AIBV genomes", "TREATMENT", 229, 249], ["6 TCoV genomes", "TREATMENT", 254, 268]]], ["I examined the pattern of nucleotide substitution in the S gene in order to test the hypothesis that this gene is subject to an unusually high rate of nucleotide substitution, which might account for the high level of divergence in this region, even in the absence of recombination.", [["nucleotide", "CHEMICAL", 26, 36], ["nucleotide", "CHEMICAL", 151, 161], ["nucleotide", "CHEMICAL", 26, 36], ["nucleotide", "CHEMICAL", 151, 161], ["S gene", "DNA", 57, 63], ["nucleotide substitution", "TREATMENT", 26, 49], ["an unusually high rate of nucleotide substitution", "PROBLEM", 125, 174], ["nucleotide substitution", "OBSERVATION", 151, 174]]], ["In addition, I conducted a phylogenetic analysis of S proteins from a wide variety of coronaviruses in order to test the hypothesis that the S protein of TCoV is derived from a distantly related virus.Materials and methodsI analyzed 17 representative complete genomes of avian infectious bronchitis virus (AIBV) and turkey coronavirus (TCoV; Table 1).", [["avian infectious bronchitis virus", "DISEASE", 271, 304], ["turkey coronavirus", "DISEASE", 316, 334], ["coronaviruses", "ORGANISM", 86, 99], ["TCoV", "GENE_OR_GENE_PRODUCT", 154, 158], ["avian infectious bronchitis virus", "ORGANISM", 271, 304], ["AIBV", "ORGANISM", 306, 310], ["turkey coronavirus", "ORGANISM", 316, 334], ["S proteins", "PROTEIN", 52, 62], ["S protein", "PROTEIN", 141, 150], ["TCoV", "PROTEIN", 154, 158], ["avian infectious bronchitis virus", "SPECIES", 271, 304], ["turkey coronavirus", "SPECIES", 316, 334], ["TCoV", "SPECIES", 154, 158], ["infectious bronchitis virus", "SPECIES", 277, 304], ["AIBV", "SPECIES", 306, 310], ["turkey coronavirus", "SPECIES", 316, 334], ["TCoV", "SPECIES", 336, 340], ["a phylogenetic analysis", "TEST", 25, 48], ["S proteins", "PROBLEM", 52, 62], ["coronaviruses", "PROBLEM", 86, 99], ["the S protein of TCoV", "PROBLEM", 137, 158], ["a distantly related virus", "PROBLEM", 175, 200], ["methodsI", "TREATMENT", 215, 223], ["avian infectious bronchitis virus", "PROBLEM", 271, 304], ["coronaviruses", "OBSERVATION", 86, 99], ["virus", "OBSERVATION", 195, 200], ["infectious", "OBSERVATION_MODIFIER", 277, 287], ["bronchitis", "OBSERVATION", 288, 298]]], ["Only genomes including open reading frames corresponding to the 11 protein-coding genes in the AIBV isolate BJ (AY319651) were used so that phylogenies of each gene could be constructed for the same set of genomes, and attenuated laboratory strains were avoided.", [["open reading frames", "DNA", 23, 42], ["11 protein-coding genes", "DNA", 64, 87], ["attenuated laboratory strains", "PROBLEM", 219, 248]]], ["Sequences of each protein-coding gene (Table 2) were aligned at the amino acid level with the CLUSTAL X program [16], and the alignment was imposed on the DNA sequences.", [["amino acid", "CHEMICAL", 68, 78], ["amino acid", "CHEMICAL", 68, 78], ["amino acid", "AMINO_ACID", 68, 78], ["DNA", "CELLULAR_COMPONENT", 155, 158], ["protein-coding gene", "DNA", 18, 37], ["DNA sequences", "DNA", 155, 168], ["each protein", "TEST", 13, 25], ["the amino acid level", "TEST", 64, 84], ["the CLUSTAL X program", "TREATMENT", 90, 111], ["the DNA sequences", "TEST", 151, 168]]], ["In addition, additional S protein sequences from 37 representative coronaviruses were downloaded from the NCBI protein sequence database and aligned using CLUSTAL X.", [["coronaviruses", "ORGANISM", 67, 80], ["S protein sequences", "DNA", 24, 43], ["NCBI protein sequence", "DNA", 106, 127], ["additional S protein sequences", "TEST", 13, 43], ["coronaviruses", "PROBLEM", 67, 80], ["the NCBI protein sequence database", "TEST", 102, 136]]]], "PMC7242007": [["AbbreviationsGlobally, the severe acute respiratory syndrome coronavirus 2 (SARS\u2010CoV\u20102) virus has variably affected the various parts of the world and has been a major cause for significant morbidity and mortality.", [["acute respiratory syndrome coronavirus", "DISEASE", 34, 72], ["SARS\u2010CoV\u20102", "ORGANISM", 76, 86], ["severe acute respiratory syndrome coronavirus", "SPECIES", 27, 72], ["SARS\u2010CoV\u20102) virus", "SPECIES", 76, 93], ["the severe acute respiratory syndrome coronavirus", "PROBLEM", 23, 72], ["SARS\u2010CoV\u20102) virus", "PROBLEM", 76, 93], ["significant morbidity", "PROBLEM", 178, 199], ["severe", "OBSERVATION_MODIFIER", 27, 33], ["acute", "OBSERVATION_MODIFIER", 34, 39], ["respiratory syndrome", "OBSERVATION", 40, 60], ["significant", "OBSERVATION_MODIFIER", 178, 189], ["morbidity", "OBSERVATION", 190, 199]]], ["Coronavirus disease 2019 (COVID\u201019), the disease caused by SARS\u2010CoV\u20102, has been reported to have multiple clinical manifestations, although primarily they have been pulmonary manifestations.", [["pulmonary", "ANATOMY", 165, 174], ["Coronavirus disease", "DISEASE", 0, 19], ["SARS", "DISEASE", 59, 63], ["SARS\u2010CoV\u20102", "ORGANISM", 59, 69], ["pulmonary", "ORGAN", 165, 174], ["Coronavirus disease 2019 (COVID\u201019", "SPECIES", 0, 34], ["SARS\u2010CoV\u20102", "SPECIES", 59, 69], ["Coronavirus disease", "PROBLEM", 0, 19], ["the disease", "PROBLEM", 37, 48], ["SARS", "PROBLEM", 59, 63], ["multiple clinical manifestations", "PROBLEM", 97, 129], ["pulmonary manifestations", "PROBLEM", 165, 189], ["disease", "OBSERVATION", 41, 48], ["multiple", "OBSERVATION_MODIFIER", 97, 105], ["pulmonary", "ANATOMY", 165, 174], ["manifestations", "OBSERVATION", 175, 189]]], ["Hepatic manifestations have variably been present in up to 50% of infected individuals.1,2The spectrum ranges from asymptomatic abnormalities in hepatic biochemical tests to the rare case of acute liver failure.", [["Hepatic", "ANATOMY", 0, 7], ["hepatic", "ANATOMY", 145, 152], ["liver", "ANATOMY", 197, 202], ["1,2", "CHEMICAL", 87, 90], ["acute liver failure", "DISEASE", 191, 210], ["Hepatic", "ORGAN", 0, 7], ["hepatic", "ORGAN", 145, 152], ["liver", "ORGAN", 197, 202], ["Hepatic manifestations", "PROBLEM", 0, 22], ["infected individuals", "PROBLEM", 66, 86], ["The spectrum ranges", "TEST", 90, 109], ["asymptomatic abnormalities", "PROBLEM", 115, 141], ["hepatic biochemical tests", "TEST", 145, 170], ["acute liver failure", "PROBLEM", 191, 210], ["manifestations", "OBSERVATION", 8, 22], ["up to 50", "OBSERVATION_MODIFIER", 53, 61], ["infected", "OBSERVATION", 66, 74], ["asymptomatic", "OBSERVATION_MODIFIER", 115, 127], ["abnormalities", "OBSERVATION", 128, 141], ["hepatic", "ANATOMY", 145, 152], ["acute", "OBSERVATION_MODIFIER", 191, 196], ["liver", "ANATOMY", 197, 202], ["failure", "OBSERVATION", 203, 210]]], ["The cause for hepatic manifestations is unclear at this stage and may be caused by a variety of reasons, such as a manifestation of a systemic illness, ischemic liver injury, immune\u2010mediated liver injury, drug\u2010induced liver injury, or a direct cytopathic effect of the virus.3,4,5,6Not uncommonly, patients have concomitant infections, such as human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV) infection, either alone or as co\u2010infections, and the impact of the pandemic and SARS\u2010CoV\u20102 on these infections and associated liver diseases is unknown.", [["hepatic", "ANATOMY", 14, 21], ["liver", "ANATOMY", 161, 166], ["liver", "ANATOMY", 191, 196], ["liver", "ANATOMY", 218, 223], ["liver", "ANATOMY", 559, 564], ["hepatic manifestations", "DISEASE", 14, 36], ["systemic illness", "DISEASE", 134, 150], ["ischemic liver injury", "DISEASE", 152, 173], ["liver injury", "DISEASE", 191, 203], ["liver injury", "DISEASE", 218, 230], ["infections", "DISEASE", 324, 334], ["human immunodeficiency virus (HIV), hepatitis B", "DISEASE", 344, 391], ["hepatitis C virus (HCV) infection", "DISEASE", 409, 442], ["pandemic", "DISEASE", 500, 508], ["SARS", "DISEASE", 513, 517], ["CoV\u20102", "CHEMICAL", 518, 523], ["infections", "DISEASE", 533, 543], ["liver diseases", "DISEASE", 559, 573], ["hepatic", "ORGAN", 14, 21], ["liver", "ORGAN", 161, 166], ["liver", "ORGAN", 191, 196], ["liver", "ORGAN", 218, 223], ["patients", "ORGANISM", 298, 306], ["human immunodeficiency virus", "ORGANISM", 344, 372], ["hepatitis B virus", "ORGANISM", 380, 397], ["HBV", "ORGANISM", 399, 402], ["hepatitis C virus", "ORGANISM", 409, 426], ["HCV", "ORGANISM", 428, 431], ["SARS\u2010CoV\u20102", "ORGANISM", 513, 523], ["liver", "ORGAN", 559, 564], ["patients", "SPECIES", 298, 306], ["human immunodeficiency virus", "SPECIES", 344, 372], ["hepatitis B virus", "SPECIES", 380, 397], ["hepatitis C virus", "SPECIES", 409, 426], ["human immunodeficiency virus", "SPECIES", 344, 372], ["HIV", "SPECIES", 374, 377], ["hepatitis B virus", "SPECIES", 380, 397], ["HBV", "SPECIES", 399, 402], ["hepatitis C virus", "SPECIES", 409, 426], ["HCV", "SPECIES", 428, 431], ["hepatic manifestations", "PROBLEM", 14, 36], ["a systemic illness", "PROBLEM", 132, 150], ["ischemic liver injury", "PROBLEM", 152, 173], ["immune\u2010mediated liver injury", "PROBLEM", 175, 203], ["drug\u2010induced liver injury", "PROBLEM", 205, 230], ["a direct cytopathic effect of the virus", "PROBLEM", 235, 274], ["concomitant infections", "PROBLEM", 312, 334], ["human immunodeficiency virus", "PROBLEM", 344, 372], ["HIV", "PROBLEM", 374, 377], ["hepatitis B virus", "PROBLEM", 380, 397], ["HBV", "PROBLEM", 399, 402], ["hepatitis C virus (HCV) infection", "PROBLEM", 409, 442], ["SARS", "PROBLEM", 513, 517], ["these infections", "PROBLEM", 527, 543], ["associated liver diseases", "PROBLEM", 548, 573], ["cause for", "UNCERTAINTY", 4, 13], ["hepatic", "ANATOMY", 14, 21], ["manifestations", "OBSERVATION", 22, 36], ["systemic", "OBSERVATION_MODIFIER", 134, 142], ["illness", "OBSERVATION", 143, 150], ["ischemic", "OBSERVATION_MODIFIER", 152, 160], ["liver", "ANATOMY", 161, 166], ["injury", "OBSERVATION", 167, 173], ["liver", "ANATOMY", 191, 196], ["injury", "OBSERVATION", 197, 203], ["liver", "ANATOMY", 218, 223], ["injury", "OBSERVATION", 224, 230], ["cytopathic", "OBSERVATION_MODIFIER", 244, 254], ["virus", "OBSERVATION", 269, 274], ["concomitant", "OBSERVATION_MODIFIER", 312, 323], ["infections", "OBSERVATION", 324, 334], ["infections", "OBSERVATION", 533, 543], ["liver", "ANATOMY", 559, 564], ["diseases", "OBSERVATION", 565, 573]]], ["Further, the implications in people who inject drugs (PWIDs) may be unique.", [["people", "ORGANISM", 29, 35], ["people", "SPECIES", 29, 35], ["drugs (PWIDs", "TREATMENT", 47, 59]]], ["Observations continue to evolve regarding hepatic manifestations and challenges with COVID\u201019 and the liver, and as such, expectations and guidance on issues relevant to the multiple viral infections are important.AbbreviationsA meta\u2010analysis, primarily involving reports from China, noted a 3% prevalence rate of underlying chronic liver disease in those with COVID\u201019, although it does not provide specific data on the prevalence of HBV and HCV infections.7HBV and HCV are chronic infections that are frequently encountered worldwide, and the former is particularly common in China, where the first cases of COVID\u201019 were reported.", [["hepatic", "ANATOMY", 42, 49], ["liver", "ANATOMY", 102, 107], ["liver", "ANATOMY", 333, 338], ["viral infections", "DISEASE", 183, 199], ["chronic liver disease", "DISEASE", 325, 346], ["HCV infections", "DISEASE", 443, 457], ["chronic infections", "DISEASE", 475, 493], ["hepatic", "ORGAN", 42, 49], ["liver", "ORGAN", 102, 107], ["liver", "ORGAN", 333, 338], ["HBV", "ORGANISM", 435, 438], ["HCV", "ORGANISM", 443, 446], ["7HBV", "ORGANISM", 458, 462], ["HCV", "ORGANISM", 467, 470], ["HBV", "SPECIES", 435, 438], ["HCV", "SPECIES", 443, 446], ["HBV", "SPECIES", 459, 462], ["HCV", "SPECIES", 467, 470], ["hepatic manifestations", "PROBLEM", 42, 64], ["COVID\u2010", "TREATMENT", 85, 91], ["the multiple viral infections", "PROBLEM", 170, 199], ["underlying chronic liver disease", "PROBLEM", 314, 346], ["HBV", "PROBLEM", 435, 438], ["HCV infections", "PROBLEM", 443, 457], ["HBV", "PROBLEM", 459, 462], ["HCV", "PROBLEM", 467, 470], ["chronic infections", "PROBLEM", 475, 493], ["hepatic", "ANATOMY", 42, 49], ["liver", "ANATOMY", 102, 107], ["infections", "OBSERVATION", 189, 199], ["chronic", "OBSERVATION_MODIFIER", 325, 332], ["liver", "ANATOMY", 333, 338], ["disease", "OBSERVATION", 339, 346], ["HBV", "OBSERVATION", 435, 438], ["HCV", "OBSERVATION", 443, 446], ["HCV", "OBSERVATION_MODIFIER", 467, 470], ["chronic", "OBSERVATION_MODIFIER", 475, 482], ["infections", "OBSERVATION", 483, 493]]], ["Thus, there has been concern about the impact of SARS\u2010CoV\u20102 infection on the course of HCV and HBV.", [["SARS", "DISEASE", 49, 53], ["infection", "DISEASE", 60, 69], ["CoV\u20102", "GENE_OR_GENE_PRODUCT", 54, 59], ["HCV", "ORGANISM", 87, 90], ["HBV", "ORGANISM", 95, 98], ["HCV", "SPECIES", 87, 90], ["HBV", "SPECIES", 95, 98], ["SARS", "PROBLEM", 49, 53], ["CoV\u20102 infection", "PROBLEM", 54, 69], ["HCV", "TREATMENT", 87, 90], ["HBV", "TREATMENT", 95, 98], ["infection", "OBSERVATION", 60, 69]]], ["Thus far, fortunately, COVID\u201019 has been reported infrequently in those with HBV and HCV infections in the United States.", [["HBV and HCV infections", "DISEASE", 77, 99], ["HBV", "ORGANISM", 77, 80], ["HCV", "ORGANISM", 85, 88], ["HBV", "SPECIES", 77, 80], ["HCV", "SPECIES", 85, 88], ["HBV", "PROBLEM", 77, 80], ["HCV infections", "PROBLEM", 85, 99], ["HCV", "OBSERVATION", 85, 88]]], ["In a large series of 5700 hospitalized patients with COVID\u201019 in the northeastern United States, HBV and HCV infections were encountered in 0.1% and <0.1% of patients, respectively8(Table 1).", [["HBV and HCV infections", "DISEASE", 97, 119], ["patients", "ORGANISM", 39, 47], ["HBV", "ORGANISM", 97, 100], ["HCV", "ORGANISM", 105, 108], ["patients", "ORGANISM", 158, 166], ["patients", "SPECIES", 39, 47], ["patients", "SPECIES", 158, 166], ["HBV", "SPECIES", 97, 100], ["HCV", "SPECIES", 105, 108], ["HBV", "PROBLEM", 97, 100], ["HCV infections", "PROBLEM", 105, 119], ["large", "OBSERVATION_MODIFIER", 5, 10], ["HBV", "OBSERVATION", 97, 100], ["HCV infections", "OBSERVATION", 105, 119]]], ["In contrast, a large hospitalized patient series from Wuhan, China, observed that 2.1% (23/1099) of patients were HBV infected and represented 2.4% of nonsevere cases and 0.6% of severe cases.9A single\u2010center retrospective study from China noted that 12.2% (15/123) of patients with COVID\u201019 had HBV infection, and a higher percentage with comorbid HBV, relative to HBV\u2010negative patients, had higher total bilirubin levels, developed a more severe course (46.7% versus 24.1%), and had a higher mortality rate (13.3% versus 2.8%).10Zha et al.11noted a background HBV prevalence rate of 6.5% (2/31) while reporting on their experience with the use of corticosteroids in COVID\u201019; further, they observed delayed SARS\u2010CoV\u20102 clearance in those with HBV infection.AbbreviationsThere have been only sparse reports, involving case series, on the impact of COVID\u201019 in patients with HIV infection.12,13,14,15A Barcelona experience with hospitalized patients with COVID\u201019 noted that HIV\u2010infected individuals accounted for close to only 1% of these patients.", [["HBV infected", "DISEASE", 114, 126], ["COVID", "DISEASE", 283, 288], ["HBV infection", "DISEASE", 296, 309], ["bilirubin", "CHEMICAL", 406, 415], ["SARS", "DISEASE", 709, 713], ["HBV infection", "DISEASE", 744, 757], ["HIV infection", "DISEASE", 874, 887], ["COVID", "DISEASE", 954, 959], ["HIV\u2010infected", "DISEASE", 974, 986], ["bilirubin", "CHEMICAL", 406, 415], ["corticosteroids", "CHEMICAL", 649, 664], ["patient", "ORGANISM", 34, 41], ["patients", "ORGANISM", 100, 108], ["HBV", "ORGANISM", 114, 117], ["patients", "ORGANISM", 269, 277], ["HBV", "ORGANISM", 296, 299], ["HBV", "ORGANISM", 349, 352], ["HBV", "ORGANISM", 366, 369], ["patients", "ORGANISM", 379, 387], ["bilirubin", "GENE_OR_GENE_PRODUCT", 406, 415], ["CoV", "ORGANISM", 714, 717], ["HBV", "ORGANISM", 744, 747], ["patients", "ORGANISM", 860, 868], ["HIV", "ORGANISM", 874, 877], ["patients", "ORGANISM", 940, 948], ["HIV", "ORGANISM", 974, 977], ["individuals", "ORGANISM", 987, 998], ["patients", "ORGANISM", 1039, 1047], ["patient", "SPECIES", 34, 41], ["patients", "SPECIES", 100, 108], ["patients", "SPECIES", 269, 277], ["patients", "SPECIES", 379, 387], ["patients", "SPECIES", 860, 868], ["HIV", "SPECIES", 874, 877], ["patients", "SPECIES", 940, 948], ["HIV", "SPECIES", 974, 977], ["patients", "SPECIES", 1039, 1047], ["HBV", "SPECIES", 114, 117], ["HBV", "SPECIES", 296, 299], ["HBV", "SPECIES", 349, 352], ["HBV", "SPECIES", 366, 369], ["HBV", "SPECIES", 562, 565], ["HBV", "SPECIES", 744, 747], ["HIV", "SPECIES", 874, 877], ["HIV", "SPECIES", 974, 977], ["HBV infected", "PROBLEM", 114, 126], ["nonsevere cases", "TEST", 151, 166], ["severe cases", "PROBLEM", 179, 191], ["A single\u2010center retrospective study", "TEST", 193, 228], ["COVID", "TEST", 283, 288], ["HBV infection", "PROBLEM", 296, 309], ["comorbid HBV", "PROBLEM", 340, 352], ["higher total bilirubin levels", "PROBLEM", 393, 422], ["a higher mortality rate", "PROBLEM", 485, 508], ["a background HBV prevalence rate", "TEST", 549, 581], ["corticosteroids", "TREATMENT", 649, 664], ["delayed SARS", "PROBLEM", 701, 713], ["HBV infection", "PROBLEM", 744, 757], ["COVID\u2010", "TREATMENT", 848, 854], ["HIV infection", "PROBLEM", 874, 887], ["HIV\u2010infected individuals", "PROBLEM", 974, 998], ["large", "OBSERVATION_MODIFIER", 15, 20], ["infection", "OBSERVATION", 300, 309], ["HBV", "OBSERVATION", 562, 565], ["infection", "OBSERVATION", 748, 757], ["infection", "OBSERVATION", 878, 887], ["infected", "OBSERVATION", 978, 986]]], ["Those with HIV infection were younger than 50 years, they self\u2010identified as men who have sex with men, their clinical picture was similar to those who were HIV negative/COVID\u201019 positive, and there was no mortality reported.12There have been only sporadic reports of COVID\u201019 in those co\u2010infected with HIV and HCV, and unique considerations in either HIV mono\u2010infected or HIV/HCV co\u2010infected patients would be of adjustments to antiretroviral therapy (ART) based on potential drug\u2010drug interactions (DDIs); further, antibody response to SARS\u2010CoV\u20102 may be impaired or delayed in this population.16Thus far, studies have not been presented on the frequency and impact of COVID\u201019 in PWIDs, a population vulnerable to the consequences of SARS\u2010CoV\u20102 due to several comorbidities, such as other viral infections, heart disease, and renal disease.17", [["heart", "ANATOMY", 809, 814], ["renal", "ANATOMY", 828, 833], ["HIV infection", "DISEASE", 11, 24], ["HIV and HCV", "DISEASE", 303, 314], ["HIV/HCV co\u2010infected", "DISEASE", 373, 392], ["SARS", "DISEASE", 538, 542], ["SARS", "DISEASE", 736, 740], ["viral infections", "DISEASE", 791, 807], ["heart disease", "DISEASE", 809, 822], ["renal disease", "DISEASE", 828, 841], ["HIV", "ORGANISM", 11, 14], ["men", "ORGANISM", 77, 80], ["men", "ORGANISM", 99, 102], ["HIV", "ORGANISM", 303, 306], ["HCV", "ORGANISM", 311, 314], ["HIV mono\u2010infected", "ORGANISM", 352, 369], ["HIV/HCV", "ORGANISM", 373, 380], ["patients", "ORGANISM", 393, 401], ["CoV\u20102", "ORGANISM", 543, 548], ["heart", "ORGAN", 809, 814], ["renal", "ORGAN", 828, 833], ["HIV", "SPECIES", 11, 14], ["men", "SPECIES", 77, 80], ["men", "SPECIES", 99, 102], ["HIV", "SPECIES", 303, 306], ["HIV", "SPECIES", 352, 355], ["HIV", "SPECIES", 373, 376], ["patients", "SPECIES", 393, 401], ["HIV", "SPECIES", 11, 14], ["HIV", "SPECIES", 157, 160], ["HIV", "SPECIES", 303, 306], ["HCV", "SPECIES", 311, 314], ["HIV", "SPECIES", 352, 355], ["HIV", "SPECIES", 373, 376], ["HCV", "SPECIES", 377, 380], ["SARS\u2010CoV", "SPECIES", 538, 546], ["SARS\u2010CoV", "SPECIES", 736, 744], ["HIV infection", "PROBLEM", 11, 24], ["HIV", "TEST", 157, 160], ["mortality", "PROBLEM", 206, 215], ["COVID\u2010", "TREATMENT", 268, 274], ["HIV", "PROBLEM", 303, 306], ["HCV", "PROBLEM", 311, 314], ["HIV/HCV", "PROBLEM", 373, 380], ["antiretroviral therapy", "TREATMENT", 429, 451], ["potential drug\u2010drug interactions", "PROBLEM", 467, 499], ["further, antibody response", "TEST", 508, 534], ["SARS", "PROBLEM", 538, 542], ["COVID\u2010", "TREATMENT", 670, 676], ["SARS", "PROBLEM", 736, 740], ["several comorbidities", "PROBLEM", 754, 775], ["other viral infections", "PROBLEM", 785, 807], ["heart disease", "PROBLEM", 809, 822], ["renal disease", "PROBLEM", 828, 841], ["HIV", "OBSERVATION_MODIFIER", 11, 14], ["infection", "OBSERVATION", 15, 24], ["HCV", "OBSERVATION", 311, 314], ["viral", "OBSERVATION_MODIFIER", 791, 796], ["infections", "OBSERVATION", 797, 807], ["heart", "ANATOMY", 809, 814], ["disease", "OBSERVATION", 815, 822], ["renal", "ANATOMY", 828, 833], ["disease", "OBSERVATION", 834, 841]]]], "PMC7472671": [["DDr.", [["DDr.", "SPECIES", 0, 4]]], ["P. Fischer diskutiert anhand dreier F\u00e4lle die Wichtigkeit, gegen diesen Trugschluss einzutreten.Was k\u00f6nnen wir beim Schlaganfall unter NOAK (nicht-Vitamin-K-abh\u00e4ngigen oralen Antikoagulanzien) tun?", [["nicht", "TEST", 141, 146], ["Vitamin", "TREATMENT", 147, 154], ["K-abh\u00e4ngigen oralen Antikoagulanzien)", "TREATMENT", 155, 192]]], ["Und wie behandeln wir multidisziplin\u00e4r Dysphagie nach Schlaganfall? ::: Aktuelle Themen ::: Neurologie und Psychiatrie im Kontext von COVID-19Diese hochaktuellen Themen werden von O\u00c4 Dr. C. Brunner et al., Dr. S. Beirer und Logop\u00e4din PhDr M. Trapl-Grundschober, MAS, MSc. einpr\u00e4gsam begangen.Wenn Epilepsiepatienten Verhaltensauff\u00e4lligkeiten entwickeln \u2013 ist es das Antikonvulsivum? ::: Aktuelle Themen ::: Neurologie und Psychiatrie im Kontext von COVID-19Dr.", [["COVID-19Diese hochaktuellen", "CHEMICAL", 134, 161], ["Neurologie und Psychiatrie im Kontext von COVID-19Diese hochaktuellen", "SPECIES", 92, 161], ["Neurologie und Psychiatrie im Kontext von COVID-19Dr", "SPECIES", 407, 459], ["COVID", "TEST", 134, 139]]], ["T. Kapfer und Dr. E. Kacar et al. haben die aktuellen Daten aufgearbeitet und geben klinische Hinweise aus diesem Dilemma.Das Konzept der Mentalisierung bei St\u00f6rungen aus dem schizophrenen Formenkreis \u2013 wie treten Defizite der Mentalisierung in Erscheinung? ::: Aktuelle Themen ::: Neurologie und Psychiatrie im Kontext von COVID-19Als Neurologe fand ich besonders das Konzept der Mentalisierung und deren spezifische Ausformungen sehr interessant.", [["Das Konzept der Mentalisierung bei St\u00f6rungen aus dem schizophrenen", "TREATMENT", 122, 188], ["ich", "PROBLEM", 351, 354], ["diesem Dilemma", "OBSERVATION", 107, 121]]], ["Diese Lekt\u00fcre gibt auch der Neurologie wertvolle Stimuli f\u00fcr den Patientenkontakt.Das Konzept der Mentalisierung bei St\u00f6rungen aus dem schizophrenen Formenkreis \u2013 wie treten Defizite der Mentalisierung in Erscheinung? ::: Aktuelle Themen ::: Neurologie und Psychiatrie im Kontext von COVID-19Dr.", [["Neurologie und Psychiatrie im Kontext von COVID-19Dr", "SPECIES", 242, 294], ["Das Konzept der Mentalisierung bei St\u00f6rungen aus dem schizophrenen", "TREATMENT", 82, 148]]], ["P. Grafenauer stellt besondere Aspekte bei der Betreuung von Myasthenia-gravis-Patienten vor und geht dabei auf ganz wichtige und klinisch relevante Aspekte der Patientenversorgung ein.Das Konzept der Mentalisierung bei St\u00f6rungen aus dem schizophrenen Formenkreis \u2013 wie treten Defizite der Mentalisierung in Erscheinung? ::: Aktuelle Themen ::: Neurologie und Psychiatrie im Kontext von COVID-19Ich hoffe, Sie finden die Lekt\u00fcre ebenso spannend wie hilfreich in unserer t\u00e4glichen Aufgabe.Das Konzept der Mentalisierung bei St\u00f6rungen aus dem schizophrenen Formenkreis \u2013 wie treten Defizite der Mentalisierung in Erscheinung? ::: Aktuelle Themen ::: Neurologie und Psychiatrie im Kontext von COVID-19Ich w\u00fcnsche Ihnen, dass Sie gesund bleiben und mit Ihren Patientinnen und Patienten gemeinsam gut durch die Krise kommen.Das Konzept der Mentalisierung bei St\u00f6rungen aus dem schizophrenen Formenkreis \u2013 wie treten Defizite der Mentalisierung in Erscheinung? ::: Aktuelle Themen ::: Neurologie und Psychiatrie im Kontext von COVID-19Mit freundlichen Gr\u00fc\u00dfenDas Konzept der Mentalisierung bei St\u00f6rungen aus dem schizophrenen Formenkreis \u2013 wie treten Defizite der Mentalisierung in Erscheinung? ::: Aktuelle Themen ::: Neurologie und Psychiatrie im Kontext von COVID-19Walter Struhal", [["Myasthenia-gravis", "DISEASE", 61, 78], ["P. Grafenauer stellt besondere Aspekte bei der Betreuung von Myasthenia-gravis-Patienten vor und geht dabei auf ganz wichtige und klinisch relevante Aspekte der Patientenversorgung ein", "SPECIES", 0, 184], ["Neurologie und Psychiatrie im Kontext von COVID-19Ich hoffe", "SPECIES", 345, 404], ["Neurologie und Psychiatrie im Kontext von COVID-19Ich w\u00fcnsche Ihnen, dass Sie gesund bleiben und mit Ihren Patientinnen und Patienten gemeinsam gut durch die Krise kommen", "SPECIES", 648, 818], ["Neurologie und Psychiatrie im Kontext von COVID-19Mit freundlichen Gr\u00fc\u00dfenDas Konzept der Mentalisierung bei St\u00f6rungen aus dem schizophrenen Formenkreis \u2013 wie treten Defizite der Mentalisierung", "SPECIES", 979, 1171], ["Neurologie und Psychiatrie im Kontext von COVID-19Walter Struhal", "SPECIES", 1212, 1276], ["Myasthenia", "TEST", 61, 71], ["Das Konzept der Mentalisierung bei St\u00f6rungen aus dem schizophrenen", "TREATMENT", 185, 251], ["Das Konzept der Mentalisierung bei St\u00f6rungen aus dem schizophrenen", "TREATMENT", 488, 554], ["Das Konzept der Mentalisierung bei St\u00f6rungen aus dem schizophrenen", "TREATMENT", 819, 885], ["COVID", "TEST", 1021, 1026], ["Mit freundlichen Gr\u00fc\u00dfenDas Konzept der Mentalisierung bei St\u00f6rungen aus dem schizophrenen", "TREATMENT", 1029, 1118]]]]}